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Abstract 
 
Throughout the world squamous cell carcinoma of the oesophagus seems to be an 
increasing problem. There is a huge variation in prevalence globally; locations such as 
Japan, Iran, China and Finland can have ten times the prevalence compared to other 
western countries. One place that is hugely affected is Transkei, a 16,000 square mile 
area of South Africa. Some of the factors proposed to be implicated with squamous 
cell carcinoma in this region include tobacco smoking, alcohol consumption, bacterial 
infections and fungal infection of common food crops. In addition, the ‘Sammon 
theory’ links carcinogenesis in Transkei to the high consumption of maize by the 
population. Through a chain of reactions it is postulated that a component of maize 
inhibits the breakdown of growth factors, which have already been implicated in 
cancer.  
This study investigates the Transkei population and updates the Sammon theory with 
current research to predict a theory at a molecular level. This theory is then tested 
with novel research to show PGE2, shown here in high concentrations in gastric fluid 
samples, directly increases the proliferation of oesophageal cell lines. Gastric fluid 
samples from the Transkei population are then shown to have a mitogenic effect on 
oesophageal cells, supporting a theory that gastric fluid regurgitation commonly 
found in this population predisposes them to cancer. Further experimentation on the 
expression of related proteins shows how high PGE2 may increase its own production 
by increasing COX 2 expression, leading to a positive feedback loop causing constant 
proliferative stimulation of the oesophageal squamous tissue in the presence of the 
COX 2 substrate, aracadonic acid.  
Therefore this thesis suggests that a high maize diet provides the correct conditions 
for regurgitation of increased concentrations of PGE2 into the oesophagus leading to 
squamous hyper-proliferation over long periods of time through self stimulated 
production, which would normally have ceased over a much shorter time if only 
localised PGE2 was produced through natural restitution.  
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 1. Introduction 
 
1.1. Introduction 
The following chapter will provide the underlying information required to understand 
the work that has taken place in this thesis. This will start with the basic physiology 
and histology of the oesophagus and provide information on general oesophageal 
cancer. Much of this information is provided for a background of oesophageal cancer 
to complete the readers understanding and not required to understand the study itself. 
Information relating to the epidemiological aspect of oesophageal cancer factors 
world wide are briefly explained, along with some molecular pathology and the 
proteins relating to this study. This study has been based on a theory originally 
developed by cancer surgeon, Alistair Sammon, therefore his work and research has 
been explained at the end of the chapter. As one of the aims of this work was to 
develop his theory and to extend the research by adding a molecular understanding to 
carcinogenesis in the target population, new concepts and factors are introduced and 
discussed in subsequent chapters.  
 
According to a full literature survey the research in this thesis has never been carried 
out before in this target area, presenting interesting novel work. Due to the nature of 
this research the study is more than the pathological analysis of the target population. 
A large area of this research is based on the epidemiological effects on the population 
and how this can drive changes at a molecular level to better understand the local 
pathology. Although this study is essentially biological, a great amount of work has 
been necessary to understand the underlying sociological factors of the target 
population. Therefore, chapter 2 discusses these factors with reference to carcinogenic 
and molecular effects. Chapter 3 evaluates the environmental investigation of the 
target population in chapter 2 and links this with previous molecular research and the 
Sammon Theory outlined below (section 1.9). This postulated molecular pathogenesis 
provides a platform for the experimental research in this study. Chapter 4 explains the 
ethics and sample collection carried out in South Africa. Chapter 5 investigates the 
gastric fluid samples used in the study, studying sample number, Prostaglandin E2 
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(PGE2) content, the detrimental effect of transportation on the samples, and checking 
their significance and validity for the study. Chapter 6 describes the models used to 
test the proliferative effects the gastric fluid and its components could have on the 
oesophagus in the target population. This provides the fundamental information as to 
how a high maize diet may lead to hyperplasia in the oesophagus, predisposing this 
epithelium to cancer. Chapter 7 investigates suggested molecular changes within the 
target population caused by a high maize diet. Changes in the amounts of growth 
promoting proteins acting on these oesophageal cells are therefore studied. An 
important novel molecular positive feedback pathway is discovered in chapter 7 that 
is investigated and evaluated in chapter 8. This is then concluded and summarised in 
chapter 9 and further work is discussed.  
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1.2. The Oesophagus. 
 
1.2.1. Anatomy of the Oesophagus 
 
 
Figure 1.1:  The anatomy of the Oesophagus (Drake, Vogel & Mitchell, 2005) 
 
The oesophagus is a tubular muscular organ of around 25-30 cm in length. It runs 
from the pharynx joining the cardia of the stomach, via the diaphragm. It passes 
anterior to the trachea, down the front of the spine, and makes up the first part of the 
digestive system to encounter food after ingestion (fig 1.1) (Rubin & Farber, 1988; 
Vander et al., 1994). The oesophagus runs straight through the mediastinum of the 
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thorax and through the muscular right crus of the diaphragm at the oesophageal 
hiatus, joining the stomach at the cardiac orifice (Drake, Vogel & Mitchell, 2005). 
There is a large vascular network round the oesophagus consisting of both a 
cardiovascular system and the lymphatic system (Cotran et al., 1999). 
The oesophagus can be subdivided in to three separate sections: The cervical 
oesophagus, the thoracic oesophagus, and finally the lower oesophagus. Throughout 
these different sections there are narrowings, including two 3cm areas that remain 
contracted even in the resting phase of the surrounding muscle, which are known as 
the upper oesophageal and lower oesophageal sphincters. These aid the muscular 
lumen in carrying out its primary function of channelling food boli and fluids to the 
stomach via a peristaltic motion avoiding reflux of the gastric contents back into the 
oesophagus. In order for the upper oesophageal muscle to cause this propulsion there 
is striated muscle, however the lower oesophagus is mainly comprised of smooth 
muscle under autonomic neural control (Rubin & Farber, 1988; Gray, 1991), see 
Figure 1.2. The lower oesophageal sphincter is tonically active but relaxes on 
swallowing. Control seems to rely on four complementary factors: diaphragmatic 
contraction, greater intra-abdominal pressure than intragastric pressure being exerted 
upon the abdominal part of the oesophagus, unidirectional peristalsis and maintenance 
of correct anatomical arrangements of the structure (Young et al. 2006). A contraction 
of the muscle is present under vagal release of acetylcholine and a relaxation of the 
muscle is due to nitric oxide and vasoactive intestinal polypeptide release (Ganong, 
2003). This tight control prevents reflux of gastric contents back into the oesophagus. 
The contents of normal fasting gastric fluid contains a number of substances that may 
have an effect on the oesophagus. The gastric fluid contains cations (Na+, K+. Mg2+, 
H+), anions (Cl-, HPO42-, SO42-), pepsins, lipase, mucus and intrinsic factor (Ganong, 
2003). 
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 Figure 1.2:  Oesophagogastric junction. (Mittal & Balaban, 1997) 
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1.2.2. The Histology of the Oesophageal Tract 
 
Figure 1.3:  The defined cellular layers of the oesophageal tract (Wheater et al., 
1979).  
 
There are three distinct layers of the oesophageal tissue, the mucosa, submucosa and 
muscularis (Fig 1.3). The mucosa is around 500-800 µm thick made up of the non-
keratinizing stratified squamous epithelium supported by the connective tissue, the 
lamina propria. The muscularis mucosae is a 300µm thick smooth muscle layer, 
which moves and folds the mucosa (Wheater et al., 1979). The squamous epithelial 
layer has a basal area occupying around 10-15 percent of the epithelium consisting of 
several layers of cuboidal or oblong basophilic cells with dark nuclei (Day & Dixon, 
1995) (Fig 1.4). It is this basal layer that proliferates to replace those cells sloughed 
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off as food passed through the lumen. Squamous cell carcinoma (SCC) is derived 
from this layer (King, 2000). Between the squamous cells, Langerhans cells, part of 
the immune surveillance system, can be found (Day & Dixon, 1995). The lamina 
propria is the non-epithelial part of the mucosa consisting of lymphocytes, plasma 
cells, connective tissue, vascular structures and oesophageal cardiac glands, which are 
mucus secreting (Cotran et al., 1999). It is from these glands that adenocarcinoma 
arises (Rubin & Farber, 1988).  
 
L  
Squamous cells 
BPapillae of 
amina Propria 
Figure 1.4: Normal oesophageal Squamous epithelium with narrow basal zone (Day 
& Dixon, 1995).  
 
Just short of the gastro-oesophageal junction, a 3 –5 cm long segment is lined with 
surface mucin-secreting columnar epithelium, rather than the usual squamous 
epithelium (Day & Dixon, 1995).  
The submucosa consists mainly of loose connective tissue supporting the mucosa 
containing the blood vessels and a network of lymphatics. As well as parasympathetic 
nerve fibres and leukocytes, the submucosal glands can be found (Wheater et al., 
Basal cells 
Lamina 
Propria 
asal Lamina 
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1979). These vessels are normally found in high amounts around either end of the 
oesophagus, although they can be found all the way along it (Day & Dixon 1995). 
The glands are thought to be continuations of minor salivary glands secreting both 
mucus and sulphomucins (Cotran et al., 1999).  
The third layer, the muscularis, is subdivided into two histological layers: an inner 
circumferential layer and an outer longitudinal layer of smooth muscle. These layers 
are sitting at right angles to each other therefore offer the basis of the peristaltic 
movement (Gray, 1991).  
In much of the gastrointestinal tract there is a fourth layer, the subserosa/serosa. 
Instead of this the oesophagus has a fibrous adventitia composed entirely of 
connective tissue, which blends with surrounding structures along its route. The 
absence of a subserosa/serosa, exacerbated by a prominent lymphatic network, can 
facilitate the spread of infections and tumours from the oesophagus into the posterior 
mediastinum. (Cotran et al., 1999). 
 
1.3. Cancer 
 
There is no one factor that causes the development of cancer. There are many 
different aspects to investigate when assessing why and how a cancer is progressing. 
Some of the influential factors that can affect processes include cell death, 
proliferation rate, cell differentiation, surrounding cell response, immune attack, 
control of blood supply, and composition of extra cellular matrix.  All of these have 
been extensively researched. 
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 1.3.1. Tumourigenesis 
 
The generation of cancer is termed tumourigenesis, and has many different states 
resulting from accumulation of errors in vital regulatory pathways that control normal 
cell growth. The process by which this takes place is split into a series of stages 
termed initiation, promotion and progression (Figure 1.5). The term tumourigenesis is 
refers to more of a physical genesis and is often staged by changes in tissue growth 
characteristics. The term carcinogenesis is often characterised as changes in the tissue 
at a molecular level through changes in chemically induced cancer. In this thesis both 
tumourigenesis and carcinogenesis are used in the same context, as the overall 
generation of cancer, both at a tissue and molecular level. 
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Figure 1.5: The process of carcinogenesis (Gerhäuser, 2002) 
 
The irreversible stage of initiation is presumed to be a consequence of a genetic 
mutation (such as transitions, transversions and deletions) that increases a cell’s 
propensity to proliferate. This can be via external or internal influences, for example 
radiation or the presence of free radicals. It is mainly postulated that the points of 
these mutations can coincide with protooncogenes/cellular oncogenes or tumour 
suppressor genes. Examples of these are Bcl-2, which translates a protein that 
normally blocks apoptosis, and p53 which encodes a protein which can halt cell 
division and induce abnormal cells to kill themselves (Larsen, 1994).  The cellular 
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and molecular changes reflecting the stage of initiation in gastrointestinal 
carcinogenesis have been extensively researched and further explained below (section 
1.7). 
A promotional agent drives a tumour to the premalignant state and encourages its 
expansion in cell number; this agent does not have to be geno-toxic, and can be 
reversible at both genetic and cellular level. With the enhancement or repression of 
gene expression by receptors, which are specific to the promoting agent, then cellular 
proliferation or inhibition of apoptosis can promote cell population.  
Following promotion, two important processes occur: The formation of blood vessels 
which is called angiogenesis, allowing tumours to grow larger than 1mm in diameter; 
and a change in the amount of cellular proliferation, termed hyperplasia. From this 
point and through the progression, further mutations may take place. This results in 
the loss of basic control of cellular growth, changing the differentiation state of the 
cells and the cells surrounding it, leading to dysplasia and in situ carcinoma. Common 
examples of promotional factors that have been researched in squamous oesophageal 
cancer are tobacco smoke (Yu et al., 1988) and alcohol (Hu et al., 1994).  
Progression induces cells into a stage of irreversible promotion via complex genetic 
alterations such as deletions, translocations and gene amplification, driving 
phenotypic instability. This state of dedifferentiation demonstrates increased 
autonomous growth and aggressive behaviour (King, 2000). At this stage the 
promotion agent no longer needs to be present for the tumour to develop.  
Several changes can be seen in progression, including an altered sensitivity for the 
surrounding cells, changes in the amount of growth factors and receptor changes. This 
allows the growth characteristics to change and to grow out of its normal tissue. These 
metastasise round the body via surrounding blood vessels or the lymphatic system 
(Woodman, 2001). 
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1.4. Oesophageal Cancer 
 
Oesophageal cancer is the sixth most common cancer worldwide (Morris et al., 1998) 
with an estimated 335,000 deaths a year (Altorki, 2003). In the UK Oesophageal 
cancer is the fifth most common cancer with around 7230 deaths in 2004 (Office for 
National Statistics, 2007) There are various types of oesophageal cancer but most 
occurrences are restricted to two: Squamous cell carcinoma and Adenocarcinoma. A 
majority of cases around the world are due to squamous cell carcinoma, the principal 
cancer investigated in this study, although much of the research has been carried out 
on adenocarcinoma because of links to western lifestyles like alcohol and tobacco 
consumption, stress etc.  
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1.4.1. Squamous Cell Carcinoma 
 
 
Figure 1.6: Well-dedifferentiated Squamous cell carcinoma with central keratinisation 
in many of the cell clumps. (Day & Dixon, 1995)  
 
Squamous cell carcinoma (Fig 1.6) arises from the mucosa of the oesophagus in the 
squamous epithelium. It is histologically characterized by being invasive, with a 
distinct ragged stromal-epithelium (Anderson & Lad, 1982) or “exophytic, ulcerating 
or infiltrating lesions or a combination of these, and often result in a stricture which is 
usually irregular and haemorrhagic” (Day & Dixon, 1995). These are mainly located 
in the thoracic oesophagus; about 60 percent of cases in the middle third and 30 
percent of cases in the distal third (Anderson & Lad, 1982). 
 
Keratinised 
clumps 
Squamous cell 
carcinoma 
(atypical nuclei) 
Inflammatory 
infiltrate 
(e.g. neurophils) 
 13
  
1.4.2. Adenocarcinoma 
 
Figure 1.7:  Well differentiated adenocarcinoma underling oesophageal epithelium 
from the lower end of the oesophagus. (Day & Dixon, 1995) 
 
Adenocarcinoma is usually found in the lower third of the oesophagus (Cotran et al., 
1999) (Figure 1.7) arising from the oesophageal glands. Gastric cancers arising at the 
gastro-oesophageal junction are often mistakenly assumed to be oesophageal 
adenocarcinoma (Day & Dixon 1995). A considerable amount of research has gone 
into the pathogenesis of a condition called Barrett’s oesophagus/mucosa. This is 
where squamous epithelium is replaced by columnar epithelium resembling the cells 
that line the stomach, and is associated with chronic gastric reflux. This is thought to 
be a major premalignant predisposing condition that leads to adenocarcinoma. The 
incidences of this are increasing, mainly in white men. This is thought to be due to the 
increased consumption of alcoholic beverages and tobacco smoke in many areas of 
 14
the world (Rubin & Farber, 1998) and/or increasing stress (Ronson, 2006). A study of 
the genetic expression between adenocarcinoma and squamous cell carcinoma cell 
lines showed no gene was up or down regulated between the two. However, the 
microarray used had only limited numbers of genes related to oesophageal cancer 
(Kan et al., 2001). 
 
1.4.3. Small cell carcinoma 
 
This may also be known as oat cell carcinoma, argyrophil cell carcinoma, 
neuroendocrine carcinoma or anaplastic carcinoma. First described by McKeown 
(1952) it is only seen in the bottom two thirds of the oesophagus. Only a small 
percentage of all oesophageal cancer cases present this type, once reviewed at 2.4 
percent of all primary oesophageal carcinomas with this morphology (Day & Dixon, 
1995). Histologically, they are renowned for a rosette like formulation, from both 
squamous and glandular tissue. Some people view these to be a metastasis from lung 
tissue (Briggs & Ibrahim, 1983)  
 
1.4.4. Benign tumours 
 
Benign tumours of the oesophagus are usually leiomyomas (benign smooth muscle 
tumours e.g. uterus and digestic tract) and seen in the smooth muscle of the 
oesophageal wall. However, lymphangiomas (benign angioma e.g. lymphatic system), 
lipomas (benign tumour of fat cells) and fibromas (benign fibrous tissue e.g. 
extracellular matrix) can also be present. A mass of vascular, fibrous and adipose 
tissue covered by an intact mucosa are seen in mucosal polyps and are often just cut 
out with endoscopy if they grow too big and impede bolus food from being swallowed 
(Cotran et al., 1999). 
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 1.5. Diagnosis, Prognosis and Treatment of Oesophageal Cancer 
 
1.5.1. Symptoms 
 
Progressive weight loss in a short time is seen in up to 70 percent of the patients, 
mainly due to dysphagia (Ojala et al., 1982; Galandiuk & Hermann, 1986). This 
primarily begins with difficultly swallowing bolus solids and can progress to liquids, 
owing to around two thirds of the lumen being obstructed. Little pain can be seen up 
to this stage; hence cancer can advance without the patient reporting the case. As the 
cancer increases and the lumen size diminishes then other than uncomfortable 
swallowing, pain can be associated with the dysphagia (called odynophagia) radiating 
in the back, arms, neck and jaw (Rubin & Farber, 1988). Pain can arise if the cancer 
spreads to the local lymph nodes, liver, lungs and pleura. Severe suffering as the 
disease develops could be due to tracheo-oesophageal fistulas (Braunward, 2001). 
These and cervical oesophageal tumours are thought to be related to the coughing and 
hoarseness seen in around a quarter of all cases. In between a third and a half of all 
cases, vomiting and regurgitation has been seen making the symptoms more 
aggravated and painful (Galandiuk & Hermann, 1986). 
 
1.5.2. Diagnosis 
 
Owing to the lack of symptoms at the early stages of oesophageal cancer 
development, a high index of suspicion is required to diagnose early. There are two 
primary techniques that can be used to diagnose oesophageal cancer: the 
oesophagoscopy or a barium swallow. Magnetic resonance imaging (MRI) and 
ultrasonography may also be used in diagnosis, although this is mainly restricted to 
just providing further information on the staging of oesophageal cancer. Because the 
lungs are the most common site of distant metastasis then a chest x-ray can be 
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performed (Morris et al., 1998). The use of much of this equipment for diagnosis in 
the poor areas with endemic cancer of the oesophagus is limited due to lack of 
resources making early diagnosis problematic (section 2.1.3). 
 
1.5.3. Staging 
 
The staging of the tumour is of major importance to determine the prognosis and the 
direction of the treatment. A majority of cancers are staged by the tumour-node 
metastasis (TNM) status. This is split into three main sections as suggested by the 
three letters in the title: primary tumour (T), presence of tumour in regional lymph 
nodes (N) and distant metastasis (M). The primary tumour staging offers information 
on the progressive degree (1-4) of invasion of the tumour into the oesophageal wall. 
Regional lymph nodes refer to the nodal involvement. Distant metastasis represents if 
the metastasis has spread (Table 1.1) 
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Table 1.1    American Joint Commission on cancer TNM staging (AJCC) for 
oesophageal cancer (Heitmiller, 2001) 
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Although CT and MRI scans are used for the staging of the primary tumour the gold 
standard is the endoscopic ultrasound (EUS).  
 
1.5.4. Treatment 
 
The type of treatment is dependent on the stage of the cancer itself. Surgery is the 
most common form of treatment for oesophageal cancer ( 2002) although this is only 
feasible in 40 percent of the cases due to poor patient recovery (Braunward, 2001).  
When a patient is not responding to other treatments then surgery might be the only 
option. A recent debate that took place at the Service de chirurgie digestive et 
generale, Lille, France argued with little conclusions of whether there was still a place 
for surgery in oesophageal cancer treatment due to the improvements in 
chemotherapy (Mariette, Piessen and Triboulet, 2007). 
As an alternative to surgery, owing to a weakened physical state or advancement of 
disease in the patient, then radiation therapy is an option. Eighty percent of cancer 
sufferers that undergo radiational therapy seemed to be cured of dysphagia, although 
temporarily, and half of these cases may have tumour regrowth in six months 
(Hishikawa et al., 1991).  
If surgery is not possible then a blockage in the oesophagus may be removed using 
laser therapy. A neodymium:yttrium-aluminum-garnet (ND:YAG) laser degrades the 
tissue by using short, one second bursts of high intensity light (80-129 watts). 
Lumenal damage is rare. Repeated treatment sessions may be required, up to 6 times 
(Nava et al., 1989). 
In poor areas such as much of Transkei in South Africa treatment is restricted to 
surgery, due to the high costs of the methods above. Prevention, as in many cases of 
disease, would provide a much cheaper alternative to treatment. 
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 1.6. Epidemiology of Squamous Cell Carcinomas of the Oesophagus 
 
Previously 90 percent of all oesophageal cancer patients had squamous cell 
carcinoma, (Turnbull et al., 1973) although this has changed in the last decade with 
the increased incidence of adenocarcinoma. Men are 4 to 6 times more likely to 
develop oesophageal cancer than women (Office for National Statistics, UK, Cancer 
Statistics registrations, 2004), and it is five times more common in afro-Americans 
(Ferlay, 1992). Most cases of squamous cell carcinomas occur in adults over the age 
of 60. In 2004 in the UK there is a yearly average of 7,400 cases (Office for National 
Statistics, UK, Cancer Statistics registrations, 2007). 
Globally, there is huge variation in prevalence. Incidence is a lot higher in South 
Africa, China, Japan, Switzerland, Iran, France and Finland at 4 to 20 times that of 
other western countries (Franceschi et al., 2000). Within these countries, regional 
incidence may also vary widely (Naidoo & Chetty, 1999). In most countries the 
incidence rates of oesophageal squamous cell carcinoma (OSCC) are around 2.5 to 5 
per 100,000 for males and 1.5 to 2.5 for females (Office for National Statistics, UK, 
Cancer Statistics registrations, 2007), although this can be 100 fold higher in specific 
ethnic groups in certain countries. In Transkei this is around 357/100.000 males aged 
35 to 64 and in Kazakhstan 547/100,000 males aged 35 - 64 (Parkin et al., 2005).  
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 Figure 1.8: Incidence rates for oesophageal cancer in males around the world in 1988 
(taken from Ghandirian et al., 1992) 
 
Figure 1.9: Incidence rates for oesophageal cancer in females around the world in 
1988 (taken from Ghandirian et al., 1992) 
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 1.6.1. Tobacco Smoke and Alcoholic Beverage Consumption  
 
Substantial research points to tobacco smoke and alcohol consumption being the main 
factors leading to oesophageal cancer for both men and women (De Stefani et al., 
1999). Dose dependent studies of the effect of tobacco smoke and the development of 
squamous cell carcinoma have demonstrated a decrease in risk with smoking 
cessation (Choi & Kahyo, 1991). This has also proved true for smokeless tobacco 
products, such as snuff and chewing tobacco (Christen et al., 1989). It has also been 
shown that a moderate intake of beer and spirits increases the risk of oesophageal 
cancer, although this has not been proven in the case of wine consumption (Gronbaek 
et al., 1998). This could be owing to the fact that carcinogens such as nitrosamines 
and polycyclic hydrocarbons have been linked to alcoholic beverages (Cotran, et al., 
1999). The use of tobacco and alcohol together dramatically increases the risk, as 
shown by Castellsague et al. (1999). This group postulated that tobacco has a strong 
role both in the initiation and promotion of carcinogenesis, and alcohol just in 
promotion. A team from China recently examined questionnaires given by over 400 
squamous cell carcinoma patients to conclude that increases in poor diet, smoking and 
alcohol consumption due to cultural changes can be strongly linked to huge increases 
in cancer (Wang et al., 2007). This may partly explain tumour development in the 
western world but a number of papers have shown that in high incidence areas, such 
as Transkei, South Africa, they have little, if any, alcohol consumption related cancer 
(Sammon, 1992). A paper has shown that the white population of South Africa 
smokes more than the black population, but does not have the same incidence of 
cancer of the oesophagus (Rose, 1979). This questions the value of smoking being the 
single powerful carcinogen in this area, but is an additional predisposing factor. A 
positive relationship between smoking and the high incidence areas such as Transkei 
and India has been disputed elsewhere (Ghadirian et al., 1992).  Smoking has been  
postulated as being a carcinogenic factor in the Transkei population (Sammon & 
Alderson, 1998) and one of the factors of the theory developed in this thesis.  
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1.6.2. Dietary Effects 
 
The most common and varied external environmental factors that could be the cause 
of, or connected to oesophageal cancer development and progression must be the 
ingestion of substances, and it is thought that one third of all cancers are related to 
what we eat (Naidoo & Chetty, 1999). Ghardirian (1992) in particular stated that 
populations with a high incidence of oesophageal cancer shared similar diets and 
dietary habits. A German cohort study of over 520,000 people showed oesophageal 
cancer was linked to socioeconomic status due to the patients poor diet (Nagel et al., 
2007). This factor has a major importance on this project as a positive correlation 
between the consumption of maize and oesophageal cancer has been found (Sammon 
& Alderson 1998), discussed below (section 1.9).  
Several epidemiological studies have stated the negative relationship with fruit and 
vegetable consumption and cancer of the oesophagus (Ghadirian, 1992; Gao, 1994). 
An association to increased dietary levels of protein, carotene, vitamins C and E, and 
riboflavin (vitamin B2) found in few meats, fruit and vegetables, and a decrease in 
oesophageal cancer risk is also well documented (Gao, 1994; Block et al., 1992; 
Launoy et al., 1998). This relationship of high vitamin intake lowering squamous cell 
carcinoma oesophageal cancer risk has also been seen with the intake of supplements 
(Barone et al., 1992).  Studies in endemic areas of Linxian, North Central China, 
showed that residents have low blood concentration of beta-carotene, vitamin C and 
riboflavin (Munoz et al., 1982). In some cases high intake of protein with fat, butter, 
eggs and starchy foods have been implicated with an oesophageal cancer increase 
(Franceschi et al., 2000). A high intake of certain meats has been linked to squamous 
cell carcinoma (Brown et al., 1998; Barone et al., 1992; De Stefani et al., 1999). The 
opposite of this has been shown with the intake of monounsaturated fatty acids, olive 
oils (Tzonou et al., 1996) and vitamins (Franceschi et al., 2000) in two Italian studies. 
One study has stated a strong inverse relationship between oesophageal cancer risk 
and consumption of all micronutrients of plant origin (Launoy et al., 1998). Niacin, a 
vitamin heavily associated with poultry and fish, when deficient, can cause 
oesophageal lesions linked to cancer of the oesophagus (Franceschi et al., 1990). A 
Chinese study by Gao (1994) showed that drinking green tea appears to reduce the 
 23
risk of oesophageal cancer, as it is known to contain polyphenols and other 
antioxidants. 
It is not just the consumption of the foods but also how they are consumed that may 
be an underlying factor of oesophageal cancer. A Japanese study of 720 men and 
women showed that those most at risk from cancer of the oesophagus are those 
drinking scalding hot tea (Kinjo, 1998) shown again with hot soups and porridge (Gao 
et al., 1994). N-nitroso compounds used to preserve vegetables and salted foods in 
Chinese high incidental areas were shown in one American study (Bogovski & 
Bogovski, 1981). Although a case control study from Washington suggested the 
opposite of this, and that they protected the aerodigestive tract (Rogers et al., 1995). 
Physical irritants in the Caspian Littoral have been implicated with high risk areas 
such as scratchy breads often contaminated with extraneous seeds such as the 
phalaris. The phalaris seed surfaces contain a large amount of fine fibrous silica 
particles. These silica particles are also seen in human cancer patients and the gullets 
of cancer suffering chickens in China. A possible cause was that the particles are from 
millet bran provide an anchorage for the spread of the growth (O`Neill, 1980).  In 
Transkei, people consume a daily diet of roughly ground maize that has been mixed 
with silica from the grind stone used. It was suggested “an irritant” like silica or even 
the roughly ground maize “may play a part, at least in determining the site of the 
cancer”, hence the ingestion through the oesophagus (Rose, 1979). 
 
1.6.3. Infectious Agents 
 
Human papillomavirus (HPV), Herpes-simplex virus (Galloway & McDougall, 1990), 
cytomegalovirus and Epstein-Barr virus (Chang et al., 1992) have all been implicated 
as a possible cause of oesophageal squamous cell carcinoma, although there is no 
direct proof of this. The data on whether  HPV could be part of carcinogenesis seems 
conflicting (Sur & Cooper, 1998; Monsonego, 1995; Qi et al., 2006). HPV may have 
some action on oesophageal cancer by inactivation of normal p53 function, by the 
binding of E6 protein to the p53 protein functioning as a tumour suppressor. This E6 
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protein has been shown to up regulate the VEGF gene (VEGF suggested tumour 
method explained in section 1.7.1.d) via its promoter region. It has been postulated in 
oral squamous cell carcinomas that the E6 protein in HPV could lead to p53 
degradation (Min et al., 1994; Furihata et al., 1993).  Murono et al. (2001) found the 
Epstein-Barr virus induces COX 2, an important protein relating to this study (section 
1.7.1), and Jenson et al. (1997) found Epstein-Barr virus in small tissue tumours 
induced the epithelium growth factor receptor (EGFR). In the target population of this 
study there are mixed views of whether HPV is prevalent in the South African high 
oesophageal cancer areas. Cooper et al. (1995) found the presence of HPV genes in 
52% of the DNA of 48 archival oesophageal carcinoma biopsies. Van Rensburg 
(1996), using the same techniques, found little relationship between HPV DNA and 
the oesophageal squamous cell carcinoma samples.  
Helicobacter pylori is associated with gastric cancer and is classified as a class 1 
carcinogen by the International Agency for Research on cancer (Jiang & Wong, 
2003). Little proof has come to light as to whether Helicobacter pylori could be a 
factor in the oesophageal squamous cell carcinoma development, although a link may 
occur through gastric infections and reflux shown in adenocarcinoma tissue of the 
stomach (Wu et al., 1996). Calam suggested that the eradication of H. pylori can 
increase the likelihood of oesophagitis developing (1999) which itself has been linked 
to oesophageal cancer development (Rubin & Farber, 1994). An experiment carried 
out by Wu et al. showed that investigating 300 people with and without oesophageal 
squamous cell carcinoma concluded that H. pylori may be a factor in protecting 
against oesophageal squamous cell carcinoma although it is not known why (2006). 
Previously it was suggested that H. Pylori infection may induce atrophic gastritis, 
which results in a less acidic gastric reflux, and H. Pylori may also neutralise gastric 
acid by producing ammonia (Richter, Falk & Vaezi, 1998). One other paper has 
investigated the relationship between H. pylori infection and increasing risk of 
oesophageal squamous cell carcinoma showing a borderline positive result thought to 
be connected to increased intragastric nitrosation (Limburg et al., 2000).  
Gastric tissue in rats treated with H. pylori and bile, promoted COX 2 expression 
compared to controls (jiang & Wong, 2003) and increased levels of prostaglandin E2, 
the product of COX 2 (Al-Marhoon et al., 2004). This would support the Sammon 
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theory explained in section 1.9. Although a study carried out by Sammon in 2003 
stated the results were not significant in the sample population with only half of the 
samples registering H. pylori positive in the 30 samples tested. 
There are a number of fungal and bacterial infections in the oesophagus that have 
links to the aetiology of oesophageal squamous cell carcinoma. Infections by Candida 
species in the oesophagus are by far the most common (Bartelsman & Tytgat, 1991), 
and in China this has been shown to correlate with a degree of dysplasia (Yang, 
1980). On a number of occasions a pure culture of Candida albicans can be isolated 
from hyperplastic epithelium and carcinoma in-situ of the oesophagus (Yang, 1980). 
A bacterium, which is normally present in the upper alimentary tract, may convert 
nitrate into nitrite, which at high levels in saliva have been seen in patients with 
marked epithelial dysplasia and carcinoma (Linxian Research Team, 1978). 
Fungal contamination of foodstuffs like maize, millet and other grains have been 
investigated as a possible cause, mainly in Africa (Marasas et al., 2001) and China 
(Chang et al., 1992). Common species like Fusarium (i.e. Oxysporum) and 
Aspergillus (i.e. flavous) are known to reduce nitrates to nitrites have also been shown 
to decompose proteins and increase the amounts of amines promoting nitrosamine 
formation in China (Yang, 1980). In one study, Alternaria alternata and Penicillium 
cyclopium fungal contaminated cornbreads were fed to rats resulting in the induction 
of oesophageal carcinomas (Zhen et al., 1991). Fusarium moniliforme and Aspergillus 
flavous found in maize of Transkei releases the mycotoxins fumonisin B1 and 
aflatoxin B1, respectively. This has been shown to be closely related to oesophageal 
cancer in these areas (Marasas 1986). Aflatoxin B1 in the contaminated food supply 
in these areas is associated with G:C to T:A transversions leading to a serine 
substitution at residue 249 of the p53 gene in hepatocellular carcinoma (Harris, 1993). 
This research in South Africa is often discussed although little hard evidence of its 
mechanism to increase oesophageal cancer has been published. Isaacson in 2005 
concluded in his review of the subject that more fungal testing of South Africas food 
should be taking place, “If nitrosamines are detected, their carcinogenic potential 
should be studied experimentally. Should these tests prove positive, it would be vital 
to break the Fusarium-nitrosamine-cancer chain”. It is still be discussed whether the 
increase in oesophageal cancer is more about maize consumption and not the increase 
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of mycotoxins found on the maize. The South African Medical Research Council has 
this subject as one of their research areas with little new information.  
 
1.7. Molecular Pathogenesis 
 
The pathogenesis of normal oesophageal tissue to carcinoma via squamous dysplasia 
is a multi-step process and is thought to be driven by multiple genetic events caused 
by continuous exposure to the carcinogens described in section 1.2 (Farber, 1984). 
These genetic changes could be due to oncogenes, the inactivation or mutation of 
tumour suppressor genes, enhanced intracellular transcription or the amplification of 
growth factors and their receptors. Once such changes have taken place then any of 
the following could take place: tumour suppression to a cell may be lost, increased 
cell proliferation, changes in cell death control, changes in cell differentiation, loss of 
cellular cohesion and finally the induction of metastasis mechanisms may occur. The 
molecular control of all of these pathways is being extensively researched to increase 
the understanding of pathogenesis. 
 
1.7.1. Cyclooxygenase 
 
COX is a haem-containing glycoprotein, also known as PG endoperoxide synthase, 
PG synthase or PG G/H synthase. There are two isoforms of COX, COX 1 and COX 
2. 
Although the two enzymes share 60% of the same amino acids, their functions are 
thought to be very different. COX 1 is known as a “house keeping gene” as it 
mediates physiological tissue homeostasis. The main study of COX 1’s biological 
function is through its ability to synthesise cytoprotective prostaglandins in the 
healthy gastrointestinal tract (Flower, 2003), although other areas of its cellular 
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effects such as depression of platelet aggregation are still being researched (Mitchell 
et al., 1993). COX 2 is known as the inducible enzyme, induced by many different 
stimuli such as Interleukins, hormones, oncogenes and growth factors (Tanabe & 
Tohnai, 2002). Due to huge increases in the expression of COX 2 and its production 
of Prostaglandin E2 (PGE2) (the basis of this thesis) it has been linked to 
inflammation (Williams, 1999). However it is also involved in pain, fever, ovulation, 
bone formation and thought to be linked to Alzheimer’s disease, because of the high 
concentration present (Murakami et al., 2001). Much of this is thought to be due to 
PGE2 release (section 1.7.2). While Simmons and colleagues (1999) examined COX 
expression, they came across a COX 1 variant that they have dubbed COX 3, although 
little research has been done on its function in the body. 
The actions of the COX enzymes have been investigated by the use of gene 
transfection and gene knockout in mice (Loftin, 2002) and also COX 1 and COX 2 
specific inhibition. There are many drugs on the market now that are known to inhibit 
COX action, Aspirin being the most common.  Aspirin is known as a non-steroidal 
anti-inflammatory drug (NSAID). It works by suppressing the prostanoid production 
of COX 2 that leads to an inflammation response. One of aspirin’s side effects is the 
development of stomach ulcers. This is thought to come from the inhibition of the 
COX 1 enzyme suppressing its gastro-protective effect. This has led to commercial 
interest in the development of COX 2 inhibitors that can have a suppressive effect on 
inflammation reaction seen in rheumatoid arthritis, without the gastric side effects. It 
has been stated that this industry was worth in excess of US $ 4 billion in the year 
2000 (Merrill Lynch, 2001). Those include drugs like Celecoxib (Celebrex, Pfizer), 
Rofecoxib (Vioxx, Merck), Valdecoxib (Bextra, Pfizer) and Etoricoxib (Arcoxia, 
Merck).  The safety of these drugs has recently been questioned. The FDA in March 
2005 released the following statement: “Based on emerging information, including 
preliminary reports from one of several long term National Institutes of Health (NIH) 
prevention studies, the risk of cardiovascular events (composite endpoint including 
MI, CVA and death) may be increased in patients receiving Celebrex. FDA will be 
analyzing all available information from these studies to determine whether additional 
regulatory action is needed”. This caused the FDA to withdraw the release of these 
NSAIDs until further tests have been carried out. NICE also withdrew Rofecoxib in 
the UK. Therefore a majority of modern research carried out with COX 2 relates to 
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the therapeutic effect of its inhibition and side effects of decreasing PGE2 production 
that leads to inflammation.  
 
 
1.7.1.a.   COX 2 and Cancer 
 
This thesis will be concentrating on the mechanisms of COX 2 and its relationship 
with cancer. 
COX 2, as well as in many other tissues of the body, is found in the gastrointestinal 
system including the oesophagus.  Within the cell, COX 2 functions in the 
endoplasmic reticulum and the nuclear envelope. Over expression of COX 2 was first 
studied in Colon cancer, therefore much of the research has taken place in this field 
(Kawai, 2002). Now a number of studies have demonstrated that COX 2 expression 
was elevated in carcinomas of not only the colon, but, also stomach, breast, lung, 
liver, pancreas and importantly the oesophagus (Yu, 2003; Miyashita et al., 2006). By 
using COX 2 inhibitors, such as aspirin and ibuprofen, in patients with rheumatoid 
arthritis, it was discovered there was a fall in the number of colorectal cancers 
(Giovannucci et al., 1995). This has led to the discovery that COX 2 inhibitors in 
different tissues, such as oesophagus (in both in-vitro and in-vivo studies), have 
shown to suppress cellular proliferation and induce apoptosis, therefore suppressing 
the important factors in cancer genesis (Farrow et al., 1998). Various papers have 
shown how even occasional use of aspirin or other NSAIDs is inversely related to the 
risk of oesophageal cancer: the reduction of relative risk varies from 50% to 90% 
(Altorki, 2004; Funkhouser, 1995). Significant over-expression of COX 2 has been 
seen in cancer tissue. This has been studied and is thought to be related to the grade or 
differentiation of the tumour (Wolff et al., 1998). This has also been shown in 
immunostaining of squamous cell carcinoma of the oesophagus (Zimmermann et al., 
1999). Li et al. (2000) reported that aspirin treatment resulted in significant growth 
inhibition of 10 oesophageal cell lines. Rubio (1984) previously showed that another 
NSAID, indomethacin, suppressed the development of oesophageal cancer induced in 
mice by N-nitrosomethylbenzylamine, a potent carcinogen. Ranka and his team 
(2006) at Norwich University Hospital have shown that NSAID treatment can help 
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protect the oesophagus from cancer by decreasing lower oesophageal sphincter 
relaxation. 
There are many possible mechanisms of how increased COX 2 expression and protein 
could aid carcinogenesis. Due to the COX 2 enzyme having both oxygenase and 
peroxidase functions, one carcinogenic action could be to catalyse the conversion of 
pro-carcinogens to carcinogens. COX 2 activity is thought to be responsible for the 
conversion of the pro-carcinogen benzo(a)pyrene, present in tobacco smoke, into the 
carcinogen of mutagen benzo(a)pyrene diolepoxide (Kelley et al., 1997). Ultraviolet 
B (UVB) light is a risk factor in skin cancer. Irradiation of human keratinocytes by 
30mJ/cm2 UVB light results in a 6 fold increase in COX 2 levels (Buckman et al., 
1998).  
 
1.7.1.b.   COX and Apoptosis 
 
Apoptosis is controlled cell death mediated by the cells to control tissue 
reconstruction and unwanted cells. Between this and cellular proliferation there is a 
fine balance that keeps the tissues at an optimum turn over. Should this balance be 
upset by increasing cellular proliferation or decreased apoptosis it leads to prolonged 
survival of abnormal cells and tumour growth, hence cancer. COX 2 has been 
associated with suppressing apoptosis causing this unbalance. COX 2 concentrations 
have been shown to have a positive correlation with the induction of the anti-
apoptotic protein Bcl-2 and reduce levels of Bax, a pro-apoptotic protein (Li, 2000). 
The suppression of these proteins, by treating with COX 2 inhibitors has been shown 
in a number of tissues, including oesophageal cancer cells (Weitzman & Gordon, 
1990). There are reports that aspirin induces release of cytochrome C, a pro-apoptotic 
molecule, from mitochondria by increasing pore permeability (Zimmermann, 2000).  
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1.7.1.c.   COX and Invasion and Metastasis 
 
Invasion and metastasis are two common characteristics of cancer development. It has 
been suggested that COX 2 activates enzymes that digest the collagen matrix of the 
basement membrane, therefore allowing cells to break off from the main tumour and 
spread to the rest of the body (Tsujii et al., 1997). However, some studies carried out 
in intestinal epithelial cells showed that elevated COX 2 protein levels are related to 
increased adhesion to extra-cellular matrix proteins. This can therefore aid cell 
survival due to stronger adhesion (Tsujii & DuBois, 1995). COX 2 over expression is 
also associated with the induction of CD44, a cell surface receptor implicated with 
invasions and metastasis (Dohadwala et al., 2001). CD44 is expressed in many types 
of migratory cells and metastasis tumour cells. The inhibition of COX 2 in oral 
squamous cell carcinoma cell lines was shown to reduce the expression of CD44, 
hence the invasiveness of the cells (Kinugasa et al., 2004). This is backed by in-vivo 
experiments that have shown COX 2 inhibitors to reduce the number and size of 
metastases in animal experiments (Tomozawa et al., 1999). 
 
1.7.1.d.   COX and Angiogenesis 
 
Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is 
important in tumour genesis, and is required for tumours to grow. This is one of the 
most researched areas of COX 2 and its carcinogenic effects. COX 2 has been shown 
to regulate vascular endothelial growth factor (VEGF), claimed to be the most 
important growth factor in the proliferation of new vascular tissue (Gallo et al., 2001). 
Using COX 2 knock out mice tumour growth, VEGF production and microvessel 
density were all reduced compared to control (Williams et al., 2000). This has also 
been shown in a phase II clinical study, where treatment of COX 2 inhibitors with 
patients that are suffering from lung cancer showed reduced circulating levels of 
VEGF (Ohm & Carbone, 2002). It was shown that in COX 2 knock out mice colon 
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tumours produced few tumours over 1mm thick, this is commonly known as the limit 
tumours can grow to without angiogenesis (Seno et al., 2002). In In-vitro studies, 
hypoxia induces COX 2 that increases the VEGF level inducing angiogenesis. This 
may be the method used by tumours to grow when cells start loosing the ability to 
reach the oxygen due to tumour expansion (Liu et al., 2001), therefore COX 2 aids 
this process. Other pro-angiogenic growth factors in colon cancer have shown to be 
expressed following COX 2 expression. These include bFGF, bFGF-binding protein, 
TGF-β and PDGF (Shiff, 2003) although a small number of papers have been written 
on this. The angiogenesis that takes place from the presence of COX 2 is suggested to 
be a natural response that is required during blastocyst implantation and 
decidualisation, therefore a vascular environment for the nutritional requirements of 
an embryo (Williams et al., 1999). This theory is backed up by the fact that COX 2 
deficient mice show multiple reproductive failures in early pregnancy, such as 
ovulation, fertilisation, implantation and decidualisation (Dinchuk et al., 1995). The 
COX 2 levels would indirectly stimulate natural vascular growth; although COX 2s 
over expression could push the progression of the tumour.  
In February 2004 the FDA approved the use of Avastin (Genentech Inc) for colon 
cancer patients which it thought to work by reducing tumour stimulated angiogenesis 
by inhibiting VEGF. This is marketed in the UK by Roche and is called Bevacizumab 
and was given NICE appraisal in January 2007. 
 
1.7.1.e.   COX and Immuno Suppression 
 
It is for the very same reasons of promoting embryo development through 
vascularisation that COX 2 and prostaglandin E2 (PGE2), its product, are implicated 
with immuno-suppression. PGE2 has been shown to inhibit the production of tumour 
necrosis factor and induces the production of interleukin-10, an immunosuppressive, 
therefore avoiding the attention of surveillance macrophages in the microenvironment 
(Kunkel et al., 1986). COX 2 inhibitors have been shown to attenuate tumours 
through immuno-suppression in vitro (Stolina et al., 2000).  
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 1.7.2. Prostaglandins 
 
Much of the research on prostaglandins are aimed at the manipulation of COX 2 
enzyme, through inhibiting COX 2 by chemical treatment or by using knock out mice. 
The main effects of COX 2 are thought to be due to the production of the 
prostaglandins and one in particular, prostaglandin E2 (PGE2). PGE2 seems to be the 
mediating factor causing the inflammation and induced effects. PGE2 is the most 
common prostanoid studied and is critical for numerous biological processes, 
including inflammation, ovulation, implantation, angiogenesis, platelet aggregation 
and immunologic function (Morita, 2002). These effects are produced via three 
sequential enzyme reactions (Figure 1.10):  
 
• The release of arachidonic acid (AA) (20 carbon unsaturated fatty acid 
distributed throughout the lipid bilayer of the cell) from membrane 
glycerophospholipids by phospholipase A2 (PLA2),  
• Conversion of AA to the unstable intermediate prostanoid PGH2 by 
cyclooxygenase (COX) 
• Isomerisation of PGH2 to PGE2 by prostaglandin E synthase (PGES). 
 
Arachidonic acid (AA) is derived from the essential polyunsaturated fatty acid, 
linoleic acid. This is commonly available in dietary fat. Other than the COX pathway, 
the AA can be metabolised by the lipoxygenase pathway and the cytochrome P-450 
monooxygenase pathway. 
Langenbach showed that the deficiency of COX 2 reduces the levels of PGE2 
production by approximately 75%, while the deficiency of COX 1 reduces PGE2 level 
by 25 %, therefore PGE2 production can still be taking place in the absence of COX 2 
(Langenbach et al., 1999).  
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 Figure 1.10: An overview of prostaglandin synthesis and metabolism (Permission 
granted by Dr J. F. D. Wolff, 2006)  
 
All prostaglandins, including PGE2, are thought to build up within the cytoplasmic 
compartment of the cell. Following enough synthesis, the prostaglandins efflux across 
the plasma membrane to enter the extracytoplasmic compartment, through simple 
diffusion (Schuster, 2002). The PGs can then be transported further a field by 
prostaglandin transporter proteins (Kanai et al., 1995). They are hormone-like, but 
just induce responses via their own receptors (named TP,IP,EP,FP and DP) locally in 
a paracrine or autocrine fashion. Prostaglandins are thought to be produced in short 
bursts in response to specific stimuli. Following stimulation PGs can be detected 
within 10-30 seconds and their synthesis proceeds for 1-5 minutes, followed by rapid 
degradation (Klein, 1990). As prostaglandin has a short half-life and a huge response, 
this acts to restrict effects in the locality of its production. The most typical action of 
these PGs are relaxation and contraction of various types of smooth muscles. PGs 
regulate secretion and motility in the gastrointestinal tract as well as the transport of 
ions and water in the kidney (Narumiya et al., 1999). Plasma levels in humans are 
between 10-100 pg/ml (Leonhardt et al, 1997). PGE2 (3.27 ng/min) and two of their 
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receptors, EP1 and EP3, have shown to be expressed moderately in both the 
oesophagus and the stomach (Sarosiek et al., 1994; Morimoto et al., 1997). Its natural 
action here is thought to be the modulation of inflammatory stimuli, as PGE2 levels 
appear to parallel the degree of tissue damage in acid damaged oesophagus in rabbit 
models. This is also seen in human patients suffering from oesophagus damaged by 
oesophagitis (Ottignon et al., 1987). This natural regulation could be required due to 
pathological substances that could enter with food, or the suppression of 
immunological homeostasis in cases where foods may irritate the gastrointestinal 
system. It is suggested that the PGE2 is trapped within the mucus layer and released 
under the impact of acid and pepsin (Jimenez et al., 1997). One study stated that 
salivary PGE2 concentration increased by 132% when control patients chewed on a 
tasteless parafilm (Sarosiek et al., 2000).  
It is established that PGE2 suppresses the immune system. T-helper lymphocytes 
mediate delayed-type hypersensitivity reactions. PGE2 inhibits T-cell proliferation, 
thought to be a cause of a number of different processes. These include inhibition of a 
required polyamine (i.e. spermine), inhibition of intracellular calcium release, and the 
decrease in protein tyrosine kinases (Choudhry et al., 1999). This is thought to be a 
natural negative feedback response as in inflammation the mucosal T-cells up-
regulate and express EP receptors, reducing the T-cell production (Cosme et al., 
2000). It has been shown that PGE2 induces CD4+ and CD8+ thymocytes to undergo 
apoptosis, both in-vitro and in-vivo (Cosme et al., 2000). It is through this suppression 
of the immune system in times of high PGE2 production, that it is thought that tumour 
cells, would otherwise be destroyed and broken down, can continue to grow which 
increasing mutations and tumour size. 
 
1.7.3. PGE2 and Carcinogenesis 
 
Increases in PGE2 have been shown in colorectal cancer tissue compared to normal 
colonic mucosa (Pugh & Thomas, 1994). An increase in tumour progression from the 
effects of PGE2 have been documented before, where it was suggested that PGE2 
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altered cell morphology and increases cell motility (Gately, 2000). Pharmacological 
inhibition of EP1 and genetic disruption of EP2, two receptors for PGE2, both result in 
a significant reduction of aberrant crypt foci in colorectal cancer tissue (Murakami, 
2002). It has been suggested that suppression of angiogenesis in polyps can be carried 
out by inhibiting the EP2 receptor, which suppresses the release of VEGF (Seno et al., 
2002). Administration of PGE2 to a growing prostate cell line has been shown to 
increase cellular proliferation (as measured by the cell number) (Tjandrawinata et al., 
1997). 
  
1.7.4. p53 and Related Proteins 
 
p53 is a transcription factor tumour suppressor gene, which stimulates DNA repair 
and regulates cell proliferation and apoptosis to prevent the division of potentially 
malignant cells. p53 gene mutations and changes are some of the most common 
aberrations that occur in 40-50 percent of oesophageal cancers. This was 
demonstrated by Hollstein and colleagues (1990) who showed that p53 mutations are 
part of the tumourgenic process of oesophageal cancer, and recently supported by Qi 
et al. (2006).  The p53 gene activates the production of p21, which itself is an 
inhibitor of cyclin and cyclin dependent kinase complexes (Ng et al., 1999). This is 
not expressed if the p53 is in a mutated form (El-Deiry et al., 1993), which has been 
shown in squamous tumours leading to malignant phenotype. This can be reversed 
when wild type p53 is restored (Schantz, 1995). One paper also stated over expression 
of p21 protein in squamous cell carcinoma, was present, even independent of p53 
mutation (Ng et al., 1999). A gene that encodes for a p53 auto-regulatory feedback 
loop protein called murine double minute 2 (mdm2) oncogene has been found, that 
when over expressed stops the action of p53. This leads to malignancies in squamous 
carcinomas (Heinzel et al., 1996).  Ng et al.  (1999) questions whether mdm2 was that 
important in carcinogenesis putting the weighting on p21, as only 20-30 percent of 
SCC cells expressed it. Wales and colleagues speculated in one paper, that there 
might be another tumour suppressor gene similar to p53 such as HIC1 that has a 
larger part in tumourigenesis, although this has not been shown in squamous cell 
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carcinoma (Wales et al., 1995). The absence of p53, another apoptotic protein called 
Bax, and the sporadic expression of Bcl-2 and mdm-2, was reported in a paper several 
years ago, suggesting the link between premalignant and malignant squamous lesions 
(Schoelch et al., 1999). This was backed by a South African research group using 
oesophageal cancer models at the University of the Witwatersrand, Johannesburg (Sur 
et al., 2003). 
 
1.7.5. Growth Factors  
 
Growth factors, as well as other cellular regulation factors, mainly promote 
proliferation of cells by intervening in the cell cycle. If cells are deprived of growth 
factor there will be a senescence and inhibition of growth. This is due to extracellular 
growth factors being specific to their receptors, leading to promotion of cell signal 
pathways to gene expression, notably c-fos and c-jun. This in turn allows cells to 
progress from a non-proliferative state called G0 into the replicative cell cycle, G1. 
The rest of the cell cycle is normally then driven by intracellular processes (Meyers, 
1995).  
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1.7.5.a.   Epidermal Growth Factor 
 
- 
Figure 1.11: Key molecular pathways of cell cycle regulation. Growth factor 
signaling, such as that from EGF, results in the expression of target genes, including 
cyclin genes essential for cell cycle progression. (Pecorino, 2005) 
 
Epidermal growth factor (EGF) is a protein (53 amino acids) with three disulphide 
bonds and two distinct foldings. EGF and its relating growth factors, such as 
transforming growth factor α (TGFα), amphiregulin and cripto have been extensively 
researched (Meyers, 1995). All over the body this growth factor is essential for 
stimulation the cell cycle, hence new tissue proliferation. Should this mechanism be 
over stimulated then this could increase the chances of cancer initiation. EGF is 
secreted with saliva into the gastrointestinal mucosa and oesophageal epithelium, 
attracting research in this area (O’Keefe et al., 1974). In 1989 it was discovered that 
an EGF increase was closely correlated with progression in oesophageal squamous 
cell carcinomas and their prognosis, due to the raised levels from high EGF 
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expression in proportion to the amount of EGF receptors present (Ozawa et al., 1989). 
This has been demonstrated in a number of papers (Cowley et al., 1984; Banks-
Schlegel & Quintero, 1986), although questioned in a number of others (Kamata et al. 
1986; Barnes, 1982) with one stating that EGF is proliferative in-vivo but not in-vitro 
(O’Keefe et al., 1974).  Subcutaneous EGF has been shown to cause oesophageal 
epithelial hyperplasia in pigs and rats (Juhl, 1995). EGF treated vascular smooth 
muscle cells have been shown to induce COX 2 mRNA and the COX 2 protein (Pash 
& Bailey, 1988). This has also been reported with EGFR, a receptor commonly over 
expressed in oesophageal cancer (Mestre et al., 1997). It has been demonstrated that 
EGFR is present in ten times the concentration in oesophageal squamous cell 
carcinoma than gastric cancer cells. EGFR is commonly over expressed in 71% of 
oesophageal squamous cell carcinomas (Stemmermann, 1994). It has been suggested 
that this up regulation of ligand and receptor found in carcinomas could be one of the 
major causes of epithelial cancers (Stemmermann, 1994). A team in Japan have 
examined a potential new drug called Gifitinib that inhibits the tyrosine kinase 
pathway down stream from the EGFR, inhibing the growth of squamous cell 
carcinoma cell lines (Teraishi et al., 2005). 
 
1.7.5.b.   Hepatocyte Growth Factor (HGF) 
 
Hepatocyte growth factor (HGF) is a 105 kDa protein known for its mitogenic action 
on hepatocytes (Takada, 1995). HGF, also known as scatter factor, is a 
multifunctional heterodimeric polypeptide that binds to the cMet tyrosine kinase 
receptor (Bottaro et al., 1991). Some of these functions include the growth and 
scattering of various cell types (Bottaro et al 1991), promotion of angiogenesis (Rosen 
et al., 1993) liver generation, and wound healing (Burr et al., 1998). HGF has been 
suggested to have an action in gestation, as high HGF has been found in embryonic 
tissues (Chan et al., 1988). The HGF and its receptor function almost exclusively in 
close proximity to tissues. The HGF is released from the cells in a paracrine and 
autocrine method stimulating localised tissue only (Di Renzo et al., 1991). The cMet 
receptor has been shown to be present in rabbit oesophageal epithelial cells, and HGF 
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stimulated restitution in these cells (Takahashi et al., 1995). Jimenez et al. (1998) also 
showed how HGF can stimulate cell restitution in damaged rabbit oesophagus 
epithelium. Takada et al. (1995) stated that the average HGF levels in a normal 
sample were 80 ± 183 ng/100 mg protein from the normal oesophagus mucosa. They 
found mean levels of 600 ± 416ng/100mg protein in carcinoma tissues; a significant 
increase. It has been suggested that autocrine stimulation of the cMet receptor from 
HGF, induces amplification of cMet, therefore having positive feedback characteristic 
(Boccaccio et al., 1994). It has been demonstrated in human gastrointestinal tumours 
that the cMet gene, coding for the HGF receptor, can be over expressed (Kuniyasu et 
al., 1992). Naughton et al. showed that HGF serum levels are increased in men with 
prostatic cancer, implying that it may be a potential tumour marker (Naughton, 2001). 
Prostaglandins have been shown to induce HGF expression in gastric fibroblasts in-
vitro (Takahashi et al., 1995). It was also demonstrated that HGF induces COX 2 
expression in gastric epithelial cells in-vitro (Jones et al., 1999). Baater et al carried 
on this research, to show how Celecoxib (a COX 2 inhibitor) significantly suppresses 
cMet mRNA increased in rat oesophageal ulcer healing by the treatment with acetic 
acid (Baater, 2002). Therefore, autocrine cMet stimulation could lead to constant 
epithelial stimulation aiding in carcinogenesis. 
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1.8. History Of The Epidemic Squamous Cell Carcinoma In South Africa 
 
1.8.1. Transkei 
 
 
 Figure 1.12: This figure shows where Umtata, the Transkei capital, a 250km square 
region is in South Africa (World Atlas, 2002) 
 
Transkei, the area shown surrounding the capital Umtata, is a rolling grassland area of 
South Africa covering about 16,000 square miles (Rose, 1982). This starts from the 
Drakensberg Mountains down to the Indian Ocean coastline, itself extending 250km. 
There is a subtropical climate with nearly all of the rain falling in the summer months 
of October to March (Sammon, 1999). 
Transkei has a population of around two million people, who are predominantly 
Xhosa (the X in English is swapped for a C and a distinctive click sound). They owe 
their origin to the East African migration of Nguni people. Sotho speakers make up 
four percent and Zulu speakers make up the remaining one percent of the population 
with very few Caucasians. Migrant labour, subsistence farming and limited industry is 
the main employment. A number of men will work for one to two year spells for 
“white” South African farmers to support the family. A significant percentage of the 
Transkei populations live in poor conditions with many people to a hut, without 
sanitation or clean water.  
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Umtata is a large city towards the south of Transkei consisting of 100,000 people with 
a bustling town centre. The general hospital and the University of Transkei offer the 
samples and local scientific expertise for this project (Sammon, 1999). 
 
1.8.2. Local Squamous Cell Carcinoma  
 
In Transkei, oesophageal cancer is the most common malignancy encountered in men 
(Naidoo & Chetty 1999). An estimated 20 percent of men will be affected by the 
tumour before the age of 75 years, if other causes of death are excluded 
(Environmental Associations with oesophageal cancer in Transkei (E.A.O.C.T) 1979). 
In Transkei 357/100,000 males aged 35 to 64 suffer from oesophageal cancer (Parkin 
et al., 2005). It was virtually unknown before 1940 for an epidemic of oesophageal 
cancer in black South Africans, although there seemed to be massive increases after 
1949. This could be linked to either poor diagnosis, or increased risk factors. A local 
study in Natal found an association between oesophageal cancer and socioeconomic 
status, associated with lower social status and less education (Van Rensburg et al., 
1985). This therefore makes a good sample population to study the causes of 
oesophageal cancer, since discovery of an obvious common predisposing factor 
should aid oesophageal cancer research worldwide. However, it seems unlikely that a 
single etiological factor can account for such ranges in incidence rates (Parkin et al., 
1988) and with the oesophagus mucosa being in direct contact with so many 
environmental factors, a plethora of factors could be the cause of pathogenesis. 
Over the last century the spread of maize as the main crop over Africa has taken 
place, which along with bread, margarine, beans and pumpkin, forms the staple diet of 
Transkeians. Maize is a high yield crop, which grows easily in relatively poor soils. 
This diet is sometimes supplemented with meat and garden vegetables (Sammon, 
1999). Maize is used in many forms to produce drinks and foods. Maize consumption 
has already been connected with high incidence areas of Africa for oesophageal 
cancer (Van Rensburg, 1987). All oesophageal cancer patients in significant papers 
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used both maize and beans, identifying the “at risk” group as being users of this staple 
diet (E.A.O.C.T, 1979; Marasas et al., 1988).  
Heartburn was seen in 60 percent of individuals in a study in Transkei people, who 
see this symptom to be normal following a meal and do not seek medical attention for 
it. Heartburn was commonly accompanied by a symptom strongly suggestive of 
gastro-oesophageal reflux, namely the regurgitation of fluid into the mouth following 
the ingestion of umqa wethanga and amarewu (maize based foods). When the patients 
were given aspirin the heartburn was abolished or alleviated (Sammon, 1994).  
Oesophagitis (inflammation of the oesophagus) has been reported in the high 
oesophageal cancer incidence areas, seen in 84 percent of one sample population in 
Linxian, China (Munoz et al., 1982). In Johannesburg, 28 children that had died 
between the ages of 2 and 18 years had their oesophagus examined, to find 15 had 
non-specific oesophagitis characterised by atypical basal cell hyperplasia (Hamilton 
& Issacson 1985). Rose found inflammation of the oesophagus in cases negative for 
oesophageal cancer in post mortems of Transkei people. However, there are no 
numbers in this paper to base any conclusions on (Rose, 1982). 
Smoking tobacco and alcoholic beverage intake, as mentioned in section 1.6.1, is 
linked to cancer and is just as significant in Transkei, where home grown tobacco has 
been shown to have a higher mutagenic potency than commercial tobaccos 
(E.A.O.C.T, 1979). There are three arguments questioning whether tobacco could be 
the sole factor in oesophageal cancer. 
• Smoking has been common for over a century (Van Rensburg, 1981), but the 
disease appears to be relatively new major cause of local death.  
• Significant papers have shown a sizeable amount of non-smokers affected by 
oesophageal cancers (Sammon, 1992; Van Rensburg et al., 1985).  
• Van Rensburg shows that the total mean quantity of tobacco used in nearby 
Natal is considerably less than used in rich western communities where 
oesophageal cancer is rare (Van Rensburg, 1981).  
In the endemic areas of Transkei, there has been no connection between oesophageal 
cancer and alcohol abuse (Rose, 1982; Sammon, 1992). A difference between high 
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and low incidence areas were that in high incidence areas a majority of the traditional 
beer produced used maize instead of malt (Bradshaw, et al., 1983). Therefore tobacco 
and alcohol use could be predisposing risk factors, although the evidence does not 
point to these being the sole factors of carcinogenesis. 
 
1.9. The Sammon Theory 
 
1.9.1. Basis of the Theory 
 
Alistair M. Sammon, with the help of colleagues, over the last ten years of working in 
the U.K. and in Africa, postulated a theory on the carcinogenesis of squamous cell 
carcinoma oesophageal cancer in “black” South Africans, in 1998 (Sammon & 
Alderson).  
He stipulated that there might be four factors associated with the endemic squamous 
cell carcinoma: 
• Heavy dependence on a maize based diet over a very long term 
• Slow rise in incidence 
• Relative poverty 
• Tobacco use at a high-risk level. 
The first three factors are all related, as the slow rise in SSC over the last fifty years 
seems to have a relationship with the increase use of maize. This itself has become a 
primary component of the Transkeian diet, due to poverty in the area. The link 
between oesophageal cancer and tobacco use is well documented and is likely to be 
part of the carcinogenic process (Fig 1.13).  
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This theory is split into three parts: 
• A high level of linoleic acid ingestion via maize is associated with increased 
prostaglandin E2 production in the stomach. Other dietary factors increase this 
effect. 
• PGE2 inhibits gastric acid secretion and reduces the tone of the pyloric and 
lower oesophageal sphincters, resulting in a chronic alkali duodenogastro-
oesophageal reflux (DGOR). 
• Chronic low-acidity DGOR predisposes to squamous carcinogenesis. 
 
1.9.2. Prostaglandin E2 Production in the Stomach 
 
 
Figure 1.13: A diet based on maize with deficiency of other elements will lead to high 
prostaglandin E2 production and a chronic low acid oesophageal reflux, with 
consequent predisposition to cancer (Sammon & Alderson, 1998) 
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 Van Rensburg (1981) concluded that prolonged exposure to maize is greatly linked to 
oesophageal cancer. In a latter paper Van Rensburg et al. (1985) explains how the risk 
changes for various forms of maize ingested due to linoleic acid release in the 
stomach. Maize oil is rich in linoleic acid and very low in other essential fatty acids. 
Dupont (1990) stated that 59 % of corn oil is linoleic acid. Whole kernels are poorly 
digested releasing little oil in the stomach. Stamped maize has the oil-containing husk 
removed and provides no linoleic acid at all. These two are shown to be low risk for 
oesophageal cancer. Conversely, Maize meal provided all the linoleic acid to the 
stomach in an easily digestible form. Consumption of maize meal has been shown in 
Italy to be linked to high-risk areas (Rossi et al., 1982). It has been proved that 
Linoleic acid is a prostaglandin (PG) E2 precursor and when a high linoleic acid diet 
is fed to a rat, there is an increase in gastric prostaglandin E2 (Schepp et al., 1986). 
PGE2 production is promoted by lack of dietary fatty acids which cause competitive 
inhibition (Raederstorff & Moser, 1992) and riboflavin deficiency, (Pelliccione et al., 
1985) which can be seen in the Transkeian diet. Riboflavin deficiency has also been 
implicated with oesophageal cell proliferation and dysplasia (Munoz et al., 1987). 
Dietary linoleic acid in one study was shown to be an immunosuppressive, therefore 
linked to the PGE2 immuno suppression discussed above (Bennett et al., 1987; 
Sammon, 1999). Sammon has suggested this may be the cause of another common 
disease in South African children that present a low immune system, called 
kwashiorkor (1999).  
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1.9.3. The Implication of Increased PGE2 . 
 
 
Figure 1.14: Reflux of a high pH and ingestion of protease inhibitors ensure excess 
growth factor activity in the oesophagus. (Sammon & Alderson 1998) 
 
As stated before, heartburn is very common in the Transkei area, affecting 60 percent 
of the local healthy people following a meal (Sammon, 1994). Increased PGE2 affects 
two things; it causes a reduction in the lower oesophageal and pyloric sphincter 
pressures (Milenov & Golenhofen, 1982; Hausken et al., 1991), and reduces basal and 
stimulated gastric acid output (Schepp et al., 1986). These could well be the 
underlying factors causing the heartburn via an increase in oesophageal reflux of 
gastric fluid of reduced acidity. Sammon, along with Iputo and their team (2003), 
measured the pH of fasting gastric fluid in the sample population. They discovered a 
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bi-modal distribution of pH peaks at 2 and 7. The lower pH group equates to a 
relatively normal pH distribution. The higher pH group was significantly associated 
with maize consumption.  
 
1.9.4. Chronic low –acidity DGOR predisposes to squamous carcinogenesis 
 
Various studies have shown that duodenal regurgitation into the oesophagus, in rats 
and partial gastrectomy patients can be the cause of squamous cell carcinoma (Seto et 
al., 1991; La Vecchia et al., 1994), which itself could be connected to the reflux of 
high pH into the oesophagus. PGE2, which could be in the reflux, has been shown in 
rats to promote oesophageal carcinogenesis (Shimizu, 1986). It is this DGOR that 
could be the key to the carcinogenesis. In the gastrointestinal tract over expression of 
Epidermal growth factor (EGF) and transforming growth factor (TGF) α, which are 
normally products of the salivary glands, oesophageal mucosa and stomach, has been 
linked to proliferative drive and carcinogenesis (Yoshida et al., 1990). These growth 
factors are partly or wholly inactivated by the enzymes trypsin (Marchbank et al., 
1995) and pepsin at a low pH (Playford et al., 1995). Therefore a DGOR of high pH 
gastrointestinal fluid could inactivate these enzymes, allowing the growth factors in 
the reflux and salivary growth factors to remain active. The growth factors may then 
cause carcinogenesis directly or via pre-disposition, which could be born from a 
proliferative drive. Beans and pumpkin are the staple diets of many Transkeians, these 
has been postulated to contain trypsin inhibitors, therefore, large amounts of growth 
factors are not naturally broken down, increasing this local proliferative drive 
(Bradbury et al., 1985). The vegetable solanum nigrum used in Africa has been shown 
to contain a pepsin inhibitor (Akhtar & Munir, 1989), also shown to be connected to 
cancer of the oesophagus (Sammon, 1992). It has been demonstrated that bile acids 
can induce COX 2 expression and PGE2 production, therefore increasing any 
carcinogenic effect they may already have in the oesophagus (Li, 2000). 
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1.10. Aims and Objectives 
 
1.10.1. Aim 
 
The literature reviewed so far suggests that generally, oesophageal cancer may have 
many causes and contributing factors. However, the rise in incidence in Transkei in 
parallel with other factors suggests a particular mode of carcinogenesis in this region, 
as postulated by the Sammon theory.  
The aim of this project is to investigate the Sammon theory (Sammon & Alderson, 
1998) at a molecular level with the intension of providing evidence to support a link 
between diet and predisposition to cancer through PGE2 and its molecular pathways 
in the population of Transkei, South Africa rather than the commonly researched 
Western World.1
 
 
                                                 
 
1 The Sammon theory (section 1.9) forms a basis of how epidemiological factors could lead to 
increased cancer progression, it is of major importance to update this research with an investigation of 
the target population and further investigate the carcinogenesis of this oesophageal cancer. This 
increases the breath of understanding of how the disease initiates and ideally its prevention. Treatment 
is expensive and labourous; making is difficalt to afford in Transkei a more cost effective approach 
needs to be investigated. 
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1.10.2. Objectives 
 
• Observe and understand a rural South African population and evaluate any 
risk factors that may predispose oesophageal cancer and have not yet been 
tested in present theories. 
• Extend the present theories of the development of oesophageal cancer in the 
target population and provide a novel understanding to how these factors 
affect the expansion of carcinogenesis in cells, at a molecular level. 
• Discover whether gastric fluid from the sample population has a mitogenic 
potential in-vitro and investigate what may cause this effect, if it occurs. 
• Develop an in-vitro model to manipulate proteins that may drive this 
mitogenic force in oesophageal squamous cell carcinoma. 
• Investigate how specific dietary components in the sample population may 
modulate the increased proliferation of oesophageal cancer through the in-
vitro model. 
• Evaluate whether or not this research supports the Sammon theory of whether 
PGE2 is the major factor in the development of oesophageal cancer, and 
therefore give evidence and understanding as to why this may be the case at a 
molecular level. 
• Suggest cost effective methods to help the target population suffering from 
oesophageal cancer. 
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 2. A Study of the Sample Population  
 
2.1. A Study of the Sample Population 
 
2.1.1. Introduction 
 
An understanding of the target populations’ difficulties at a local level was important 
due to the sample population inhabiting an area quite different to the UK in terms of 
social and financial status, environment, and health care. It was hoped that the 
questioning of local people would help the epidemiological aspect of the project. 
Hence a greater understanding of incidence and aetiology would facilitate theory 
development for the rest of the project. This is of generic importance for oesophageal 
cancer throughout the world, as from population to population the molecular biology 
changes may be very similar.  
 
2.1.2. Methods  
 
The methods used were general observation, questioning, note-taking, photos and my 
personal diary taken throughout the trip. The majority of the questions were asked of 
Mr Sammon, with whom I travelled. He had spent much of his time there for the last 
ten years. Some information has been asked of the local inhabitants, hospital staff, 
university staff and students. The following chapter is written from my personal 
experiences. 
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 2.1.3. Results and Discussion: Experiences of Transkei and Local Questioning  
 
The journey took us from Johannesburg airport, in the North of South Africa, on a 
drive to Umtata, Transkei in the south (Eastern Cape) of the country. This took two 
days in a car with an overnight stop off at Pietermaritzburg. This gave a chance to 
take in the rich culture of South Africa and gain a better picture of the land. During 
this journey, to and from Transkei, we visited hospitals and health centres that have 
been set up by Christian missionaries, again to gain a clearer understanding of the 
social situation of the South African population, hence, potential cancerous factors. 
 
2.1.3.a.   General Impressions of the High Incidence Areas 
 
It has been widely published that Transkei is the worst affected area for oesophageal 
cancer in South Africa (Burrell, 1962; Rose, 1979; Rensburg, 1987). Sammon found 
that the disease mainly affected rural people, principally the poor who own and farm 
land, but not the very poorest that have no income. This was reported in previous 
papers. A case-control study by van Rensburg (1985) of Zulu men, showed that most 
affected were in a transitional state between tribal subsistence farming and Western 
living. Cancer of the oesophagus patients in Durban were found to have more 
schooling and speak English more often than lung cancer patients (Bradshaw, 1968). 
Rose (1979) has reported that semi-westernisation was an apparent risk factor in 
Transkei.  
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This raised three points to question:  
• Was the risk factor related to items that someone with a small disposable 
income may be able to afford, that some one very poor could not? 
• Is there is an occupation health risk?  
• Do the people with a little education have more confidence to approach the 
often “politically white” medical centres to gain a diagnosis? 
These three items have been woven into the findings and experiences below and will 
be commented on later. 
According to the local medics it was commonly thought that the South East of 
Transkei, near Butterworth, has been more affected than the Northern part (Jaskiewicz 
et al., 1987). This has been questioned because of the different recording methods 
taken of disease from different medical services, and the way they are recorded in 
different ways.  
The Northern areas also seemed to have large “white” farming areas that employ the 
local “black” communities for labour. Perhaps in Southern regions that have not had 
to rely on this income due to the food availability of the coast, having greater 
independence from the “White” farmers. This increases the cultural gap between the 
two races. This highlights further questions, as when evaluating the areas of high 
oesophageal cancer incidence, are these a real representation of the high oesophageal 
cancer areas, or do people respond differently to medical research depending on their 
culture clashes. For example, are the local population going to trust and respond 
honestly with the often Caucasian sampling scientists, due to previous political 
mistrust? This presents a number of social-political issues that cannot all be addressed 
here due to the biological scientific nature of the project. Therefore it is to be made 
clear that all of the factors raised have been reviewed with social issues in mind. 
It was asked if there were poverty stricken areas, or whether there were areas that 
people healthily lived in and due to “non-western influence” they are misinterpreted 
as poverty areas. The general response seemed to be that there was genuine poverty 
there. In Mr Sammons experience of people in the townships, they knew how to eat 
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properly, and wanted to eat properly, but did not have the money to buy fruit, 
vegetables or adequate protein sources. 
People with a lack of income seemed more apparent when we travelled south, out of 
the city of Umtata on the few hours of journey towards to the coast. Many families 
seemed to have come to depend on the now dying trade of the tourists who travel to 
the coast. They were selling nuts, fruits and items made from shells and empty cans 
by the side of the road, and when the car was stopped, people seemed desperate to sell 
these items sometimes surrounding the car. This could have been a sign of poverty or 
a tourist sales technique. The array of foods on offer seemed limited and the people 
occupying the areas seemed more spread out, but still with limited land, due to a 
majority of surrounding area being owned by rich caucasian South Africans and used 
for farming. 
This may suggest that the food available in these high incidence areas is limited to 
what the locals grow themselves. They also have limited access to health care. Nearer 
the coast, where the incidence levels decrease, there seemed to be more western 
development where tourists had once regularly visited in large numbers before the 
change in the political situation and public perception of South African areas being 
unsafe. 
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2.1.3.b.   Landscape and Vegetation 
 
  
Figure 2.1: Left: Photo taken from the road two hours drive north east of Umtata of 
the Drakensberg Mountains (Ukhahlamba - the Barrier of Spears). Right: Photo taken 
from the Umtata hospital over looking the valley of Umtata. 
 
The area was visited in May, which is classed as winter. The weather was cloudy with 
mixed rain and sun. There were vast amounts of vegetation, but even in winter the 
plants were yellow and dried out from droughts of the rest of the year. The plants that 
did appear to be green are hardy vegetation that cannot be eaten. This may cause 
malnutrition problems if the population rely on the vegetation and self grown 
produce. Much of northern and central areas of South Africa seemed to be well 
farmed with plenty of produce like sugar beet. This is mainly owned by the caucasian 
farmers and many of the poorer “black” people from the townships have worked for 
them during certain crop picking and sowing seasons and then return to their family 
following the work. With so much political change, Mr Sammon with whom I 
travelled stated that many of these farms seem to be reducing in size and productivity, 
therefore having income issues on the workers that have learnt to rely on this finance.  
Tarmac roads were used to drive south rather than the usual dust roads, which maybe 
financed by the richer farmers indirectly through there tax income, therefore it is in 
unfair to say these green fruitful vegetation, the roads on which we through, are 
typical of Northern South Africa where oesophageal cancer is not as prevalent as that 
found in Transkei. A study by Jaskiewicz and colleagues (1987) showed variation 
within the Transkei area, with a higher incidence in the south-western districts than 
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the north-eastern districts, but all had very high cases of oesophageal cancer (Makaula 
et al., 1995). 
Driving south it was apparent that the areas were very dry and there were many signs 
of where locals have burnt massive areas of the dry vegetation to make way for new 
growth. Even though the plants, in the picture (Figure 2.1, Right) taken from the damp 
hills of Umtata, appear very green they are not a representation of the dry and dusty 
crop fields that can be seen in the distance and in the other picture taken north east of 
Umtata (Figure 2.1, Left). The lands can be dusty for around 6 months a year; this 
presents an environmental issue that may affect the oesophagus through irritation. 
When asking if there were many cases of hay fever, which has been implicated with 
PGE2, cases were not reported, as large amounts of pollen are not present. 
 
2.1.3.c.   Housing and Families 
 
There was a huge variation in the social and economic status of the various 
populations in South Africa.  Many of the townships have developed small shops and 
built their own economy through help from governmental schemes. This has increased 
income allowing families to produce different products to trade, increasing the 
variation of items like different food groups in poverty suffering areas. Many of the 
townships driven through represented small dusty busy villages with market areas of 
apparently healthy happy people rather than the often-perceived shantytowns. 
The people that have a higher economic status tended to live in brick housing, very 
much like a basic three bedroom bungalow seen in the United Kingdom. Many of the 
people in the townships used to live in the traditional huts, but now live in more 
modern “tin houses”, so called because of the thin metals they are made from. 
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Figure 2.2: Left: Photo taken an hour drive south of Umtata but very typical of the hut 
housing that many townships are made up of. Right: Photo taken of the houses around 
the hospital of Umtata typical of the newer tin housing that is replacing the traditional 
huts. 
 
There do not seem to be any essential health hazards of living in the housing and they 
appeared clean and dust free. Less family members live together in the houses than a 
few decades ago. Many have between two and five children per family. The houses 
are much more communal than expected in western society, where all the young 
brothers will share one part and the sisters another. There are many single parents for 
various reasons that including parents travelling to find work or death by diseases 
such as AIDS. Traditionally the women would have worked in the fields although 
nowadays there is a chance that in large populated areas they will have a paid job. 
Examples of this include local shop work, and employment in schooling and health 
centres. 
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 Figure 2.3. Photo taken from the road in the north of South Africa of a tin house 
township, now typical round the developed cities with large populations like here near 
Johannesburg. 
 
Up to a few decades ago there were no toilets and people used to use the fields. Little 
black pigs were plentiful and tidied up afterwards. Now there appears to be quite a 
number of pit toilets. The source of the bathing water would previously have come 
from the nearby rivers, but the cities for several years have had running water taps 
piped in. Traditionally the unmarried girls collected the water from the nearest river or 
lake. There seemed to be no tradition of treating or boiling the drinking water. 
 
2.1.3.d.   Health 
 
There are about thirty rural hospitals in Transkei staffed by doctors, each with a 
system of surrounding health clinics run by nurses. This means that everyone in 
Transkei is less than two hours away from receiving medical attention. Some local 
people also use two kinds of traditional healers: Witchdoctors and Herbalists. The 
witchdoctors depend on a spiritual content to their approach, with divination by 
throwing bones, and casting spells and curses. Some witchdoctors use medicines, 
although it was not asked about their content. Herbalists treat with locally grown 
plants and have no significant spiritual content to their approach. Due to the small 
percentage of people using these methods for healing they do not appear to be the 
single significant cause of the oesophageal cancer epidemic.  
 58
When asked if the traditional cultures are scared of going to seek medical attention, 
the general response was no, but they do tend to only see the nurse when the 
symptoms are greatly developed. This presents a problem in oesophageal cancer due 
to the fact that symptoms tend to present at a late stage of tumour development, when 
swallowing is affected. 
There are a number of prolific diseases more prevalent in South Africa than most 
western countries: Tuberculosis and AIDS are rife. According to the National 
Department of Health, 25.2% of the population in the Eastern Cape have both 
tuberculosis and AIDS together (The 1997/8 Annual Report; Strides and Struggles in 
TB Control, DOH, RSA). 
There are a moderate amount of sexually transmitted diseases. Malnutrition is also 
common. There are lots of gut parasites – roundworm particularly. Hepatitis is 
common as shown by the majority of people having antibodies to Hep A and many 
with antibodies to Hep B (Sammon – Personal communication). Following a review 
of the papers there does not seem to be a link between the presence of Hepatitis and 
oesophageal cancer. 
Ikhelebha is an acute inflammation and ulceration of the lower lip seen in the sample 
population. This has been linked to a time of the year when vegetables are scarce 
leading to riboflavin deficiency (Jackson, 1952). 
As PGE2 is linked to giving birth by modulating contractions and baby development 
then it was asked if they have many problems with child development and there did 
not seem to be any more reported than the rest of the world. 
When asked if there were any factors that are exacerbated by poverty the only answer 
was that of health caused by malnutrition and increased cases of tuberculosis (TB).  
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2.1.3.e.   Exposure Risk Factors 
 
There was a lot of exposure to smoke in most traditional Transkei huts. These huts 
had a fire in the middle of the floor but no chimney, the smoke just dissipated up 
through the roof. Some unpublished work carried out by Mr Sammon looked at the 
relationship between open fires and oesophageal cancer, but he failed to find any 
correlation (Sammon – personal communication). 
Relating to occupational threats, a high amount of silicosis and TB has been seen due 
to many of the Transkeians having worked in mines. Again there are many farming 
jobs where there is high contact with open fires. 
A large number of the local community standing around in the town appear to smoke, 
although this could be a poor representation of the community as a whole. Sammon 
stated that around 72% of the patents with cancer of the oesophagus in the Transkei 
area smoked tobacco, compared to 53% without oesophageal cancer who did not 
smoke (Sammon, 1992). Many of the educated students and staff at the university said 
they did not smoke. Therefore smoking appears to be a significant local risk factor for 
oesophageal cancer. A high percentage of the cancer suffers do not smoke, 
questioning whether this is the single most important factor in carcinogenesis, 
although not ruling out a multi-factorial approach. 
 
2.1.3.f.   Food 
 
Mr Sammon provided much of the following information of the food groups and their 
descriptions.  
Many of the foods consumed in the locality contain maize meal in one form or 
another. This appeared to be a staple diet since the 1940s and several cooking 
methods have been developed to exploit maize for recipes, meals and drinks.  
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Many of the most common meals are explained below. 
 
The three main foods consumed: 
• Maize – This is eaten as whole kernels, stamped or ground.  
• Lima Beans 
• Flat white pumpkin and Usolontsi – Locally grown pumpkins 
Other foods 
• Umqa Wethanga – Maize meal and white pumpkin cooked together and 
eaten in the form of a mash. * 
• Amarewu – Non- alcoholic drink made by fermenting maize flour and wheat 
flour * 
• Imithwane – Relish made from green pumpkin leaves  
• Animal fats – Saved following slaughter 
• Sour Porridge – Maize meal porridge left to naturally sour or soured with 
herbs 
• Wild Vegetables and herbs – African spinach (amananthus), Nettles 
(Chenopodium), Irwabe, Umsobo (solanum).  
• Xhosa beer – Traditionally made from millet, but now made with maize. 
• Meats – Cattle, Goats and sheep depending on the wealth of the family 
Commercial food items that are slowly becoming popular: 
• Bread 
• Holsum – A commercial cooking fat made from 95% fish oil 
• Sunflower Oil 
• Margarine 
 
Items that are no longer being extensively used: 
• Sorghum 
• millet 
* Mr Sammon said these are being commonly blamed for heartburn. 
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Self-induced vomiting (cleansing as it was known) and regurgitation following a meal 
was said to take place more than once a week, this seemed common in much of South 
Africa.   
The regular food habits for the majority seemed to consist of maize porridge in the 
morning and stamped maize and beans in the evening. Maize beer is the usual 
alcoholic drink, but this is not generally consumed in large amounts.  
The foods often seemed spicy and some of the teas I was offered seemed to contain 
high amounts of cinnamon, which can cause a burning sensation on the throat. 
Although none of these meals gave an impression that they would cause physical 
irritation, the plants solanum nigrum and chenopodium album are both used in 
cooking and have been previously related to oesophageal cancer (Sammon, 1992). 
 
2.1.4. Further Discussion 
 
Although there seem to be a number of issues that may well effect carcinogenesis of 
the oesophagus in the local population, there were few new factors that could be 
identified. This may be due to the short stay during my visit, problems with not being 
able to speak Xhosa, and the number people not speaking clear English. Some locals 
may mistrust the “white” population because of local politics (personal stories of 
violence were shared), and many scientists use these target populations as a study, 
taking samples but never returning with further help and findings. It was apparent that 
in the main population there was a lack of understanding of health issues and 
understanding of disease, similar to the lack of education found in western poverty 
areas. The human resources that could help educate people about detection of early 
symptoms are stretched and are busy educating people about more common killers 
such as AIDS and its prevention. One of the main issues to prevent the development 
of cancer in a patient is catching the disease before it metastasizes. Therefore it is 
important to diagnosis cancer before it develops too far, but locally many patients 
only seek medical attention when the symptoms are advanced making cancer 
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treatment and prevention almost impossible, and the prevalence increase. In addition, 
local medical services are stretched; as trained staff gain experience many move on to 
areas where they can receive increased wages abroad or in the cities like Durban, 
Cape Town or Johannesburg, sending money home. 
One issue was concerning the population with a small income, rather than none, that 
seem to be affected by oesophageal cancer more. There does not seem to be any 
obvious occupational health risks and it was mentioned that people with all education 
levels use the medical facilities available. However, many health centres can be up to 
two hours away which may take all day to reach if you do not have transport, so this 
may not always be used if people fear they will loose their income for the day as a 
result. The most evident reason for increased prevalence in this subset of people may 
be linked to individuals being able to justify spending the extra income on smoking, 
presenting an additional risk for cancer development. 
There did not seem to be a “single” social factor that could be an obvious cause of 
cancer other than the lack of dietary variation. This may be due to lack of money to 
buy the right tools for irrigation systems like those found in the green farms in 
northern areas of South Africa. This leaves large farming areas dry, cracked and 
damaged such that few plants that can grow to support the large populations found in 
many areas. Therefore, many of the foods available in such areas were reliable, 
moderately fast growing crops such as maize. There is an obvious concern in the area 
about lack of varied diet especially for their children, but little money to do anything 
about it. This, along with lack of education about the spread of disease, prevalent 
smoking and common bile regurgitation seem to be obvious cancer predisposing 
factors to be investigated further. Although these areas have never been rich, the 
problems may have worsened with changes in politics, decreases in tourism and an 
increasing population. There are occupational risks stated above though they would 
only affect a small number of people. There are many common diseases in these areas 
but little research shown any relationships between oesophageal cancer and these 
diseases, such as Tuberculosis and Hepatitis other than the predicted decreases in the 
immune system having a knock-on effect.  
There is a great deal of information to be collected and case studies to be carried out 
to discover the connection between the components of the poverty areas, and its 
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malnutrition, and the relationship with oesophageal cancer. For the purpose of this 
project this information was used to understand the history of the samples and suggest 
further work, but could not directly shed light on the aims and objectives of this 
project other than it is likely that we are dealing with a multifactoral affect resulting 
from these often poverty stricken factors. 
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 3. The Expanded Sammon Theory and its Molecular Implications 
 
3.1. Introduction  
 
It was important at this stage to collate the present peer reviewed research to 
investigate the process of molecular carcinogenesis of oesophageal squamous cell 
carcinoma in the target population. This was to bind the knowledge of the previous 
peer reviewed research in chapter 1, and the observations of the population studied in 
chapter 2. Figure 3.1 was therefore composed, along with the relevant references to 
provide my interpretation of the Sammon theory (Sammon & Alderson, 1998) 
explained in section 1.9. Figure 3.2 then looks further into the cellular interaction of 
some of these components of interest in this project and how they may be driving this 
tumourigenesis.  
The experimental work of this thesis was based on testing individual areas of this 
predicted molecular carcinogenesis of oesophageal cancer shown in Figure 3.1. A 
large amount of the time was spent on the development and understanding of these 
theories, for example transposing environmental factors in this target population to 
molecular factors that could push the progression of cancer from hyperplasia to a pre-
malignant state. This was not just through literature review but through oral 
communication of scientists at conferences, student think-tanks and feedback of 
presentation of the work. This was important to solidify, develop and peer review the 
theories.   
Due to the novel aspect of this research some components of the theory have been 
developed using research papers of other tissue types and populations. Therefore the 
references have been colour coded to show what has been peer reviewed in the target 
population and tissues, and what has not. 
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Figure 3.1: Developed theory of the carcinogenesis of oesophageal squamous cell 
carcinoma in the target population with the knowledge of the previous peer reviewed 
research in chapter 1, and the observations of the population studied in chapter 2. 
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Abbreviations 
 COX 2 – Cyclooxygenase 2, PGE2 – Prostaglandin E2, LOX – Lypoxygenase, 
NDGA - Nordihydroguaiaretic acid, HPV – Human Papilloma virus, NSAID – Non 
steriodal anti-inflammatory drugs. 
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16. Schmassmann et al., 1997 (gastric) 
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3.1.1. Development of the Sammon Theory 
 
Over the first twelve months of the project the theory pictured in Figure 3.1 was 
developed, by reviewing available literature (section 1.7), local work (section 1.8 and 
1.9) and studying the target population (Chapter 2).  This shows the complexity of the 
Sammon theory, when a number of carcinogenetic factors that have been peer 
reviewed are added. To simplify Figure 3.1 it has been split into two sections, 
increased proliferation on the left-hand side and decreased apoptosis on the right-hand 
side, two of the most common characteristics of cancer tissue. This thesis investigates 
proliferation caused by increased dietary PGE2, therefore the molecular components 
that drive this proliferation have been further reviewed and their connections linked in 
Figure 3.2. The production of PGE2 can take place via three enzymic pathways: 
Cyclooxygenase (COX), Lypoxygenase and the p450 enzymes. A majority of the 
research published in this area has investigated COX 2. COX 2 has become an 
exciting and popular enzyme to research, not only due to its suppression leading to 
tumour suppression, but the large financial gains manipulation can bring (section 
1.6.1). 
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Stated in the Sammon theory one action of PGE2 maybe to relax the oesopho-gastric 
sphincter, allowing gastric reflux (Figure 1.13). The oesophageal damage seems to 
mainly arise from the squamous tissue, progressing to squamous cell carcinoma. Once 
the hypo-acidic reflux has washed through the oesophagus the Sammon theory 
predicts that the increase in pH is not optimum for the action of the natural enzymes 
that breakdown the growth factors present, allowing them the drive further 
proliferation. Due to the very short half life of growth factors this is unlikely. Also 
repeated growth factor stimulus in normal cells would cause receptor desensitisation 
through changes in the G protein response. It may be postulated that this reflux 
promotes further growth factor release, stimulation or activation, in other ways 
increasing the overall proliferation of the oesophageal tissue. It is probable that the 
PGE2 and growth factor interaction is essential in the carcinogenesis of squamous cell 
carcinoma in this target population, by researching the expression of these growth 
factors following treatment of the predicted components of the gastric reflux could 
help investigate the Sammon Theory.  
Following the visit to South Africa it is obvious that there are factors that could 
promote oesophageal squamous cell carcinoma carcinogenesis. These may include the 
side effects of diseases like AIDS, Hepatitis B, gut parasites, HPV and tuberculosis 
perhaps by the inhibition of the immune system suppressing cancer protection. Many 
cancer researchers in South Africa believe that aflatoxin from mouldy maize is the 
leading carcinogen, and as reviewed in the introduction this research is still primitive 
but may be an inclusive factor. It is clear that there is not a single major factor that 
could suggest the development of oesophageal cancer.  
The hyper proliferation that maybe driven directly or indirectly by the PGE2 would 
provide the right environment for initiation of carcinogenesis to develop and the 
factors mentioned above may progress this carcinogenesis further. Hence, decreasing 
the rate of hyper proliferation may reduce the incidences of oesophageal cancer in the 
target population. This provided the first area of investigation. 
The gastric fluid samples were tested for PGE2 content and mitogenic activity on 
oesophageal cell lines, should the PGE2 content be high and cellular proliferation 
increased, then time could be spent on researching any proliferative proteins involved. 
The obvious proliferative proteins are growth factors (section 1.6.10), therefore 
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developing the theory shown in Figure 3.2, based on the interaction of growth factors 
and PGE2, the product of COX 2. 
 
3.1.2. The Cellular Components and their Predicted Interactions in the 
Development of Oesophageal Carcinogenesis Examined in this Research 
 
From Figure 3.1 factors were selected and investigated in order to develop a 
molecular basis for the hyperplasia in the Sammon theory. In Figure 3.1 all the 
components between the high maize diet box and the increased PGE2 box have been 
investigated and peer reviewed in the target population. Therefore it was important to 
carry out some fundamental research studying any proliferative affects of PGE2. If 
PGE2 has a proliferative effect on the oesophageal cells, then the cause of  this 
cellular drive, and potential therapies could be investigated. 
It is commonly known that growth factors drive cellular proliferation. A large number 
of studies have addressed the subject of growth factors in oesophageal tissue, and 
investigated the effects of EGF (Juhl et al., 1995; Jankowski et al.,1992; Jimenez et 
al., 1998, Fosslien, 2000; Pai et al., 2002). A study by Abiru and colleagues (2002) 
showed how non-steroidal anti-inflammatory drugs (NSAID) such as aspirin, inhibit 
the invasiveness of HGF. Jones et al. (1999) showed that HGF triggers activation of 
the COX 2 gene in rat gastric epithelial cells, through activation of the ERK 2 
signalling pathway. Gastrin, a component of gastric fluid, was shown to increase the 
expression of COX 2 and HGF in gastric tissue (Konturek et al., 2003). In 
oesophageal tissue it was shown that inhibition of COX 2 suppressed ulcer repair by 
inhibition of ulceration triggered HGF receptor induction (Baater et al., 2002). 
Therefore HGF seems a key growth factor to research in the current project. By 
measuring the HGF expression and protein content in the oesophageal cell lines then 
the effect that treatment of these with PGE2 has may add additional value to this 
investigation (see chapter 7). Both EGFR and VEGF are two of the major factors in 
the development of carcinogenesis (sections 1.7.5.a and 1.7.1.d). This has provoked 
companies such as Merck to develop anti-colonic cancer drugs that interact and stop 
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the action of these growth factors. Bevacizumab (successfully known as Avastin in 
the USA) is an antibody based VEGF inhibitor and Cetuximab is an antibody based 
EGFR inhibitor. EGFR is commonly over-expressed in oesophageal cancer (Mestre et 
al., 1997). It has been claimed that VEGF is the most important growth factor in the 
proliferation of new vascular tissue (Gallo et al., 2001). A study into the effect of 
Hypoxia discovered that induced COX 2 increased VEGF levels that induced 
angiogenesis (Liu et al., 2001).  
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Figure 3.2: Part of the molecular carcinogenesis of oesophageal cancer to be 
investigated in this research. 
 
This postulated carcinogenesis opens many areas of research to help answer why 
PGE2 produced due to a high maize diet may have a proliferative effect on the 
oesophageal tissue and its links to cancer in the target population. The following 
chapters will deal with small areas of this theory. 
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 4. Gastric Fluid Sample Collection From the Sample Population of Transkei 
 
4.1. Sample Collection 
 
4.1.1. Introduction  
 
Once there was an understanding of the sample population and theory development, 
then samples could be collected to investigate the molecular aspects of the dietary 
effect on the oesophageal cancer.  
 
4.1.2. Methods / Results: Ethical Approval and Sample Collection 
 
Ethical approval was agreed by the Research Ethics & Biosafety Committee, 
University of Transkei for the taking of the samples for oesophageal cancer related 
investigations within Transkei. The ethical committee cleared the use of these samples 
in UK under the agreement that the samples are not used for any other work (refer to 
appendix B for agreed ethical approval by the Research Ethics & Biosafety 
Committee, study information sheet and patient agreement form).  
The samples for investigation were gastric fluid samples taken by Prof. Iputo and his 
team from visitors to a health centre in Umtata, Transkei, South Africa, under ethical 
conditions. Patients were excluded who were smokers, had symptoms of upper 
gastrointestinal disease or were receiving non-steroidal anti-inflammatory drugs. An 
explanation of the research and the use of samples were given to the sample donors in 
their own language (Xhosa). The patient forms were then explained to the patient and 
a signature or fingerprint, depending on their literacy, was given to show 
understanding and agreement to the use and collecting of gastric fluid samples. A 
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dietary study using these samples was performed which indicated that maize was a 
large component of their daily diet (Sammon et al., 2004). 
A hollow rubber medical tube was closed at one end, with small perforations in the 
bottom of tubing, and was connected to a syringe at the other end. The tube was 
swallowed and some gastric fluid was sucked back up the tube using the action of the 
syringe before the tube was removed. The samples were transported in liquid nitrogen 
and stored at –40oC. The samples were kept in 2ml eppendorf tubes, wrapped in 
parafilm and placed in two seal-it bags. These were packed in dry ice in a domestic 
cooler bag, and placed in a domestic food cooler box. The samples were driven for 36 
hours, picking up fresh dry ice after 24 hours, to an airport. The samples were loaded 
in baggage and travelled on an aeroplane for 10 hours. It was noted that the sample 
cooler box was found opened on the baggage carousel at London without the packing 
ice bars from the top. These travelled for a further two hours until reaching a –80 
freezer for permanent storage. 
As the samples were also taken for ongoing investigations undertaken by the 
University of Transkei the sample number was restricted to the samples that they had 
more than 1ml, allowing further studies to carry on in Umtata. By carrying out 
preliminary studies with the small but significant number of samples in the UK the 
concept was if there was time then return and increase research progression by 
teaching other students cell biology and molecular laboratory techniques that they 
could use on the rest of the samples. This dictated the sample number to 24 samples. 
The analysis of whether this sample size was enough is evaluated in the following 
chapter.  
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 Figure 4.1: An example of the syringe and tubing used to take the gastric fluid 
samples. 
 
4.1.3. Discussion 
 
There are several factors, which may affect the investigation of gastric fluid samples. 
Although the samples were kept on ice or dry ice throughout the journey from Umtata 
to Johannesburg, by the time the airport was reached much of the dry ice had melted 
relying on the ice blocks to keep the sample cool. Although guaranteed by the check 
in-staff that the samples were to be kept as “fragile”, the sample were opened in 
London and arrived at room temperature. This may well have had a detrimental effect 
on the samples as the proteins in these samples will denature at higher temperatures. 
This means that the content of the samples may not be a true representation of the 
composition of gastric fluid in the sample population. Further testing was required to 
test the detrimental effect that this could have on the samples; this is described in the 
next chapter (Section 5.2.1).   
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4.2. Setting Up a Cell Culture Lab in South Africa. 
 
One aim of the visit to South Africa was to work with the University of Transkei to 
enable them to continue investigations along a similar line to the work carried out in 
England using cell culture techniques. At the University of Transkei I was based at 
the Biology Laboratories where someone had previously set up a cell culture lab, but 
it was not known if it had actually been used. To enable this facility to be ready for 
use, the following was carried out: 
 
• The lab was washed and cleaned with solvents. 
• Windows were air sealed. 
• Filed protocols and information sheets on equipment based on those used in 
the Cranfield laboratories were introduced 
• The equipment was tested and a list of additional required equipment was 
produced 
• Suppliers were contacted to provide catalogue information on products, 
costing and delivery methods. 
• Reagents already available were organised and the required health and safety 
documentation produced. 
 
  
Figure 4.2: Photos taken of the University of Transkei cell culture laboratory when 
ready for use. 
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 The laboratory was clean and ready for molecular work. As no cell lines were found, 
the concept was, should available funds become available, I would return with 
donated cell lines and teach other students any molecular methods carried out on the 
samples. After some unsuccessful applications for grants this did not take place.  
 
 76
5. The Measurement of PGE2 Concentration in Gastric Fluid Samples  
 
5.1. Introduction 
 
Due to the large number of risk factors shown in Figure 3.1, it is important to 
investigate these factors one at a time. Specific to this population, the Sammon theory 
is based on the increased production of PGE2 following increased ingestion of maize. 
Therefore the in-vitro investigations were initiated to develop the molecular aspect of 
the theory.  
As discussed in the introduction (section 1.6.8), increases in PGE2 have been 
implicated in the increased cellular proliferation of colorectal tissue as well as 
affecting other tumorigenic factors. Therefore, PGE2 concentration measurements of 
the gastric fluid samples were the initial route of investigation. As the journey of the 
samples may have had a detrimental effect on the PGE2 concentration, it was 
important to study this possible affect by replicating the conditions endured by the 
samples during the journey, using substitute saliva samples.  
Statistical analysis was carried out on the power of the sample number and whether 
there was confidently enough for the studies. This was achieved by analysing the 
PGE2 concentrations of the samples as the statistical variable, as this was the basis of 
the research using these samples.  
Throughout this chapter, increases in cell number or proliferation will be referred to 
as cell growth. This does not refer to the size of the cells but to cell number. Also the 
phrase “western diet” is referring to a population that ingests a full varied diet of all 
food groups including various fatty acids, where there is a lower prevalence of 
squamous cell oesophageal cancer. 
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5.2. Method 
 
For measuring PGE2 concentration, a competitive ELISA was used in a kit format 
produced by R&D Systems (Oxon, UK). Unless stated the component composition 
was not disclosed by the manufacturer. Duplicate samples were diluted 10-fold in the 
assay buffer provided in the kit. Eight PGE2 standards were produced at, 5000, 2500, 
1250, 625, 312, 156, 78 and 39 pg/ml.  
The 96 well-plate was supplied pre-coated with goat anti-mouse polyclonal antibody 
(R&D systems). For each well 100µl standards and samples was added. In to these 
wells 50µl PGE2 antibody conjugated to alkaline phosphatase was added, with 50µl 
anti-PGE2 mouse monoclonal antibody, all provided in the kit. The plate was 
incubated for two hours at room temperature and washed three times with the wash 
buffer provided in the kit (composition not given). Of the buffered p-nitrophenyl 
phosphate, 200µl was added to each well and incubated for one hour at room 
temperature. The optical density was then read at 405nm using an ELISA plate reader 
(MRX, Dynex technologies, Worthing UK).  
 
 
Figure 5.1. Binding scenarios of the competitive ELISA used and the various controls. 
The mouse antibody binds to the PGE2 goat anti-mouse antibody absorbed to the 
     Normal assay        Non specific binding       Max binding       Total activity 
Goat anti-mouse antibody        Mouse antibody          PGE2 in sample          PGE2 labelled with enzyme            Substrate 
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plate, to amplify the signal. The PGE2 in the sample and the PGE2 bound to the 
alkaline phosphate competitively bind to the goat antibody. When the p-nitrophenyl 
phosphate substrate was added to the buffered solution this gave a coloured reaction 
relating to the amount of the enzyme-bound PGE2 present. This signal is inversely 
proportional to the amount of PGE2 in the sample. 
The average non-specific binding control (assay minus antibody), minus optical 
density average from each sample was calculated. This was divided by the maximum 
binding average (everything but sample) multiplied by 100 to achieve the percentage 
of maximum response.  
 
5.2.1. Measuring PGE2 Concentration Changes in the Samples Following the 
Journey from Umtata, South Africa to Bedford, Great Britain.  
 
An evaluation of what affect the three day transportation would have had on the PGE2 
concentration of the gastric fluid samples. Table 5.1 shows the conditions under 
which the samples traveled and the conditions used the reproduce this journey.  
 
5.2.1.a.   Substitute Sample Preparation 
 
 
Substitute samples were created by chewing on parafilm, to induce saliva, and spitting 
into a 15ml tube. This was then aliquoted into four 2 ml tubes and labeled 1-4. Tubes 
labeled 1 & 2 were spiked with 0.005 µg/ml of PGE2 and 3 & 4 were untreated. Using 
the PGE2 ELISA kit (Figure 5.1) these samples was measured for PGE2 concentration 
while fresh. All the samples were placed at -80oC, similar to that of the gastric fluid 
samples. Samples 1 and 3 were left here while samples 2 and 4 underwent the 
treatment replicating the conditions endured by the samples during the journey, 
explained in Table 5.1. After the ‘Journey conditions’ were simulated the samples 
were measured for PGE2 content again. 
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5.2.1.b.   Information asked and answered by specialists about conditions the 
samples would have experienced on the airplane 
 
 
To reproduce the flight journey, information was required on the conditions the 
samples would have undergone. This includes the expected conditions experienced in 
an aeroplane flight. To gather this information questions were asked of two specialists 
in aircraft design (see appendix D for full questions and answers): 
  
• Professor John Fielding, Head of Aerospace Engineering Group, School of 
Engineering, Cranfield University. 
• Dr Craig Lawson, Airframe Systems Design, Aerospace Engineering Group, 
Power, Propulsion and Aerospace Engineering Dept., School of Engineering, 
Cranfield University 
 
The results from these were used to produce the methods for the following section. 
 
5.2.1.c.   The conditions the samples experienced and the methods used to replicate 
these conditions. 
 
 
Table 5.1: The conditions the samples experienced and the methods used to replicate 
these conditions. The conditions with a * are following the advice of the aircraft 
design specialist. 
 
The Samples Journey from Umtata, 
South Africa to Bedford, UK 
The Methods Used to Reproduce these 
Conditions 
The samples were wrapped in parafilm, 
placed in 2 seal-it bags. These were 
placed on dry-ice and placed in a 
domestic cooler bag and placed in a 
cooler box – 20-23oC for 24 hours 
The samples were wrapped in parafilm, 
placed in 2 seal-it bags. These were 
placed on dry-ice and placed in a 
domestic cooler bag and placed in a 
cooler box – 20-25oC for 24 hours 
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 The dry-ice was replaced after 24 hours 
and travelled for another 24 hours at 
around 20-23oC 
The dry-ice was replaced after 24 hours, 
and left for 24 hours at 21oC. 
The samples sat at the airport for 3 hours 
before the flight  
The samples sat at 21oC for 3 hours. 
On the plane for 11 hours The samples sat in a cool greenhouse at 
15oC for 11 hours* 
The samples could have been opened at 
customs and spent 30 minutes open on 
the carousel 
The samples were unpacked and left open 
in 21oC for 45 minutes. 
The samples travelled for 3 hours packed 
up in a car and then placed in -80oC 
The samples were packed up and stored 
at 21oC for 3 hours and placed in -80oC. 
  
 
5.2.2. Analysis of the Sample Size 
 
The analysis of sample number to predict valid conclusions required statistical 
analysis undertaken on the PGE2 concentrations of the samples. This was carried out 
using a statistical computer package called Statistica 7 (Statsoft Ltd, Bedford). A two 
–tailed (one sample mean) t-test was carried out on the PGE2 concentration results 
shown in Figure 5.3. This was chosen so either a positive or negative deviation from 
the hypothesized value could be declared significant. By analysing changes in sample 
distribution the power of the sample results was provided. This information was used 
to provide the required sample number confidently to a selective level. 
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5.3. Results 
 
5.3.1. The PGE2 Concentrations of the Gastric Fluid Samples 
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Figure 5.2: Typical standard curve taken from the average of two replicated wells for 
each standard, corrected by subtracting the non-specific binding results. From this the 
concentrations of the samples can be deduced from the optical density values. 
 
Using the standard curve in Figure 5.2 from the results given by the PGE2 ELISA kit 
the sample concentrations were calculated and are given in Figure 5.3.  
When the samples were first taken, the research team at the University of Transkei 
measured the PGE2 concentration of the samples by the same method (denoted 
‘Original Concentration’). Both of these results were compared to an average salivary 
O
ptical D
ensity (non-spec binding 405nm
) 
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PGE2 sample taken from a control group who consumed a regular western diet 
(Sammon and Morgan, 2002). 
 
 
Figure 5.3: PGE2 concentrations in gastric fluid samples taken from 24 individuals of 
the Transkei population, comparing measurements shortly after sampling in South 
Africa (Blue) and later taken following traveling 48 hours from South Africa at room 
temperature packed in bubble wrap and a domestic freezer box, followed by storage at 
-80°C prior to analysis (Green). 
 
Figure 5.3 shows that the PGE2 concentration of the samples after transportation and 
storage is much lower than the original PGE2 concentration, for all cases. The average 
PGE2 concentration of the samples before the transportation was 65571.67 pg/ml and 
606.8 pg/ml after.  However, they are still all above the average salivary PGE2 
concentration from a sample population from the UK who consume a regular western 
diet. This suggests an increased PGE2 concentration in this population.  
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5.3.2. The Detrimental Effect of Sample Transportation from Transkei, South 
Africa to Bedford. 
 
Explained by the methods in section 5.2.1.c an experiment was undertaken to 
reproduce any detrimental effect the journey from South Africa to Bedford would 
have on the samples. This was carried out by measuring changes in the PGE2 
concentration before and after travel conditions (Figure 5.4) and by looking at the 
effect this has on cellular growth changes explained in the chapter 6. 
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Figure 5.4: PGE2 Concentrations in PGE2 spiked and unspiked saliva before and after 
a journey conditions model using four repeats in a PGE2 ELISA Kit. Fresh refers to 
the PGE2 content straight after preparation. Frozen refers to the samples that where 
kept at -80oC throughout the replicated sample journey. After flight model refers to 
the PGE2 content of samples that were treated with a similar detrimental method of 
that of the original gastric samples.  
 
It is clear from Figure 5.4 that the PGE2 content within the samples has decreased 
significantly following the reproduced journey. Smaller amounts of PGE2 seem to be 
more resilient to the detrimental effects of the journey. 
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 5.3.3. Statistical Analysis of the Sample Size 
 
Using Statistica 7 (Statsoft, Bedford) a two-tailed t-test was carried out on the PGE2 
concentrations of the gastric fluid samples, these were analysed to measure the power 
of the sample size2. The statistical workings of this are in the appendix F.  
The statistical parameters used in this t-test: 
 
• Null Hypothesized Mean (Mu0) = 312  
• True Population Mean (Mu) = 606.8 
• Population standard deviation = 196.06 
• Confidence interval = 95% 
• Power Goal = 90% 
Therefore estimated sample size = 7 
 
 
 
                                                 
 
2 Under the direction of Charles Marshell, Cranfield Uinversity Statstition and checked by Dr Heather 
Whittaker, Lecturer/Research fellow, Dept. of Statistics, Open University, Milton Keynes. 
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Figure 5.5: The sample size required of the gastric fluid samples to achieve a specific 
power goal. 
 
Given the confidence level of 95% and a power level of 95% it can be stated that the 
24 samples used in this study are enough samples to research the PGE2 effects of the 
samples. 
 
5.4. Discussion 
 
This chapter has provided information on the three important factors concerning the 
required validity of the gastric fluid samples for this investigation allowing research to 
progress:  
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• Whether the gastric fluid samples contain the postulated high PGE2 content, 
therefore the right variable for this study.  
• The detrimental effect of transportation. 
• Whether the sample size is adequately significant to form valid conclusions.  
The results shown in Figure 5.3 suggest that the target population has a higher content 
of PGE2 in its gastric fluid compared to a “western” population, assuming salivary 
PGE2 concentration is similar to gastric fluid PGE2 concentrations, as discussed 
below.  
Shown in Figure 5.3, following transportation, all samples appear to have similar 
PGE2 concentrations, compared to the large changes in PGE2 concentrations seen for 
some samples before transportation. Figure 5.4 also shows a similar pattern. 
Compared to before and after the transportation method, the concentrations appear to 
fall to a certain concentration. It may be that a percentage of the PGE2 proteins are 
more stable, perhaps bound to their transporter proteins (MRP4, ABCC4) (Ruis et al., 
2005). This requires a deeper investigation, and presents a very interesting possibility. 
This would have implications with the PGE2 activity in-vivo. Klein (1990) stated that 
following stimulation PGs can be detected within 10-30 seconds and their synthesis 
proceeds for 1-5 minutes, followed by rapid degradation. It may be suggested that 
repeated reflux or localised PGE2 release in the oesophagus would be required to 
provide enough time for the PGE2 to have a direct effect on the squamous cells, due to 
protective mechanisms (further explained in chapter 6). The more stable protein 
transporter bound PGE2 proteins proposed would change this pattern. PGE2 in gastric 
reflux could wash around the oesophagus for longer periods of time. When a bolus of 
food removes the protective mucus layer this could allow a greater chance for PGE2 
squamous cellular binding. However, should the PGE2 be bound to a stabilising 
protein this may not necessarily affect the stimulatory PGE2 action, as long as the 
receptor epitope is free for receptor binding leading to secondary responses. 
Primarily, this basal level of PGE2 was thought to be due to regular release from 
cellular production but the gastric fluid samples will not have any live protein 
producing cells., supporting PGE2 stability.  
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A literature search on prostaglandin stabilisation found that Aoyama et al. (1990) 
discovered that the half life of prostaglandin I2 (similar to PGE2) was stabilised by 
apolipoprotein A-I (Apo A-I). Apo A-I is a major apolipoprotein of high density 
lipoprotein. Apolipoprotein synthesis in the intestine is regulated principally by the 
different fat contents of the diet and is implicated in heart disease, by being associated 
with the metabolism of cholesterol fats (Eichner et al, 2002). Apo A-I bound proteins 
were stabilised for up to 90 minutes compared to one to six minutes without. The 
PGE2 and prostaglandin I2 have very similar structures, produced by from 
Prostaglandin H2 both produced by COX 2 (Figure 1.9), therefore both could have 
stabilising proteins. Eichner et al. (2002) state there is a relationship between 
apolipoproteins and fat in diet, although this needs more work. Should the high maize 
diet be producing these fats, then this could drive the PGE2 effect further.  
The aims of this thesis are to work on samples from the Transkei population. A 
similar study comparing samples of a population ingesting a ‘western’ diet would 
offer further insights into why oesophageal cancer is higher in the target population.  
No studies investigating ‘normal’ PGE2 gastric fluid concentration have been found. 
However, a study by Sammon (2002) did compare salivary PGE2 in a UK population, 
and the same Transkeian population investigated by the current study. Sammon found 
content between 733 and 2357 pg/ml in the Transkeiain population with an average of 
just 312.5 pg/ml (94.5 pg/ml in the author’s saliva shown in Figure 5.4) in the British 
participants. This suggests that there could be a similar difference in PGE2 
concentration between the two populations’ gastric fluids, if not greater; this is likely 
to be due to diet.  Combining Sammons results, and those in this study would suggest 
that the PGE2 concentrations are higher in this sample population than a population 
ingesting a “western diet”.  
It was important to quantify the PGE2 in these gastric samples to provide confirmation 
that PGE2, a suggested proliferative component, had not been destroyed by 
transportation. The study on the effect the journey had on the samples showed the 
PGE2 would have decreased over this time period. Figure 5.4 shows that the PGE2 in 
the spiked saliva samples decreased to around half that of the samples that had been 
kept in the freezer. This explains why there is such a drop in PGE2 concentration of 
the same samples shown in Figure 5.4 before and after the transportation. This 
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however, does not invalidate the samples as the PGE2 levels are still higher than that 
expected in a subject consuming a low maize diet. These samples are important to 
show the mitogenic effect they may have on oesophageal cells. From these results it 
can be suggested that the gastric fluid samples could contain around double the 
amount of PGE2 and its affects had the samples been kept frozen 
Statistical analysis of the results took place to justify whether enough samples had 
been tested to gain a high enough confidence level. These results, using the two-tailed 
t-test, concluded that sufficient results were present. 
In summary, should the above results be a true representation that the PGE2 gastric 
fluid content is higher in the Transkei population (Figure 5.3) than that of a “western 
diet”, and the Sammon theory (see Introduction: section 1.9) be true in that increased 
PGE2 levels in the gastric fluid relax the smooth muscle controlling the gastric 
sphincter (Sammon, 1998), then these results would support the theory as to why a 
large number of the sample population suffer from constant regurgitation and sickness 
(referred to as ‘cleansing’ locally). This ‘cleansing’ typically follows a maize meal, 
which forms the major proportion of the target population’s diet. The high gastric 
PGE2 concentration and daily regurgitation into the oesophagus would result in 
frequent high concentrations of PGE2 in the oesophagus, especially following every 
meal of food containing high amounts of the PGE2 precursor, linoleic acid, such as 
maize.  
These assumptions suggested the subsequent investigation into the effect this 
increased PGE2 concentration may have on oesophageal cells. This may support the 
link between increased PGE2 concentrations in the stomachs of the Transkei 
population, with a high maize diet, and high rates of cancer. The next step was 
therefore to look at the proliferative changes to squamous oesophageal cell lines as a 
result of increased PGE2 concentration and the gastric fluid samples. This can be used 
to investigate changes in the cellular growth and hyperplasia, and as a precursor of 
oesophageal cancer in this population.  
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Summary of results supporting suggested theory: 
• Despite the effects of transportation in decreasing PGE2 concentration, reasons for 
their validity have been outlined. 
• The sample number was significant. 
• The results suggest that PGE2 levels are higher in the present gastric fluid samples 
from the target population than previously recorded PGE2 levels in samples taken 
from a population on a “western diet”. 
• Stable PGE2 levels may suggest that a protein present has a protective effect 
allowing longer periods of stimulation. 
• These results with studies described in Chapter 2, would suggest that these high 
PGE2 levels in the gastric fluid would reflux into the oesophagus, washing over 
the squamous cells following every regular maize meal. 
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Figure 5.6: The Sammon Pink theory and how the research to this point supports it. 
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 6. The Development of an In-vitro Model to Investigate the Effect of PGE2 on 
Oesophageal Cells. 
 
6.1. Introduction 
 
Prior to studying the effects that the individual components of the gastric samples 
may have on cells, an investigation of the samples as a whole and whether they have a 
mitogenic effect (an increase in cellular proliferation), was undertaken. This approach 
is beneficial, as we know that the causes of cancer are multi-factorial, so we can take 
a multi-factorial approach to investigating cellular effects prior to analysis of 
individual components.  As the main element that is postulated to have the mitogenic 
effect is PGE2 (section 1.7.7), then the treatment of the cellular model with various 
concentrations of PGE2 should also provide information on what could be the 
underlying pathway leading to increased cellular proliferation as a precursor of 
oesophageal carcinogenesis.  
An in-vitro model was developed to look at the effects of modulation of PGE2 
concentration and the gastric fluid samples on cellular proliferation and the expression 
of proteins, which function downstream of PGE2. This would provide a molecular 
basis for the study. 
In chapter 5 a study took place to replicate the affect transportation had on the PGE2 
content of the samples travelling from Transkei, South Africa to Bedford, UK. Using 
the in-vitro model in this chapter the affect the transportation had on stimulatory 
growth effect of the samples was studied.  
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6.2. Methods and Materials 
 
Following optimisation of methods on untreated cells, viable cell counts, the MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) cell proliferation assay 
and a colourimetric BrdU incorporating assay were used to investigate the 
mitogenicity of gastric fluid samples on cells. These were chosen as they are ‘gold 
standard methods’ of evaluating cell growth without use of radioactive substances, for 
which facilities were not available. 
 
6.2.1. Cellular Models 
 
Two oesophageal cell lines were investigated, both grown in flasks at 37°C in 5% v/v 
CO2.  
The Het1A cell line was purchased prepared from the American Type Culture 
Collection (ATCC) (Washington, USA) provided with the following information not 
carried out in this study.  
“This originated from a 25 year old black male’s squamous epithelium of the 
oesophagus following autopsy in 1986. Epithelial outgrowths were sub-cultured and 
then transfected by strontium phosphate co-precipitation with plasmid pRSV-T 
consisting of the RSV-LTR promoter and the sequence encoding the simian virus 40 
large T-antigen. Following 6-8 months of growth a colony was isolated which has 
remained non-tumourigenic in athymic, nude mice for more than 12 months. 
Karotyping of the cells showed that they are hypo-diploid (34-40 chromosomes). 
Het1a is stimulated by Ca2+, and inhibited by transforming growth factor-beta 1, and 
transforming growth factor-beta 2 (Stoner et al., 1991)”.  
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The Oe21 cell line was purchased prepared from the European collection of cell 
cultures (ECACC) (Porton Down, Wiltshire, UK) provided with the following 
information.  
“These are known as JROECL21, was taken from a 74 year old Caucasian male 
patient’s squamous cell carcinoma of mid oesophagus in 1993. The tumour was 
pathologically staged at IIA (Union  Internationale  Contre  le  Cancer (UICC))  and 
showed moderate differentiation. The cell line was established from the mincing and 
digesting the tumour samples in Dulbecco’s modified Eagle medium (DMEM). These 
were left to grow in tissue culture Petri dishes and collagen-coated standard Petri 
dishes containing DMEM with incubation at 37oC in a humidified incubator 
containing 5% v/v carbon dioxide in air. When these cells had grown sufficiently they 
were transferred selectively to fresh culture vessels using Dispase. When injected into 
nude mice, the Oe21 cells gave a tumour growth in less than 3 weeks. The Oe21 cells 
were characterized as grossly aneuploid and had only a small response to Tumour 
growth factor β1 (TGF-β1), which would normally inhibit cell growth (Rockett et al. 
1997)”.  
See the appendix E for the cell culture methods. 
 
6.2.2. Cell Proliferation Assays Used with the Cellular Model 
 
6.2.2.a.   PGE2 Mitogenicity – Viable Cell Counts 
 
For each observation, with regard to PGE2 concentration and time-point of extraction, 
two T25 flasks were seeded with each cell line at 2.5 x 105 in 6ml of media. The 
media for the Het1a cell line was DMEM, and RPMI 1640 with bicarbonate for the 
Oe21 cell line. These included the addition of 50 ml foetal calf serum (FCS), 500µl 
Penicillin (5 units/ml), Streptomycin (0.005mg/ml) and 1ml Amphotericin 
(250µg/ml).  All cell culture reagents were obtained from Sigma-Aldrich (Dorset) 
unless otherwise stated.  The medium was then spiked with PGE2 (Sigma-Aldrich).  
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The median PGE2 concentration of the gastric fluid samples found in Figure 5.3 was 
3.9 µg/ml therefore, 0, 0.0005, 0.005, 0.05, 0.5 and 5 µg/ml were used to treat the 
cells. Following 24, 48, 72 and 96 hours of cell growth the cells were removed from 
the flasks with cell scrapers (Nunc, Fisher, Loughborough, UK) and centrifuged in 15 
ml tubes at 176 x g for 10 minutes at 4oC. The cell pellets were collected and re-
suspended in 0.5 ml of PBS. Using a haemocytometer, the cells were counted using 
trypan blue exclusion and a mean cell concentration was calculated (see appendix G-
1). 
 
6.2.2.b.   PGE2 Mitogenicity - MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) Cell Proliferation Assay 
 
The MTT cell proliferation assay measures the viability of cell populations and their 
proliferation rate. The yellow tetrazolium salt MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide) (Sigma Aldrich) is reduced by metabolically active 
cells, in part by the action of dehydrogenase enzymes contained in the mitochondria, 
to generate reducing equivalents such as NADH and NADPH. The resulting 
intracellular purple formazan can be solubilised and quantified by spectrophotometric 
means. This offers an alternative to looking at the proliferation of the cell lines 
through counting (Mosmann 1983). 
Two 96 well cell culture plates (Nunc) were seeded with Het1a and Oe21 cell lines at 
6 x 104/ml with 200µl media in each well. After 48 hours of growth at 37oC, when the 
cells were at the desired concentration of about 50% confluence, the media was 
replaced with fresh media, with or without the desired concentration of PGE2.  
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Every test was repeated in four wells to allow calculation of a mean. Four test lanes 
and six sample lanes were set up: 
Test Lanes: 
• N = Cells with no treatment and with MTT assay. 
• NO = Cells with no treatment and no MTT assay. 
• BC = No cells with MTT assay. 
• NA = No cells and no assay. 
Sample Lanes: 
• A = 0 µg/ml PGE2 treated cells (negative control) 
• B = 0.0005 µg/ml PGE2 treated cells 
• C = 0.005 µg/ml PGE2 treated cells 
• D = 0.05 µg/ml PGE2 treated cells 
• E = 0.5 µg/ml PGE2 treated cells 
• F = 5 µg/ml PGE2 treated cells. 
 
These were grown for a further 48 hours and then tested for proliferation: The plate 
was centrifuged for 15 minutes at 70 x g and 150 µl of the supernatant from each well 
was removed. The MTT solution (1mg MTT powder (Sigma-Aldrich) in 1ml of PBS, 
filtered). Added to each well was 50 µl MTT solution and incubated at room 
temperature for two hours. Vigorously mixed in each well with a pipette was 100 µl 
of acidified Isopropanol (100µl concentrated HCl in 100ml Isopropanol). The 
absorbance of each well was then read in a plate reader (MRX, Dynex Technologies, 
Worthing, UK) at A550.
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6.2.2.c.   PGE2 Mitogenicity - BrdU Colorimetric Cell Proliferation ELISA Assay 
 
This is considered the gold standard method of non-radioactive assays for the 
measurement of cell proliferation (Rubmann et al., 1993). Cells are cultured in the 
presence of the respective test substance for a standard period of time in 96 well 
plates. Cells are then incubated with BrdU (Roche, Lewes, UK) (5-bromo-2’-
deoxyuridine in PBS). BrdU is a pyrimidine analogue that is incorporated in place of 
thymidine into the DNA of proliferating cells. The DNA is then denatured to allow 
access to the incorporated BrdU for detection by an antibody. This anti-BrdU 
monoclonal mouse antibody is conjugated with peroxidase, so with the addition of 
tetramethyl-benzidine (TMB) substrate, the reaction product can be quantified by 
measurement of the absorbance because of the colourimetric reaction. The developed 
colour, and therefore the absorbance values, directly correlate to the amount of DNA 
synthesis, thus to the number of proliferating cells in the wells (Porstmann et al., 
1985). 
Two 96 well tissue grade cell culture plates (Nunc) were seeded with Het1a and Oe21 
cell lines at 6 x 104/ml in 200µl media. The media, into which they were seeded, also 
contained 0, 0.0005, 0.005, 0.05, 0.5 or 5 µg/ml PGE2. There were two controls: a 
blank, which did not contain cells and a background control that did not contain the 
BrdU.  After 72 hours of growth at 37oC, the original medium was replaced with 20 
µl/well of medium containing the 20µM BrdU label. This was incubated for a further 
24 hours at 37oC. The BrdU media was removed and 200µl/well of denaturation 
solution in the kit (Composition not disclosed by the manufacturer), was added for 30 
minutes at room temperature. This was removed by tapping the inverted plate and 
100µl/well 1:100 anti-BrdU antibody was added and incubated for two hours at room 
temperature. The wells were washed three times with the wash solution, provided in 
the kit, and 100µl/well TMB substrate was added and incubated for 30 minutes. This 
caused a colourimetric change, and the reaction was stopped by adding 25µl/well 1M 
H2SO4 and placed on a shaker for 1 minute. The plate was read at 450nm on a plate 
reader (MRX, Dynex Technologies, Worthing, UK). 
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 6.2.2.d.   Serum Free Media and its Effect on Cellular Proliferation 
 
Due to the stimulatory effect of the foetal calf serum used in media, the effect that this 
had on the proliferative drive of the model was investigated. By doing this, it would 
be easier to elucidate the response directly caused by PGE2 or gastric samples. The 
cell counts were repeated with their specific media without foetal calf serum. 
 
6.2.3. Gastric Fluid Sample Mitogenicity 
 
The gastric fluid samples were tested for mitogenicity, using the MTT assay (section 
6.2.2.b) and the BrdU assay (section 6.2.2.c). The methods for these are the same as 
the PGE2 investigation mentioned above (section 6.2.2) but using gastric fluid 
samples instead of the PGE2.  
 
6.2.3.a.   Setting Up the Cellular Model to Use with Gastric Fluid Samples 
 
For each sample tested a duplicate of four wells was used so a mean could be 
calculated.  
Each cell-line was seeded in a 96 well cell culture plate at 6 x 104 cells in 200 µl of 
media for each assay and left to grow for two days. The wells were then treated with 
50 µl gastric fluid sample mixed with 50µl media. For controls, the sample was 
exchanged for an equal volume PBS. Following this treatment the MTT and BrdU 
assays were carried out on these plates by methods explained above (section 6.2.2.b & 
6.2.2.c). 
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6.2.3.b.   Non-Protein Gastric Fluid Sample Mitogenic Effects on Cellular 
Proliferation 
 
To investigate non-protein constituent effects of the gastric fluid samples some were 
heat-treated to denature the proteins. The samples were placed in 0.5ml snap top 
tubes, wrapped in Para-film and placed in a water bath for ten minutes. The water 
bath was set at 80oC, temperatures (above this temperature congealed the samples). 
These samples were then used in the MTT and BrdU assay to investigate changes in 
mitogenicity. 
 
6.2.4. A Model to Investigate the Detrimental Effect the Transportation Would 
Have Had on the Mitogenicity of the Samples 
 
 
A model was created to investigate the detrimental effect that the transportation may 
have had on the proliferative drive of the gastric fluid samples. Saliva samples treated 
and untreated were tested using the MTT assay (section 6.2.2.b). Treatment refers to 
additional spiking with PGE2 and various transport methods. The untreated samples, 
hence the samples that did not go through the replicated transportation method, 
remained at -80oC (explained in section 5.3.2). 
 
6.3. Results 
 
6.3.1. PGE2 Mitogenicity – Viable Cell Counts  
 
The following graphs represent the data of the cell count results of two different cell 
lines over four days treated with different concentrations of PGE2. 
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Figure 6.1: Relationship between cell proliferation and PGE2 treatment in Het1a cells 
over four days. Each point is the mean of two cell counts. 
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Figure 6.2: Relationship between cell proliferation and PGE2 treatment in Oe21 cells 
over four days. Each point is the mean of two cell counts. 
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 Figures 6.1 and 6.2 show that the different PGE2 concentration treatments do not fit a 
simple linear relationship with increasing PGE2 concentration and increased rate of 
cellular proliferation. The treatment of PGE2 on the Het1a cell line, shown in Figure 
6.1, at the lowest and highest concentrations of 0.0005 and 5 µg/ml, respectively, 
inhibited growth more than the control,. The 5 µg/ml treatment resulted in very little 
growth compared to the mid concentrations of 0.005, 0.05 and 0.5 µg/ml.. The cells 
treated with 0.005 µg/ml have grown almost twice as much; this increased growth is 
also seen with the Oe21 cell line, shown in Figure 6.2. Although in the Oe21 cell 
flasks the inhibitory effect has come from the two higher concentrations of 0.5 and 5 
µg/ml. For both cell lines after 4 days there is a normally distributed growth curve.  
Note that the max concentration has the highest growth at three days in Oe21, which 
is different to non-stimulatory growth effect seen with the Het1a line. 
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6.3.2. PGE2 Mitogenicity – MTT assay 
 
The following graphs represent the data of the MTT assays of two different cell lines 
with different concentrations of PGE2. 
 
 
Figure 6.3: The mean of four sets of MTT optical density readings following the 
treatment of different PGE2 concentrations on the Het1a cell line after 48 hours. The 
arrows represent the mean percentage increase in optical density compared to the 
control of 0 µg/ml PGE2. The error bars relate to the standard deviation of the mean. 
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 Figure 6.4: Graph representing the mean of four sets of MTT optical density readings 
following the treatment of different PGE2 concentrations on the Oe21 cell line after 
48 hours. The arrows represent the percentage increase in optical density compared to 
the control of 0 µg/ml PGE2. The error bars relate to the standard deviation of the 
mean. 
Figures 6.3 and 6.4 show that there is an increase in the overall number of viable cells 
when treated with PGE2. As shown with the cell counts (Figures 6.1 & 6.2) there is a 
greater maximal response from the Het1a cell line than the Oe21 cell line. The Het1a 
cell counts in Figure 6.3 show the largest increase in cell number following 
0.005µg/ml PGE2 treatment. There is an increase in response to the PGE2 treatment in 
the Oe21 cell line, although this is less than in Het1a. 
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6.3.3. PGE2 Mitogenicity – BrdU U proliferation assay 
 
The following graphs represent the data of the BrdU proliferation assay of two 
different cell lines with the treatment of different concentrations of PGE2. 
 
 
 
Figure 6.5: The mean of four sets of BrdU optical density readings then converted to a 
percentage change compared to the non-treatment control representing 100%. This 
follows the treatment of different PGE2 concentrations on the Het1a cell line. The 
error bars relate to the standard deviation of the mean, these are too small to see. 
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Figure 6.6: The mean of four sets of BrdU optical density readings then converted to a 
percentage change compared to the non-treatment control representing 100%. This 
follows the treatment of different PGE2 concentrations on the Oe21 cell line. The 
standard deviation of the mean was calculated but was so small that the error bars 
hardly show. 
Figure 6.5 shows there was a large increase in response to the PGE2 treatment in the 
Het1a cell line. With the Oe21 cell line counts in Figure 6.6 there is an increase in cell 
proliferation following 0.05 – 0.5 µg/ml treatment, showing the same normally 
distributed results as the viable cell counts in section 6.3.1.  
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6.3.4. Gastric Fluid Sample Mitogenicity 
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Figure 6.7: The mean of two sets of MTT proliferation assay optical density readings 
following the treatment of the gastric samples straight on the Het1a and Oe21 cell 
lines. N represents cells with no treatment of any kind other than a control solution 
PBS. 
 
Figure 6.7 shows that all of the gastric fluid samples have increased the optical 
density, hence cellular proliferation, of the assay compared to the untreated cells.  
 
6.3.5. Heat Treated Samples 
 
To determine whether non-protein components of the gastric fluid sample could be 
producing the mitogenic effect, some samples were heat treated to denature the 
proteins in the sample. This was to test the liability of the mitogenicity of the gastric 
fluid samples without the growth factors, PGE2 and other proteins, which may 
influence cell growth. 
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Only a small subset of gastric fluid samples were tested due to the small volumes of 
the other samples. These were chosen due to the large differences in PGE2 
concentration found in them. Sample numbers 4, 7, 8, 13 and 18 were selected for this 
part of the investigation, and their effects on the two cell lines seen in Figures 6.8 and 
6.9. 
 
Figure 6.8: The mean of duplicate MTT assays following heat treatment of a selection 
of gastric samples on the Het1a cell line. The arrows represent the percentage increase 
in optical density compared to cells without gastric fluid treatment (N). 
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Figure 6.9: The mean of duplicate MTT assays following the heat treatment of a 
selection of gastric samples on the Oe21 cell line. The arrows represent the percentage 
increase in optical density compared to cells without gastric fluid treatment (N). 
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Figure 6.10: The mean of duplicates of MTT assays following the treatment of a 
selection of heat and non-heat treated gastric samples on the Het1a and Oe21 cell line 
compared to the control (N), which is heat treated media without adding a gastric 
fluid sample. 
 
Figure 6.10 shows that in each instance the proliferative effect of gastric fluid has 
been reduced by heat treatment. There is an obvious difference in cell proliferation 
levels following treatment with and without heat treated gastric fluid samples. By heat 
treating the samples to denature the action of any proteins then there is a great 
reduction in cell proliferation in a majority of the samples compared to the normal.  
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6.3.6. Investigation of the Effect of Gastric Sample Treatment on Cells Using the 
BrdU Assay 
 
As the results were very different between the MTT assay (Figures 6.3 and 6.4) and 
the BrdU assay (Figures 6.5 and 6.6), it was important to test the gastric fluid samples 
with the BrdU assay and check that the proliferation increase is seen with both 
methods. 
 
 
Figure 6.11: The mean of duplicates of the BrdU assays converted to percentage 
change compared to control following the treatment of gastric fluid samples on the 
Het1a cell line. The dashed line representing the control average. 
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Figure 6.12: The mean of duplicates of the BrdU assays converted to percentage 
change compared to control following the treatment of gastric fluid samples on the 
Oe21 cell line. 
 
When the two cell lines were treated with the gastric fluid samples a majority exhibit 
increased cell proliferation amounts.  
 
6.3.7. The Detrimental Effect the Long Journey and its Condition May Have Had 
on the Gastric Fluid Samples 
 
These are the graphical representations of the data of the MTT assay treated with 
dummy gastric fluid samples (0.005 µg/ml PGE2 spiked saliva samples, explained in 
section 5.2.1). These samples were treated with the same detrimental travel conditions 
as the gastric fluid samples went through. These were described in the previous 
chapter (section 5.2.1.c). 
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Figure 6.13: MTT Assay Optical Density Measurements after treatment with PGE2 
spiked saliva samples treated and untreated by different environmental conditions 
(section 5.2.1.c) on Het1a Cell line 
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Figure 6.14: MTT Assay Optical Density Measurements after treatment with PGE2 
spiked saliva samples treated and untreated by different environmental conditions 
(section 5.2.1.c) on Oe21 Cell line 
 
Figures 6.13 and 6.14 show that the conditions that the samples experienced between 
their transportation from Transkei, South Africa to Bedford, United Kingdom would 
have had a detrimental effect on their ability to promote cellular proliferation. 
 
6.4. Discussion 
 
The studies carried out in this chapter have used cell lines as an in-vitro model to see 
what effect PGE2 has on their proliferative drive. The PGE2 concentrations were 
measured in gastric fluid samples and they were tested on the cellular model for their 
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mitogenic activity. Heat treatment of the samples and investigation of their cell 
growth rates was investigated along with the effect the journey had on these samples.  
Shown in Figure 6.1 het1a cells grew as normal, doubling daily. A similar result was 
produced under different concentrations of PGE2 for the first two days. The highest 
concentration clearly had an inhibitory effect on the cells, which showed little growth 
over the entire four day period when treated with 5 µg/ml PGE2. As PGE2 is naturally 
found in contact with the majority of cells in the body, this may suggest that the high 
amounts of PGE2 may lead to a enzymic negative feedback system through natural 
growth mechanisms (Morita, 2002). After four days there was little significant change 
in the growth rates between 0.0005, 0.05 and 0.5 µg/ml PGE2 treatment, but the cells 
treated with 0.005 µg/ml had the maximum effect, nearly doubling the cell number 
compared to the control with PGE2 treatment. This sigmoidal normal distribution 
shown in Figures 6.1 and 6.2, is also common with growth factor concentration 
treatment and cell growth. PGE2 stimulation of growth factor expression may suggest 
one of the many functions of PGE2, hence, increasing cellular proliferation. The 
stimulation of growth seen by the control sample, with no additional PGE2, may be 
caused by the growth factors found in the serum of the media. This would suggest that 
greater concentrations of PGE2 might suppress these growth factors via a negative 
feedback mechanism, reducing the cell numbers compared to that found by the no 
PGE2 treatment model.  
As might be expected with a characteristically altered cancer cell line, the PGE2 
treatment on the Oe21 cell line is very different from that found in the Het1a cell line. 
The growth characteristics of the Oe21 carcinoma cell line are likely to be less 
controlled. There is a smaller difference between the treatments of the various PGE2 
concentrations with the Oe21 cell line, than with the Het1a cell line, shown in Figure 
6.2 compared to Figure 6.1. The 5 µg/ml treatment of the Oe21 cell line after three 
days, led to the maximal growth of all the concentrations. This peak changed over 
another 24 hours, as the growth rate for the two larger concentrations of PGE2 are 
below that of the control after four days. This may suggest that there is a time delay, 
and all cells have to reach a certain concentration before the negative feedback system 
takes place in this cell line. The smallest of the three PGE2 concentration treatments 
resulted in a larger number of cells present than the control, with the maximum 
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growth concentration again at 0.005 µg/ml. A similar rate of cellular increase is also 
seen with the Het1a cell counts and its PGE2 concentration treatment (Figure 6.1). 
This also suggests a negative feedback system and maybe a relationship with growth 
factors. 
It seems that there needs to be enough cells present in the assay for the PGE2 to show 
changes in response compared to that of the control, as there is little change after 24 
hours (Figure 6.1). This could suggest that the PGE2 works on a component in the 
cells that has to be at a high enough concentration for stimulation; for example, 
growth factors and their receptors that can stimulate their own cells and the 
surrounding cells (autocrine and paracrine reaction). It is likely that in this model 
more than 24 hours are required for the cells to make contact with the growth surface 
and recover from stress of splitting with the protease. Also the cells have to be at a 
high enough concentration to make the assays record a significant difference. The 
Figures 6.1 and 6.2 support the suggestion that PGE2 stimulates and inhibits the 
growth of oesophageal cells at various concentrations. This has been suggested before 
in mouse osteoblastic cells although the authors did not offer specific explanation 
(Suda et al., 2000). 
As stated in the discussion of the results above, the stimulatory and inhibitory growth 
patterns caused by different concentrations of PGE2 are very similar to that found with 
growth factor characteristics. Further research has to be carried out on PGE2 and its 
effects on the expression of growth factors. It has been suggested in a number of cases 
that growth factors have an important mechanism in the hyper-proliferation of 
oesophageal tissue for the mechanism of healing (Juhl et al., 1995; Jimenez et al., 
1998; Baatar et al., 2002). As stated in the Introduction (section 1.6), PGE2 plays an 
important role in the mechanism of healing, therefore the relationship between hyper-
proliferation and PGE2 makes sense. Baatar et al.(2002) showed in rats that the 
healing of ulceration in the oesophagus can be delayed by treating the rat with 
selective COX 2 blockers, hence suppressing the PGE2 production. They have also 
shown that this healing was suppressed by inhibiting the HGF receptor. The early 
response genes such as myc, fos or jun should be investigated to support the 
connection of PGE2 and stimulation of growth factor, as the presence of these genes 
suggests growth factor stimulation (Almendral et al., 1988). The cyclins and cyclin-
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dependent kinases could also be investigated as these are expressed after a longer 
period than the early response genes (2-3 hours), following cell growth stimulation by 
growth factors (Sherr, 1993). Takeno et al. (2002) supported the view that 
measurements of cyclin B1 had prognostic value in oesophageal squamous cell 
carcinoma patients, due to its elevated levels relating to poor prognosis. Should PGE2 
increase cyclin B1, maybe through growth factor manipulation, then this could open 
up areas of investigation to explain these increased levels. It has been shown that 
PGE2 induces cellular proliferation in prostate cells, mediated through the protein 
kinase A and c-fos mechanisms, hence, regulatory proteins implicated with growth 
factors (Chen and Hughes-Fulford, 2000). PGE2 was also shown to induce c-fos and 
c-jun expressions via the EP1 subtype of PGE receptor in mouse osteoblastic cells 
(Suda et al., 2000). All these studies support the connection of PGE2 causing a hyper-
proliferative response via growth factors. This is also backed up by the knowledge 
that tyrosine kinases play an important role in the signal transduction pathways that 
are initiated due to growth factor stimuli, for example, in the induction of EGF 
receptor. In 1997 research showed that the tyrosine kinase protein was being over 
expressed in human oesophageal cancer (Nemoto et al., 1997). The investigation of 
the interaction of PGE2 with these growth factors could help provide information on 
this. 
As seen with the cell counts, the MTT cell proliferation assay results (Figures 6.3 & 
6.4) also show an increase in cell growth stimulation following all concentrations of 
PGE2 treatment. This growth is much smaller with the Oe21 than the Het1a cell line, 
and in this model 0.005 µg/ml has not produced the highest growth stimulation as 
found in the previous cell number method (Figures 6.1 and 6.2). The differences 
between both the assays will be discussed later in this section. 
All concentrations of PGE2 have a greater stimulatory effect on the Het1a cell line 
than on the Oe21 cell line. This could be owing to changes into the overall 
characteristics of the cell lines. The Het1a cell line may have a greater turn over rate 
than the Oe21 cell line, therefore when stimulated they appear to increase faster. It 
would seem more likely that Oe21 cell cycle characteristics have changed over the 
period of tumourigenesis.  
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Carcinogenesis is a huge multifactoral process causing many changes in natural 
cellular processes. It could be expected that the method that favours PGE2 to drive 
cellular proliferation in the Het1a cell line may be changed in the mutated, 
uncontrolled, Oe21 cell line. For example, the PGE2 may stimulate the cell cycle to 
progress through growth factor activation, receptor activation or through a secondary 
mediator, lifting the natural cell cycle blocks i.e. p53 (Hollstein et al., 1990) leading 
to cellular proliferation (see Figure 6.15 for what a mutation in p53 could effect). 
Should the Oe21 cell line have a mutated p53 protein, then the cell cycle may not 
allow continuation of growth if the p53 is blocking this growth pathway, but natural 
control of apoptosis would be suppressed therefore cells stimulated via other 
pathways may keep the cells growing and never be inhibited. Should the PGE2 have 
an overall stimulatory effect on the oesophageal cell lines then changes in the cell 
cycle between the two cell lines could suggest an area to investigate. This may 
provide a further area of study. 
There are many proteins that balance the cell cycle and apoptosis mechanism and fit 
the pattern found in the results e.g. p53, RAS, RAF, BCL-2, BAX etc. Investigation 
into cell cycle controlled feedback loops and their relating families may give a better 
insight into the process of carcinogenesis driving squamous cell carcinoma. Rather 
than speculating on the many examples here a deeper level of investigation is 
required, into the basic affects of PGE2 on cell growth than has been possible in this 
study. 
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 Figure 6.15: Examples of how a mutation in p53 could have an effect on other 
balances within the life of a cell (Pecorino, 2005) 
 
Figures 6.5 and 6.6 show the BrdU assay results for PGE2 treatment on cells. The 
pattern for the BrdU assay is similar to the MTT assay (Figures 6.3 and 6.4) as the 
het1a has a higher rate of  growth compared to the much lower growth rate with the 
Oe21 cells. This growth also seems to be similar to the growth pattern seen from the 
cell counts for Oe21 cell line, with the lower and higher concentrations of PGE2 
having an inhibitory effect, but the middle concentrations having a small stimulatory 
effect. The cells here are also treated over four days like those examined using the cell 
count method, compared to two days of the MTT assay. These changes between 
Het1a and Oe21 maybe due to PGE2 having a greater effect on the mitotic process of 
Het1a, that may be unstable or inhibited in the Oe21 cell line. Investigation here could 
be undertaken on the cell cycle movement from G2 to M and its checkpoint proteins 
such as cyclins, having an effect on the amount of DNA production perhaps forming 
multiple nucleus development. 
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Qureshi et al., (1997) looked directly at the Het1a Cell line and postulated that EGF is 
an initiation factor and IGF is a progression factor (explained in section 1.3.1), due to 
their synergistic ability to promote cell growth in the Het1a cell line. Negishi et al. 
(1995) have explained that that PGE2 exerts its functions by working on the PGE2 
receptors coupled with G proteins, also implicated with natural growth factor action. 
These activate or inhibit a growth factor pathway protein, inositol trisphosphate, that 
could cause an influx of calcium (Ca2+). Research at the University of Cambridge 
showed that inositol trisphosphate, an important secondary mediator in the EGF 
receptor, controls Ca2+ channels allowing Ca2+ to have an effect on transcription 
factors to stimulate the cell cycle (Berridge, 1993). As stated in section 6.2.1 the 
Het1a cell line growth is stimulated by increases in local Ca2+, which may explain the 
reasons for the increased growth of the Het1a cell line compared to Oe21 cell line. 
Changes in the presence of Ca2+ have been implicated in the interaction of EGF 
receptor although the mechanism has not been explained (Li & Villalobo, 2002).  
All these results support the theory that PGE2 has a stimulatory effect on the 
proliferation of the oesophageal cell line; no previous research has revealed this 
relationship. The BrdU and the MTT assay are regarded as the non-radioactive gold 
standards along with flow-cytometry to measure proliferation; their results slightly 
differ, but suggest the same concept that at a specific concentration of PGE2 there is a 
stimulatory effect on the oesophageal cells. The viable cell counts gave a clear 
representation of the number of viable cells present, therefore a good representation of 
the cellular proliferation that has taken place over the number of days that the cells 
were analysed. All methods have suggested that at concentrations around 0.005 – 0.05 
µg/ml there was a stimulatory effect on the growth of cell numbers of both cell lines.  
Treatment of both of the cell lines’ gastric fluid samples using the MTT assay gave an 
increased optical density reading compared with the control (Figure 6.7). Overall, the 
increases in growth were greater in the Het1a cell line than the Oe21 cell line, which 
is similar to the results from the cells treated with PGE2. A majority of the Oe21 
gastric fluid treated cells gave double the response compared to the control, and the 
Het1a cells an even greater response of between four to five times the control. This 
would suggest that the gastric fluid samples have the potential to cause increased 
oesophageal cellular proliferation using the same mechanism as PGE2. 
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These results have been achieved using PGE2 concentrations close to that found in the 
samples after there transportation (section 5.2.1). Therefore, in testing the samples 
these could be compared to the PGE2 treated results. However, in the original gastric 
fluid samples the PGE2 would have been much higher (quantified in Figure 5.3). As 
the higher PGE2 concentrations in the cell model had a suppressive effect on growth 
then a much higher concentration found in the original samples would have been 
expected to an adverse effect and suppress any localised PGE2 promoting growth. 
This does not seem to be the case, There may be a number of explanations for this. 
The oesophagus is lined by protective mucus that may not let all of this external local 
PGE2 protein through to the proliferative layer of the basal squamous tissue or 
decreases its absorption rate to this area. The PGE2 may only have a minimal effect on 
the terminally differentiated outermost cellular layers. Therefore, a much larger 
concentration may be required to have to the same effect that has been displayed in 
this in-vitro model. With the in-vitro model there will be constant stimulation from 
the introduced PGE2, although, in the sample population we have predicted that this 
PGE2 comes with and following a meal, hence, there is not likely to be constant 
stimulation.  Due to the nature of these abrasive foods and the suggested fungal 
infection of the maize then localised damage may induce the local PGE2 to aid healing 
through inflammation. The abrasive nature of these foods may also help by opening 
up patches of the squamous layer exposing basal areas to this increased PGE2, 
increasing the localised concentrations in to one area perhaps in one of the narrowing 
sections found in the oesophagus due to other organs externally pushing in.  
By heat treating the samples it has been assumed that this would have eliminated most 
of the activity of proteins in the sample. As expected, the growth of both sample-
treated cell lines was reduced compared to the non heat-treated samples (Figure 6.10). 
There are a great number of proteins that could have a multi-factor stimulatory effect 
on the cell lines, including cytokines and growth factors. The reduced growth of  the 
heat treated samples compared to the non heat-treated samples indicate that the gastric 
fluid still contains proteins that have not been denatured. This growth may be caused 
by the non-protein matter i.e. the pH, the bile salts etc. having a stimulatory effect on 
the cells, but it does suggest that proteins are a large factor in the proliferative drive 
by the gastric fluid. It is important at this stage that the results are not misinterpreted 
as suggesting that the PGE2 is the stimulatory component of the gastric fluid, as this 
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fluid will have a number of different elements that could affect the cellular growth. It 
has been suggested in two papers that bile acids have a positive effect on the growth 
of intestinal cells through the increased expression of COX 2 (Zhang et al., 2000; 
Myung-Whun Sung et al., 2003).   
An investigation on the influence of gastrin, a hormonal component of gastric fluid, 
was shown to stimulate the epithelial cell proliferation in the oesophagus of rats (Van 
Nieuwenhove et al., 1998). In gastric epithelial tissue it was shown that HGF 
expression was increased in cells when treated with gastrin (Konturek et al., 2003). It 
is not expected that the growth factors are still present in the gastric fluid due to their 
small half-life; therefore should the stimulation of growth be the result of growth 
factors then it seems likely that the cells are themselves expressing or secreting these 
growth factors through autocrine and paracrine stimulation, maybe through 
undenatured gastrin.  
The BrdU assay results (Figure 6.11 and 6.12) suggests that a majority of the gastric 
fluid samples have a stimulatory effect on the growth of the cells, therefore supporting 
the idea that the gastric fluid can increase cellular proliferation.  
As stated in the introduction (section 1.3.2), it has been shown that gastric fluid reflux 
is the predisposition factor of adenocarcinoma of the oesophagus (Heath et al., 2000), 
but this has been proved not to be the case with squamous cell carcinoma (Altorki et 
al., 2003). However, this theory has not been investigated with high concentrations of 
gastric PGE2. This current study suggests that the PGE2 content of the gastric fluid 
reflux has a proliferative drive, which itself is recognised as a predisposition to cancer 
through hyperplasia. This supports the theory that a high PGE2 substrate diet could be 
the major cause of oesophageal cancer in the sample population.  
It is clear from Figure 5.4 in the previous chapter that the transportation of the 
samples had a detrimental effect on the PGE2 levels in the samples. This also had a 
detrimental effect on the growth stimulating potential of the samples shown by 
Figures 6.13 and 6.14. The transportation did have a detrimental effect although it did 
not invalidate the samples. According to the results in Figure 5.4, the PGE2 levels 
may have been decreased by over half. However, Figures 6.13 and 6.14 show that the 
samples still had a proliferative effect on the oesophageal cell lines, much higher than 
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the control in the Het1a cell line. It can not be stated that the much higher 
concentrations in the original samples would have had a much greater stimulatory 
effect due to its higher PGE2 concentration. As explained at the start of this discussion 
the PGE2 concentrations have a sigmoidal growth curve with higher concentrations 
having a suppressive effect. The higher PGE2 concentration treated in-vivo could have 
a greater mitogenic effect. Higher localised PGE2 may suppress the closing of the 
gastric sphincter for longer periods of time and be in higher than normal 
concentrations having a greater chance of reaching the squamous cells.  
The saliva samples used in the transportation investigation differ to the gastric 
samples by a few components. The main difference is the pH of the fluids. It is 
common knowledge that the fairly neutral saliva (pH 6.4-7), soaked in a bolus of 
swallowed food, is a stimulus for promoting release of acidic gastric juice, therefore 
this pH change between the two fluids can have a large effect on the efficacy of 
enzymic reactions. Although the buffered media (pH 7.2-7.6) that the cells grow in 
would neutralise much of this pH change between the two. Saliva contains a small 
amount of calcium (1.2-2.8 mMol/L) that may stimulate Het1a cell growth (Qureshi et 
al., 1997) although this would have little effect due to the calcium content already in 
the media having an even effect on both sample treatments on cells. Gastric fluid may 
have an increased growth stimulatory effect due to gastrin content and bile salts 
explained in few paragraphs previous. Overall the basic proliferative drive between 
the two samples would be minimal although this can not be stated without testing 
fresh gastric fluid. For the purpose of this study the use of saliva in place of gastric 
fluid was sufficient to use as a model.  
In conclusion, this research shows that PGE2 increases oesophageal cell proliferation 
at particular concentrations and that the proteins in the high PGE2 containing gastric 
fluid samples from the sample population also increase oesophageal cell proliferation, 
suggesting a pre-disposition to cancer. This suggests a link between the two 
observations. It is postulated that this proliferative drive is carried out via the 
interaction of growth factors or their multi-compartmental mechanism, and the 
importance of testing this has been discussed. It has not been ruled out that another 
component of the gastric fluid could have the increased mitogenic effect, although the 
evidence supporting PGE2 in this research is strong.  
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 Summary of results supporting this theory: 
• The results suggest that at optimum concentrations there is an increase in the 
proliferative drive from PGE2 on the oesophageal cells. 
• The growth is suppressed at very high concentrations, suggesting a negative 
feedback mechanism. This system common to growth factors, may propose the 
PGE2 mitogenic mechanism seen in natural tissue healing. 
• Changes between the growth patterns for the normal and squamous cell carcinoma 
cell lines suggest a cell cycle control protein difference between the two may help 
to indicate what causes this PGE2 stimulated proliferation increase, for example a 
commonly studied protein such as p53. 
• Much higher PGE2 concentrations are seen in gastric fluid samples than are seen 
to suppress cell growth in the in-vitro model. Due to the oesophagus being mucus 
covered, larger concentrations maybe required to affect the squamous tissue and 
not affect the terminally differentiated outermost cellular layers. 
• The high PGE2 containing gastric fluid samples had a mitogenic effect on the cell 
lines. After the gastric fluid was heat-treated the mitogenic effect was largely 
reduced, suggesting that protein components, for example, PGE2, and not bile 
salts etc., in the samples, have the largest effect on the proliferative drive. 
• The transportation of the samples did have a detrimental effect although they still 
valid in this study. 
• This suggests that the high amounts of PGE2 produced by the maize diet, found in 
the gastric fluid, is reflux into the oesophagus. It is the PGE2, and not general bile 
salts, pH change (suggested in the Sammon theory) in the gastric fluids that have a 
proliferative drive on the localised squamous tissue, maybe through stimulation of 
common growth factors. Due to the mucus barrier, large concentrations are 
needed to have an effect. This is enhanced by localised infection and damage 
caused by disease and sharp foods respectively. 
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Figure 6.13. The Sammon Pink theory and how the research to this point supports it. 
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 7. Assessing the Effect of PGE2 Treatment on HGF, VEGF, EGFR and COX 2 
Expression 
 
7.1. Introduction  
 
Once the basis of the molecular model had been shown in the previous chapters, a 
more focussed molecular investigation could take place. Following the theory of 
maize induced carcinogenesis, developed from Sammons work described in the 
chapter 3 (Figure 3.1) and subsequent studies documented in chapter 6, this chapter 
focuses on the growth pattern and expression of growth factors. It investigates 
whether PGE2 has an effect on the expression of three important proteins: One 
implicated with epithelial growth promotion, Hepatocyte Growth Factor (HGF) 
(section 1.7.5), and two implicated with the tumourigenic potential of PGE2: 
Epithelium Growth Factor Receptor (EGFR) (section 1.6.10.a) and Vascular 
Endothelial Growth Factor (VEGF) (section 1.6.5). The research reviewed in Chapter 
1 showed how COX 2 inhibitors can suppress growth promoting carcinogenesis 
(section 1.6.2), although the mechanism is debatable, therefore it was important to 
examine how expression changes are to be stimulated by PGE2. The results in chapter 
6 have illustrated that PGE2 increases proliferation of oesophageal cell lines, therefore 
should the expression of COX 2 increase; this could suggest a positive feedback 
mechanism, inducing hyper-proliferation of the oesophagus. 
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7.2. Methods 
 
7.2.1. Western Blotting to Detect HGF 
 
7.2.1.a.   Sample Preparation 
 
T75 flasks (Nunc) were seeded with 1ml 50 x 104/ml of Het1a and Oe21 cells and 
grown for 48 hours. The medium was removed from the flask and the cells were 
washed with 10 ml 2% protease inhibitor (Sigma) /PBS solution (PI/PBS). Using a 
cell scraper (Nunc) and 10 ml PI/PBS solution, the cells were scraped from the T75 
and transferred to a 15 ml centrifuge tube. The tube was centrifuged at 1200 x g for 10 
minutes at 4oC. The supernatant was discarded and the cells were re-suspended in 1.5 
ml of PI/PBS. The cells were transferred to an eppendorf tube and spun at 20,000 x g 
for 15 minutes at 4oC. The supernatant was discarded and the cells were re-suspended 
in 1.5 ml CHAPS lysis buffer (appendix L). The cell solution was snap frozen and 
stored at –80oC. When required the cell solution was thawed and incubated on ice for 
one hour. This was centrifuged at 20,000 x g for 30 minutes at 4oC. The 
supernatant/protein was placed in a clean tube, labelled and stored at –80oC. The 
protein concentration was measured using the Bradford Assay.  
 
7.2.1.b.   Western Blotting Method 
 
The 1000 mg/ml protein samples (12 µl) were boiled for five minutes with 3 µl SDS 
running buffer (appendix L) to denature the protein to single polypeptide strands. 
These were spun briefly to collect the tube contents and placed on ice for two 
minutes.  The samples were loaded into a SDS stacking gel (appendix L) alongside a 
molecular weight ladder (Santa Cruz Biotech inc, Wiltshire, UK), and run through a 
8% w/v SDS resolving gel (appendix L) in an electrophoresis chamber in running 
buffer (appendix L) at a constant 125 Volts for 90 minutes. An anti-electric vinyl 
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membrane was placed on a clean blotter (Hoefer, San Francisco, USA ) with a hole 
the same size as the SDS gel. On this four layers of filter paper (Whatman, Maidstone, 
UK) were stacked, pre-soaked in transfer buffer (appendix L). A PVDF micro-porous 
membrane (Millipore, Gloucestershire, UK) was cut to the same size as the gel and 
pre-soaked in methanol then transfer buffer (appendix L) and placed on the stack. On 
top four further, pre-soaked with transfer buffer, filter paper layers were added. This 
was rolled with a 20 cm plastic tube to disperse air bubbles between the layers, and 
the blotter lid was added with further weight. Electro-transfer (Hoefer semi-phor) was 
performed for 60 minutes at 70 milliamps. A duplicate gel was checked with 
Coomassie blue (Sigma) for a clear indication that the proteins were present and have 
run correctly on the gel. The membrane was blocked with 5 % w/v powdered milk 
(Marvel, Premier Brands, UK) in TBS (appendix L) for one hour, rocking at room 
temperature. The goat anti-human HGF primary antibody (R&D Systems, Oxon, UK) 
was diluted to 1/100-1000 in 5 % w/v milk/TBS and incubated with the membrane for 
16 hours at 4oC. As a control a rabbit anti-human CD44 primary antibody was diluted 
to 1/200 in 5 % w/v milk/TBS and incubated with the membrane for 16 hours at 4oC, 
this is because CD44 is implicated in cellular binding and has always shown to be 
present in these cell lines in the laboratory. The membrane was washed five times for 
five minutes, rocking at room temperature in 0.1 % v/v tween 20 in TBS. The 
membrane was incubated in 1/1000 donkey anti-goat secondary antibody (Santa Cruz) 
in 5% w/v milk/TBS for one hour, rocking at room temperature. The membrane was 
washed five times for five minutes, rocking at room temperature in 0.1 % v/v tween 
20 in TBS. ECL detection mix (Amersham Bioscience, Little Chalfont, UK) was 
poured onto the membrane and incubated at room temperature for one minute. This 
was then placed in a film cassette with x-ray photography paper (Sigma) using a red 
safety light and left for one hour at room temperature. The film was placed in 
developer for 20 to 60 seconds until the small bands appeared on the film. This was 
washed in tap water and then placed in fixer for 5 minutes. If the specific protein was 
present then small bands will appear darker on the opaque film. 
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7.2.2. RT-PCR to Detect HGF Expression 
 
The primer sequences were taken from a previously published study (Okazaki et al., 
2002). These were checked against the cDNA sequence provided by the National 
Centre for Biotechnology Information Database (NCBI, www.pubmed.com) to be 
sure they are correct. The primers were produced by Thermo Electron Corporation, 
Basingstoke, UK. 
 
7.2.2.a.   Sample Preparation 
 
T75 flasks (Nunc, Fisher, Loughborough, UK) were seeded with 1ml 50 x 104/ml of 
Het1a and Oe21 cells and grown for 48 hours. The cells were washed three times with 
PBS. The cells were scraped from the flasks using a cell scraper (Nunc) and a further 
10ml PBS was added. This was collected into a 15 ml centrifuge tube and centrifuged 
at 1200 x g for 10 minutes at 4oC. The cell pellet was collected into a 2ml eppendorf 
tube and centrifuged at 20,000 x g for 15 minutes at 4oC. The cell pellet was snap 
frozen in liquid nitrogen and stored at –80°C prior to use. When required, the cells 
were defrosted on ice and the RNA was extracted using the RNA extraction kit 
(RNeasy Mini kit, Qiagen, West Sussex, UK). The RNA was quantified. Using the 
reverse transcriptase kit (Invitrogen Cloned AMV – first strand synthesis kit), the 
cDNA for each sample was produced, along with a RT-negative sample which 
incubated without the Reverse transcriptase in the reaction.  
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7.2.2.b.   PCR Reaction 
 
The following PCR reaction components were added together in a thin-walled PCR 
tube (Okazaki et al., 2002): 
 
• 0.5 µl cDNA sample 
• 5 µl 10 x Taq buffer, containing 25mM MgCl2 (Qiagen) 
• 1 µl dNTPs (10mM each dNTP) (Qiagen) 
• 0.5 µl Each primer (50 pMol) 
• 0.25 µl Taq (1.5 units) (Qiagen) 
• 37.25 µl Nuclease Free H2O 
 
A PCR negative control reaction was prepared containing all components except the 
cDNA, replaced by the equivalent volume of H2O. A positive control PCR reaction 
was prepared using the same cDNA as used in the first PCR test reaction, but with β-
actin primers. β-actin was chosen as it is a protein implicated with cell motility that is 
always expressed known as a house keeping gene (Raff et al., 1997). The positive 
control results for are in the appendix J. 
 
Reactions were performed for the following temperature and cycles using a Techne 
Genius Thermal cycler (Stone, UK). 
 
• 35 cycles of 94°C for 30 seconds, 61°C for 30 seconds and 72°C for 90 
seconds 
• 1 cycle of 95°C for 30 seconds, 61°C for 30 seconds and 72°C for 5 minutes. 
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Reaction products (10 µl) were resolved on 2% w/v agarose gels by electrophoresis 
(Hoefer semi-phor) at 100 volts for 25 minutes and were visualised by soaking the 
gels in 0.5µg/ml ethidium bromide and stained for 30 minutes. This was then 
visualised using a UV light box set to a wave length of 254 nm. 
 
 
7.2.3. Investigating Growth Factor Protein Expression and PGE2 Treatment 
 
T75 flasks (Nunc) were seeded with 1ml 50 x 104/ml cells and incubated in media 
(cell methods in the appendix E) for 48 hours. The cell specific media (Sigma) was 
changed for media spiked with 0, 0.0005, 0.05 or 5 µg/ml PGE2 and labelled A, B, C 
and D respectively. The cells were grown for different periods of time: 1 hour, 3 
hours, 24 hours, 48 hours and 72 hours and labelled 1, 2, 3, 4, and 5 respectively. The 
cells were collected from the flasks by washing with 10ml PBS and cell scraping in a 
further 10ml PBS. This was collected and centrifuged at 1200 x g for 10 minutes. The 
cell pellet was collected into a 2ml eppendorf and centrifuged at 20,000 x g for 15 
minutes. The cell pellet was snap frozen in liquid nitrogen and stored at –800C. When 
required the cells were defrosted on ice and the RNA was extracted using RNA 
extraction kit (Qiagen RNeasy Mini, West Sussex, UK). The RNA was quantified and 
all the samples were diluted to 50µg/ml with nuclease free water. Using a reverse 
transcriptase kit (Invitrogen Cloned AMV – first strand synthesis kit), the cDNA of 
the samples were collected, along with a RT-negative sample, which was incubated 
without the Reverse transcriptase in the reaction. The cDNA samples where diluted 
with nuclease free water at the optimised dilutions of 1/5, 1/50 and ½ for EGFR, 
VEGF and COX 2, respectively. PCR was carried out using the following reaction 
mixture in each instance: 
 
 
• 2 µl cDNA Sample 
• 5 µl 10 x Taq Buffer (Qiagen) 
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• 1 µl dNTPs (10mM of each dNTP) (Qiagen) 
• 1 µl Each Primer (20 Picomolar) (see below) 
• 1 µl Taq (1.5 Units) (Qiagen) 
• 39 µl Nuclease free H2O 
 
A PCR negative reaction was prepared without cDNA and replaced by an equivalent 
volume of H2O. A positive PCR reaction was prepared by using the same cDNA as 
that used in the first PCR reaction (A1), with β-actin primers. β-actin was chosen as it 
is a protein implicated with cell motility that is always expressed (Raff et al., 1997). 
The primers were manufactured using the cDNA sequence (see appendix K) provided 
by National Centre for Biotechnology Information Database (NCBI, 
www.pubmed.com). The primers were produced by Thermo Electron Corporation, 
Basingstoke, UK.  
 
Primers: 
 
Beta-Actin (End product size: 698 bases) 
Sense: 5’-CTA GAA GCA TTT GCG GTG GAC-3’ 
Antisense: 5’-TGA CGG GGT CAC CCA CAC TGT-3’ 
 
EGFR (End Product size: 351 bases) 
Sense: 5’-ATG TCC GGG AAC ACA AAG AC-3’ 
Anti-Sense: 5’-TTC CGT CAT ATG GCT TGG AT-3’ 
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VEGF (End product size: 224 bases) 
Sense: 5’-TGC TGT CTT GGG TGC ATT GG-3’ 
Anti-Sense: 5’-ACA CAG GAT GGC TTG AAG AT-3’ 
 
COX 2 (End product size: 305 bases) 
Sense: 5’-TTC AAA TGA GAT TGT GGG AAA AT-3’ 
Anti-Sense: 5’-AGA TCA TCT CTG CCT GAG TAT CTT-3’ 
 
The PCR reactions are run at the following thermo-cycles in a Techne Genius 
Thermal Cycler (Stone, UK). 
 
EGFR and β Actin 
• 31 cycles of 95oC for 45 seconds, 54oC for 30 seconds and 72oC for 90 
seconds 
• 1 cycle of 95oC for 45 seconds, 54oC for 30 seconds and 72oC for 5 minutes 
 
VEGF 
• 31 cycles of 95oC for 45 seconds, 60oC for 30 seconds and 72oC for 90 
seconds 
• 1 cycle of 95oC for 45 seconds, 60oC for 30 seconds and 72oC for 5 minutes. 
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COX 2 
• 35 cycles of 95oC for 45 seconds, 54oC for 30 seconds and 72oC for 90 
seconds 
• 1 cycle of 95oC for 45 seconds, 54oC for 30 seconds and 72oC for 5 minutes 
 
The RT PCR methods above were optimised to attempt to make the assay semi-
quantitative. A range of cDNA concentrations were used in the PCR until the product 
produced a faded band after electrophoresis. A range of PCR cycles were carried out, 
collecting the product at different cycle numbers. The intensity of the resulting bands, 
using band recognition software (Genesnap, Synoptics Ltd, Cambridge), were plotted 
against cycle number and the centre of the steepest part of the curve selected as the 
optimum number of cell cycles (exponential part of the reaction), where small 
changes in the amount of starting material (RNA / cDNA) would give the largest 
change in band intensity on the resulting electrophoresis gel. 
 
For optimisation of COX 2 the following was tested: 
• PCR cycles number (20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40) 
• cDNA concentration (1,2, 5, 10. 25, 50 µl cDNA) 
For optimisation of VEGF and EGFR the following was tested: 
• PCR cycles number (28, 30, 32, 34, 36, 38,) 
• cDNA concentration (0.01, 0.1, 0.2, 0.5, 1,2, 5, 10, 25, 50 µl cDNA) 
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7.3. Results 
 
7.3.1. Western Blotting to Detect HGF Expression 
 
Following optimisation of the protein transfer to membrane, the protein from the 
oesophageal, bladder and prostate cell lines that had given positive results for CD44 
western blots, did not give any positive results with the HGF antibody. Using 30 
kilodalton Millipore tubes to filter smaller polypeptides the protein was concentrated 
and retested, this did not give any improved response. Both the primary and the 
secondary antibodies were tested at an array of concentrations and this did not give 
any response. The secondary antibody was developed to bind to the molecular weight 
ladder developed by Santa Cruz Biotechnology. Therefore this was used to check the 
binding ability of the secondary antibody, should the secondary antibody not bind 
then the ladder would not appear. The ladder appeared as normal. To increase 
antibody binding the secondary binding temperature was increased to 37oC from room 
temperature, which increased the background but did not show any bands. The 
binding time and temperature was changed for the primary antibody application, 
which showed no response. The transfer method was changed from the dry blot to the 
wet blot, although this did not affect the response.  
 
7.3.2. RT-PCR to Detect HGF Expression 
 
Following the method described by Okazaki et al. (2002) that provided the primer 
sequence, bands failed to appear. Therefore a number of optimisation methods were 
undertaken. Firstly, the RT-PCR reactions were also carried out on RNA from RT112 
(bladder) and OE33 (oesophageal adenocarcinoma cell line) without any positive 
response. From the original method the annealing temperature was first tested at 50, 
52, 54, 58, 61 and 62 without any result. The PCR cycle numbers were tested at 30, 
35 and 40 cycles without any result. The primers, MgCl2, dNTP, Taq and cDNA were 
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tested at a range of concentrations without any result. New primers were designed to 
determine that the primers were working and verify that the gene was present in the 
DNA (see appendix H for sequence and placement in the gene).  
 
7.3.3. Assessment of EGFR and VEGF Expression Following Treatment using 
RT-PCR (Het1a and Oe21 cells).  
 
For all of the results the following labelling will be used: 
A = No PGE2 treatment, B = 0.0005µg/ml PGE2, C = 0.05µg/ml PGE2 and D=5µg/ml 
PGE2. 
1 = 1 hour treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 hours 
treatment and 5 = 72 hours treatment. 
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Electrophoresis of RT-PCR products of EGFR with Het1a cell line 
 
L       A1     A2     A3     A4     A5      B1      B2      B3      B4     B5 
0.0005µg/ml PGE2No PGE2
 500 bps
351 bps 
 
Figure 7.1: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. EGFR RT-PCR products from RNA extracted from 0 (A) and 
0.0005 µg/ml PGE2 (B) treated Het1a cells over different periods of time.  1 = 1 hour 
treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 hours treatment and 5 
= 72 hours treatment. 
 
L     C1      C2     C3     C4    C5      D1     D2     D3      D4     D5 
5µg/ml PGE20.05µg/ml PGE2
 500 bps
351 bps 
 
Figure 7.2: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. EGFR RT-PCR products from RNA extracted from 0.05 (C) and 
5 µg/ml PGE2 (D) treated Het1a cells over different periods of time. 1 = 1 hour 
treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 hours treatment and 5 
= 72 hours treatment. 
 
Figures 7.1 and 7.2 show similar band intensities for all Het1a cells over time. The 
results show there do not appear to be large changes in expression due to PGE2 
concentration. 
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351 bps 
 Electrophoresis of RT-PCR products of EGFR from Oe21 cell line 
 
L       A1     A2     A3     A4     A5      B1      B2      B3      B4     B5 
 
Figure 7.3: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. EGFR RT-PCR products from RNA extracted from 0 (A) and 
0.0005 µg/ml PGE2 (B) treated Oe21 cells over different periods of time. 1 = 1 hour 
treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 hours treatment and 5 
= 72 hours treatment. 
 
L       C1      C2     C3     C4      C5      D1     D2     D3      D4     D5 
0.0005µg/ml PGE2
5µg/ml PGE20.05µg/ml PGE2
No PGE2
 
 500 bps500 bps351 bps 
 
Figure 7.4: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. EGFR RT-PCR products from RNA extracted from 0.05 (C) and 
5 µg/ml (D) PGE2 treated Oe21 cells over different periods of time. 1 = 1 hour 
treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 hours treatment and 5 
= 72 hours treatment. 
 
Figures 7.3 and 7.4 show similar band intensities for PGE2 treated and untreated Oe21 
cells over time. The results show there do not appear to be large changes in expression 
due to PGE2 concentration. 
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Electrophoresis of RT-PCR products of VEGF from Het1a cell line 
 
L       A1     A2    A3     A4      A5     B1      B2      B3     B4      B5 
0.0005µg/ml PGE2No PGE2
 500 bps224 bps 
 
Figure 7.5: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. VEGF RT-PCR products from RNA extracted from 0 (A) and 
0.0005 µg/ml (B) PGE2 treated Het1a cells over different periods of time. 1 = 1 hour 
treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 hours treatment and 5 
= 72 hours treatment. 
 
 
L       C1      C2     C3     C4    C5    D1     D2     D3      D4     D5 
5µg/ml PGE20.05µg/ml PGE2
 500 bps 
Figure 7.6: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. VEGF RT-PCR products from RNA extracted from 0.05 (C) and 
5 µg/ml (D) PGE2 treated Het1a cells over different periods of time. 1 = 1 hour 
treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 hours treatment and 5 
= 72 hours treatment. 
Figures 7.5 and 7.6 show similar band intensities for PGE2 treated and untreated 
Het1a cells over time. The results show there do not appear to be large changes in 
expression due to PGE2 concentration. 
 
224 bps 
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224 bps 
 
 Electrophoresis of RT-PCR products of VEGF from Oe21 cell line 
 
L       A1     A2    A3     A4      A5     B1      B2      B3     B4      B5 
 
Figure 7.7: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. VEGF RT-PCR products from RNA extracted from 0 (A) and 
0.0005 µg/ml (B) PGE2 treated Oe21 cells over different periods of time. 1 = 1 hour 
treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 hours treatment and 5 
= 72 hours treatment. 
 
L       C1      C2     C3     C4     C5    D1     D2     D3      D4     D5 
2 0.0005µg/ml PGE2 
 
 500 bps500 bpsFigure 7.8: RT-PCR pr
Ethidium Bromide. VEGF
5 µg/ml (D) PGE2 treate
treatment, 2 = 3 hours trea
= 72 hours treatment. 
 
Figures 7.7 and 7.8 show 
cells over time. The result
due to PGE2 concentration
 No PGEoducts visualised with aga
 RT-PCR products from RN
d Oe21 cells over different
tment, 3 = 24 hours treatmen
similar band intensities for PG
s show there do not appear to
. 
1385µg/ml PGE20.05µg/ml PGE2224 bps 
 
rose gel electrophoresis and 
A extracted from 0.05 (C) and 
 periods of time. 1 = 1 hour 
t, 4 = 48 hours treatment and 5 
E2 treated and untreated Oe21 
 be large changes in expression 
 7.3.4. Assessment of EGFR and VEGF Expression Following PGE2 Treatment 
Using Serum Free Media  and RT-PCR (Het1a and Oe21 cells) 
 
It was important to repeat the RT-PCR reactions without the foetal calf serum which 
is added to the media to allow the cells natural growth stimulation, and may cause 
increased expression of the proteins that are being investigated, masking the effect of 
the PGE2. As found with other studies (Tang at al., 1997), without this foetal calf 
serum the cells eventually die therefore the cells are serum treated to the point of 
PGE2 treatment and then replaced by serum free media.  
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 Electrophoresis of RT-PCR Products of EGFR from Het1a Cell line 
 
L       A1     A2     A3     A4     A5      B1      B2      B3      B4     B5 
2 0.0005µg/ml PGE2
 500 bps351 bps 
 
Figure 7.9: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. EGFR RT-PCR products from RNA extracted from 0 (A) and 
0.0005 µg/ml PGE2 (B) treated Het1a cells over different periods of time in serum 
free media. 1 = 1 hour treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 
hours treatment and 5 = 72 hours treatment. 
 
L       C1      C2     C3     C4      C5      D1     D2     D3      D4     D5 
 500 bps 
Figure 7.10: RT-PCR pro
Ethidium Bromide. EGFR R
5 µg/ml (D) PGE2 treated 
media. 1 = 1 hour treatmen
hours treatment and 5 = 72 h
 
 No PGEducts visualised with ag
T-PCR products from RN
Het1a cells over different 
t, 2 = 3 hours treatment, 3
ours treatment. 
1405µg/ml PGE20.05µg/ml PGE2351 bps 
 
arose gel electrophoresis and 
A extracted from 0.05 (C) and 
periods of time in serum free 
 = 24 hours treatment, 4 = 48 
Figures 7.9 and 7.10 show similar band intensities for PGE2 treated and untreated 
Het1a cells over time. The results show there do not appear to be large changes in 
expression due to PGE2 concentration. 
 
Electrophoresis of RT-PCR Products of EGFR from Oe21 Cell line 
 
L       A1     A2     A3     A4     A5      B1     B2      B3      B4     B5 
0.0005µg/ml PGE2No PGE2
 500 bps351 bps 
 
Figure 7.11: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. EGFR RT-PCR products from RNA extracted from 0 (A) and 
0.0005 µg/ml (B) PGE2 treated Oe21 cells over different periods of time in serum free 
media. 1 = 1 hour treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 
hours treatment and 5 = 72 hours treatment. 
 
L       C1      C2     C3     C4      C5      D1     D
Figure 7.12: RT-PCR products visualised with ag
Ethidium Bromide. EGFR RT-PCR products from RN
5 µg/ml (D) PGE2 treated Oe21 cells over different 
media. 1 = 1 hour treatment, 2 = 3 hours treatment, 3
hours treatment and 5 = 72 hours treatment. 
 
500 bps 
 1415µg/ml PGE20.05µg/ml PGE2351 bps 
2     D3      D4     D5 
 
arose gel electrophoresis and 
A extracted from 0.05 (C) and 
periods of time in serum free 
 = 24 hours treatment, 4 = 48 
224 bps 
Figures 7.11 and 7.12 show similar band intensities for PGE2 treated and untreated 
Oe21 cells over time for the two higher concentrations of 0.5 and 5 µg/ml PGE2, 
although the 0.0005 µg/ml had slightly duller bands. As this difference is so small 
they can be accepted as insignificant. The results show there do not appear to be large 
changes in expression due to PGE2 concentration. 
 
Electrophoresis of RT-PCR Products of VEGF from Het1a Cell line 
 
L       A1     A2     A3     A4     A5      B1     B2      B3      B4     B5 
 
Figure 7.13: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. VEGF RT-PCR products from RNA extracted from 0 (A) and 
0.0005 µg/ml (B) PGE2 treated Het1a cells over different periods of time in serum 
free media. 1 = 1 hour treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 
hours treatment and 5 = 72 hours treatment. 
 
L       C1      C2     C3     C4      C5      D1     D2
Figure 7.14: RT-PCR products visualised with agar
Ethidium Bromide. VEGF RT-PCR products from RNA
5 µg/ml (D) PGE2 treated Het1a cells over different p
media. 1 = 1 hour treatment, 2 = 3 hours treatment, 3 =
hours treatment and 5 = 72 hours treatment. 
No PGE2 0.0005µg/ml PGE2
 1425µg/ml PGE20.05µg/ml PGE2224 bps 
     D3      D4     D5 
 
ose gel electrophoresis and 
 extracted from 0.05 (C) and 
eriods of time in serum free 
 24 hours treatment, 4 = 48 
224 bps 
 
Figures 7.13 and 7.14 show similar band intensities for the PGE2 treated het1a cells 
over time. The untreated cells appear to be slightly duller and not as intense, although 
this change do not appear to be enough to be significant. The results show there does 
not appear to be large changes in expression due to PGE2 concentration. 
 
Electrophoresis of RT-PCR Products of VEGF from Oe21 Cell line 
 
 
L       A1     A2     A3     A4     A5      B1     B2      B3      B4     B5 
 
Figure 7.15: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. VEGF RT-PCR products from RNA extracted from 0 (A) and 
0.0005 µg/ml (B) PGE2 treated Oe21 cells over different periods of time in serum free 
media. 1 = 1 hour treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 
hours treatment and 5 = 72 hours treatment. 
 
L       C1      C2     C3     C4      C5      D1     D2
Figure 7.16: RT-PCR products visualised with agar
Ethidium Bromide. VEGF RT-PCR products from RNA
5 µg/ml (D) PGE2 treated Oe21 cells over different p
No PGE2 0.0005µg/ml PGE2
 1435µg/ml PGE20.05µg/ml PGE2224 bps 
     D3      D4     D5 
 
ose gel electrophoresis and 
 extracted from 0.05 (C) and 
eriods of time in serum free 
media. 1 = 1 hour treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 
hours treatment and 5 = 72 hours treatment. 
 
Figures 7.15 and 7.16 shows similar band intensities for the PGE2 treated and 
untreated Oe21 cells over time. The results show there do not appear to be large 
changes in expression due to PGE2 concentration. 
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Assessment of COX 2 expression following PGE2 treatment using RT-PCR (Het1a 
and Oe21) 
 
Electrophoresis of RT-PCR products of COX 2 from Het1a cell line 
 
L       A1     A2     A3     A4     A5      B1     B2      B3      B4     B5 
0.0005µg/ml PGE2No PGE2
 500 bps305 bps 
 
Figure 7.17: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. COX 2 RT-PCR products from RNA extracted from 0 (A) and 
0.0005 µg/ml (B) PGE2 treated Het1a cells over different periods of time. 1 = 1 hour 
treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 hours treatment and 5 
= 72 hours treatment. 
 
L       C1      C2     C3     C4      C5      D1     D2     D3      D4     D5 
 500 bpsFigure 7.18: RT-PCR products visualised with ag
Ethidium Bromide. COX 2 RT-PCR products from RN
5 µg/ml (D) PGE2 treated Het1a cells over differen
treatment, 2 = 3 hours treatment, 3 = 24 hours treatmen
= 72 hours treatment. 
 
 1455µg/ml PGE20.05µg/ml PGE2305 bps 
 
arose gel electrophoresis and 
A extracted from 0.05 (C) and 
t periods of time. 1 = 1 hour 
t, 4 = 48 hours treatment and 5 
 Figure 7.19: The percentage changes of band intensities of COX 2 product taken from 
the electrophoresis gels of Figures 7.17 and 7.18 compared to the untreated control 
Het1a cells. 
 
Figure 7.19 show how the expression changes compare to expression of non-treated 
cells. From this and the Figures 7.17 and 7.18 it can be seen that expression for COX 
2 has increased with concentration, although this relationship slowly reduces to 48 
and 72 hours where additional COX 2 expression seems to be repressed compared to 
normal. It is to be stated that this method of measuring expression is just semi-
qualitative and a real-time PCR would be required for more accurate results. 
 
 
 
 
 
 
 146
Electrophoresis of RT-PCR Products of COX 2 from Oe21 Cell line 
 
L       A1     A2     A3     A4     A5      B1     B2      B3      B4     B5 
0.0005µg/ml PGE2No PGE2
 500 bps305 bps 
 
Figure 7.20: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. COX 2 RT-PCR products from RNA extracted from 0 (A) and 
0.0005 µg/ml (B). PGE2 treated Oe21 cells over different periods of time. 1 = 1 hour 
treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 hours treatment and 5 
= 72 hours treatment. 
 
L       C1      C2     C3     C4      C5      D1     D2     D3      D4     D5 
 500 bpsFigure 7.21: RT-PCR products visualised with agar
Ethidium Bromide. COX 2 RT-PCR products from RNA
5 µg/ml (D) PGE2 treated Oe21 cells over different p
treatment, 2 = 3 hours treatment, 3 = 24 hours treatment,
= 72 hours treatment. 
 
 1475µg/ml PGE20.05µg/ml PGE2305 bps 
 
ose gel electrophoresis and 
 extracted from 0.05 (C) and 
eriods of time. 1 = 1 hour 
 4 = 48 hours treatment and 5 
 Figure 7.22: The percentage changes of band intensities taken from the 
electrophoresis gels of Figures 7.20 and 7.21 compared to the untreated control Oe21 
cells.  
 
Figure 7.22 shows there is not a clear increase in band intensity compared to the non 
treated cells. After the initial one and three hours the smallest PGE2 concentration had 
an effect on the cells and increased COX 2 expression, although this gradually 
decreased over the three days.  The 0.05 µg/ml PGE2 has the opposite effect and 
steadily increases the expression for the first 48 hours. The higher concentration does 
not increase the expression above that of the untreated cells, Figures 7.20 and 7.21 
show that expression is reduced with increased PGE2 concentration after the shorter 
time period, although at 24 – 48 hours the two higher concentrations have a longer 
effect, where the band intensities are corrected by standardising against the 500 bp 
ladder band. Figure 7.22 show a different pattern of expression of COX 2 in the Oe21 
cells from that of   the Het1a cells (Figure 7.19). The expression patterns between the 
two cell lines are similar to the growth patterns shown in Chapter 6 (section 6.3). 
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7.3.5. Assessment of COX 2 Expression Following PGE2 Treatment Serum Free 
Media using RT-PCR (Het1a and Oe21 cells) 
 
Electrophoresis of RT-PCR Products of COX 2 from Het1a Cell line Using Serum 
Free Media. 
 
L       A1     A2     A3     A4     A5      B1     B2      B3      B4     B5 
0.0005µg/ml PGE2No PGE2
 500 bps305 bps 
 
Figure 7.23: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. COX 2 RT-PCR products from RNA extracted from 0 (A) and 
0.0005 µg/ml (B) PGE2 treated Het1a cells over different periods of time in serum 
free media. 1 = 1 hour treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 
hours treatment and 5 = 72 hours treatment. 
 
 
L       C1      C2     C3     C4      C5      D1     D2     D3      D4     D5 
 500 bpsFigure 7.24: RT-PCR products visualised with agar
Ethidium Bromide. COX 2 RT-PCR products from RNA
5 µg/ml (D) PGE2 treated Het1a cells over different p
media. 1 = 1 hour treatment, 2 = 3 hours treatment, 3 =
hours treatment and 5 = 72 hours treatment. 
 1495µg/ml PGE20.05µg/ml PGE2305 bps 
 
ose gel electrophoresis and 
 extracted from 0.05 (C) and 
eriods of time in serum free 
 24 hours treatment, 4 = 48 
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Figure 7.25: The percentage changes of band intensities, measured using Syngene 
GeneTools (Synoptics, Cambridge, UK) taken from the electrophoresis gels of 
Figures 7.23 and 7.24 compared to the untreated control Het1a cells. 
 
The Figures 7.23 and 7.24 show an increase in expression with PGE2 concentration 
increase. This is poorly represented by the photo due to the software exporting poor 
images. This is supported by Figure 7.25 when all concentrations have shown to 
increase expression compared to the normal. As seen with the above Figures the 
intensity of the PCR bands decline with time from PGE2 treatment,  
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Electrophoresis of RT-PCR Products of COX 2 from Oe21 Cell line Using Serum 
Free Media. 
 
L       A1     A2     A3     A4     A5      B1     B2      B3      B4     B5 
No PGE2 0.0005µg/ml PGE2
 500 bps
305 bps 
 
Figure 7.26: RT-PCR products visualised with agarose gel electrophoresis and 
Ethidium Bromide. COX 2 RT-PCR products from RNA extracted from 0 (A) and 
0.0005 µg/ml (B) PGE2 treated Oe21 cells over different periods of time in serum free 
media. 1 = 1 hour treatment, 2 = 3 hours treatment, 3 = 24 hours treatment, 4 = 48 
hours treatment and 5 = 72 hours treatment. 
 
L       C1      C2     C3     C4      C5      D1     D2     D3      D4     D5 
 500 bpsFigure 7.27: RT-PCR products visualised with agar
Ethidium Bromide. COX 2 RT-PCR products from RNA
5 µg/ml (D) PGE2 treated Oe21 cells over different p
media. 1 = 1 hour treatment, 2 = 3 hours treatment, 3 =
hours treatment and 5 = 72 hours treatment. 
 
 1515µg/ml PGE20.05µg/ml PGE2305bps 
 
ose gel electrophoresis and 
 extracted from 0.05 (C) and 
eriods of time in serum free 
 24 hours treatment, 4 = 48 
 Figure 7.28: The percentage changes of band intensities measured using Syngene 
GeneTools (Synoptics, Cambridge, UK) taken from the electrophoresis gels of 
Figures 8.26 and 8.27 compared to the untreated control Oe21 cells. 
 
Figures 7.26 and 7.27 show that after one hour there is a slight increase in COX 2 
expression after no and the smallest concentration of PGE2 treatment, although this 
disappears when treating the cells with higher concentrations of PGE2. Both the gels 
and Figure 7.28 show that there is a significant increase in COX 2 expression 
following 5 µg/ml PGE2 treatment after 24 hours showing a doubling in intensity.  
 
7.4. Discussion 
 
The investigations in this chapter have presented some exciting novel results. Due to 
the importance of the patterns seen in the cell proliferation assays of Chapter 6 
(section 6.3) the lack of conclusive results for growth factor expression seen in 
sections 7.3.2-7.3.4, does not conclusively demonstrate that growth factors are not 
implicated in the carcinogenesis of oesophageal cancer. It is predicted that the method 
of how the growth factors respond to the PGE2 has been at fault. Originally it was 
postulated that PGE2 would have a stimulatory effect on the expression, increasing 
production of VEGF and the EGF receptor, and increasing cellular proliferation. The 
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results shown here suggest this may not be the case as the expression remains 
reasonably constant throughout, regardless of stimulation. The double banding seen in 
Figures 7.5, 7.7 and 7.8 may to be due to different isoforms of VEGF (Sheen et al., 
2005). Increases in growth factor expression were expected with increased PGE2 
treatment, but this was not demonstrated in this study. It is postulated that the PGE2 
may have a stimulatory effect on the proteins that orchestrate the cell cycle, which 
would normally be activated by the growth factors. As discussed below this work has 
led to the suggestion that it maybe the intricate downstream growth factor secondary 
proteins that are affected by the PGE2 to drive cell growth. These results have also led 
to the conclusion that PGE2 stimulation may be increasing COX 2 expression forming 
a positive feedback loop that would stop should the COX 2 substrate, Aracadonic acid 
(derived from linoleic acid in maize), not be plentiful in the oesophagus. 
The optimisation of the western blotting for HGF was thorough but did not yield a 
clear picture. Due to the lack of results with the western blot, it is not possible to 
conclude whether the primary antibody was working, although it has been shown that 
the other components of the method do not appear to be the problem. A great deal of 
time was spent on this with little result, therefore this method was dropped from the 
investigation.  
The antibody (R&D Systems) did not yield positive results; it has not been tested on 
oesophageal tissue. It has been shown to work with the western blotting technique. 
DeFrances et al., (1992) do show positive results for squamous epithelium of the 
oesophagus using an antibody they developed. This was shown to demonstrate 
expression using immunohistochemistry, a very different technique with many 
binding differences. For example the antibodies may be binding to different protein 
epitopes, due to conformational changes following protein denaturation in western 
blotting. DeFrances concluded that HGF levels were high in the oesophageal 
development of rat foetuses, therefore this could be differently structured to human. 
This would suggest a proliferative drive by HGF providing cellular growth, although 
without a positive result using human cells the HGF protein can not be discussed as 
part of the developed theory of this thesis.  
The optimisation of the RT-PCR attempted with the HGF primers was thorough. All 
of the separate components worked, although there was no result from the cDNA of 
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the oesophageal cell lines. A literature review did not show any studies which have 
looked at the expression of HGF in oesophageal tissue using a PCR method. Takada 
et al. (1995) investigated the expression of HGF in human oesophageal squamous cell 
carcinoma using a sandwich ELISA. They discovered HGF expression to be higher in 
oesophageal tissue compared to normal mucosa, concluding that HGF could be used 
as a potential biomarker for cancer progression in this tissue. The positive control 
solution from the HGF primer kit provided positive results for all primers. This should 
provide the evidence that all the components of the methods work. No presentation of 
the HGF gene in the cDNA suggests that the HGF protein may not be expressed at the 
time of extraction. The positive control solution from the kit is made up using 
manufactured polynucleotides specific for the HGF assay primers. 
Further research to look at changes in HGF protein concentrations could be 
undertaken using an ELISA kit and recombinant HGF. Due to the time and money 
spent on the HGF investigation and with few solid conclusions, the investigation was 
moved on to research a different component of the theory stated in Figure 3.2. Other 
more sensitive methods could have been used for example PCR-ELISA, Surface 
Plasma Resonance (SPR) or real-time PCR, should the time and equipment be 
available. The results have not concluded that HGF is important in validating the 
theory; since, these methods may not be sensitive enough. Further investigations are 
required to reach a definite conclusion with respect to HGF. 
According to RT-PCR band intensity the expression for EGFR and VEGF appeared to 
remain constant for all PGE2 concentrations treated for all the periods of time studied. 
It is to be stated that the results from the reverse transcriptase PCR (RT-PCR) are 
semi-quantitative therefore to quantitatively measure the expression using RT-PCR 
would require a Real-Time PCR, such as the TaqMan. It appears that EGFR and 
VEGF are both being expressed fairly constantly between the one to 72 hours 
investigated. As these proteins appear to be expressed when there is no PGE2 or 
serum treatment this neither supports nor denies a connection between the PGE2 
treatment and the VEGF or the EGFR expression.  
There are still large areas to research investigating PGE2 and VEGF and EGFR 
activation. Due to the lack of changes with and without treatment over these time 
periods, it would be interesting to research any changes in the expression of growth 
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factor related proteins after just a few minutes of treatment; once a growth factor is 
released and binds its receptors, it only takes 15 minutes for the early response genes 
to be induced and over an hour for the delayed-response genes to be induced. The 
main reason behind this time difference is due to the latter requiring protein synthesis 
(Almendral et al., 1988). It is this level of growth factor activation that needs to be 
investigated next in order to secure a link to PGE2 growth stimulation and the growth 
factor activation; this will open up new areas of research and potential therapy. 
Increased amounts of VEGF and EGFR would increase the cell proliferation drive. 
However, an increase in the activation of the proteins downstream of these growth 
factor receptors could have the same stimulatory effect. Rather than investigating the 
expression of this growth factor and receptor it may provide greater information to 
research the activation of this growth factor and receptor.  By studying specific 
kinases (e.g. Tyrosine kinase), cyclins or the response genes activation (fos, jun or 
myc) then it may be found that PGE2 activates these growth factors faster or for longer 
periods of time stimulating greater epithelial growth. Both tyrosine kinase and cyclin 
D have been shown to be over-expressed in oesophageal cancer (Nemoto et al., 1997; 
King, 2000). They may have been stimulated by natural proteins such as PGE2.  
The Sammon theory postulates that the growth factors are not being broken down by 
the inhibition of the natural enzymes locally in the oesophagus, although as PGE2 in 
this study has been shown to increase cellular proliferation, this means the pre-
disposition to cancer could be due to reasons outside the theory; for example, 
increases in growth factor expression and activation. To fully investigate the channels 
in which PGE2 could activate cell growth at a molecular level would take another PhD 
project due to the complexity of these growth factor pathways, for example, Figure 
7.28 shows some of the many proteins that PGE2 could be stimulating in the EGF 
pathways. 
Stimulated PGE2 producing receptors are synthesising PGE2 within one to five 
minutes, followed by massive degradation (Klein, 1990). Therefore, should the PGE2 
stimulate the growth factor expression through this mechanism then this RNA 
production may well be initiated between this 15 and 60-minute period and the related 
cell cycle proteins remain over the three day period. Hence, a study over this short 
period may show differences in the time of expression for the proteins providing a 
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clearer understanding of what is happening on a molecular basis rather than a 
snapshot of the natural cell cycle after effects of stimulated cell growth. A majority of 
the results for COX 2 (Figures 7.25 and 7.28) show a gradual decrease in expression 
following 24 hours therefore this could be due to a reduction in localised PGE2, 
through degradation, decreasing local response. These extraction times were chosen 
due to them producing effective results in a previous study (Tjandrawinata et al., 
1997). 
- 
Figure 7.28: Key molecular pathways of Epidermal growth factor (EGF) regulation. 
Growth factor signalling from EGF, results in the expression of target genes, 
including transcription factor genes essential for cell cycle progression. (Sigma-
Aldrich study aids, 2005) 
 
Increased EGFR has already been shown to enhance tumour growth and progression 
in the oesophageal tissue (Mestre et al., 1997), thus should EGFR be up regulated or 
activated by the PGE2, this could explain the hyperplasia present. EGFR expression 
has been shown to increase in oesophageal disease, although an explanation of how is 
still to be determined (Jankowski et al., 1992; Janskowski et al., 1993). Forming a 
connection to this paper, PGE2 is implicated with the inflammation of disease, which 
could explain the proliferative findings of this study (section 1.6.7). Whether EGF, the 
ligand for EGFR, is produced in the human oesophagus is a matter of debate 
(Mukaida et al., 1990; Jankowski et al., 1992). The EGF concentration in the 
oesophagus could be the result of the EGF produced in saliva, as reports show that if 
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saliva glands are removed from a rat there is a decrease in oesophageal mucosa 
protection, which is reversed by the addition of recombinant form EGF (Poulsen et 
al., 1986).  
Regurgitation of gastric fluid in the target population could also increase the EGF 
oesophageal level, and if the Sammon theory is correct in that, an alkali environment 
suppresses the breakdown of these growth factors, there should be an increase in 
proliferation from this external influence. However, growth factors are fragile proteins 
therefore they would not be expected to last very long in the oesophagus. There are 
other suggestions of how this high PGE2 presence would have a cell growth stimulus. 
Work carried out by Pai et al. (2002) and Buchanan et al. (2003) over the period of 
this investigation makes such a suggestion. They treated human colon cancer cells 
with PGE2 and found increased EGFR phosphorylation levels, a trans-activation 
which had the effect of increasing the proliferation of the cells. Using western blotting 
and real time PCR techniques they measured phosphorylated states of intracellular 
growth secondary proteins, such as PI 3 Kinase and Akt. This suggests the need for 
the study of this PGE2 trans-activation of growth factor receptors in oesophageal 
tissue, as this could explain the whole basis of the increased proliferation seen in 
chapter 6. Ozama et al. (1989) suggested that the EGFR levels have a prognostic 
significance in oesophageal squamous cell carcinoma, as survival rates decrease as 
EGFR increases. Negishi et al. (1995) have explained that PGE2 exerts its effects by 
working on the PGE2 receptors coupled with G proteins, also implicated with natural 
growth factor mechanism. These activate or inhibit secondary messenger systems that 
could cause an influx of Ca2+. Li and Villalobo (2002) later discovered that when 
calmodulin is complexed with this Ca2+ then the activity of EGFR is inhibited via 
tyrosine kinase activity, which suggests a relationship between PGE2 and EGFR. It is 
important that changes in expression are not to be confused with the activation of the 
growth factors themselves. 
This association between PGE2 and growth factor activation is of huge importance in 
the carcinogenesis of oesophageal cancer. The method used in this study has not 
provided a great deal of information on this relationship but has opened up new 
avenues of the growth factor pathways that can be analysed. At the start of this thesis 
the general trend of cancer research was to look at the expression and maybe 
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activation that one protein has on another. New technology has expanded the direction 
of cancer research to investigate whole cellular pathways working together over one 
time period. The knowledge of common oncogenes has produced a body of research 
to show how the cell cycle pathways flow and interact together, although this should 
be taken a step further. It is often mutated proteins within these cycles that led to 
chain reactions of carcinogenesis by affecting many pathways involved in apoptosis, 
proliferation and angiogenesis. The future of cancer research is embracing new 
technology to look at cell cycle pathways as a whole, and not just individual proteins. 
This approach needs to take place in this research. PGE2 treatment of the cells, 
pushing proliferation through growth pathways, needs to be investigated as a whole. 
This may be possible now with the right facilities as equipment such as micro-array 
technology is becoming more reliable and computer capabilities to analyse the results 
are now available, for example, the GeneChip by Affymetrix, Santa Cruz, USA. 
Due to cell death with sustained serum deprivation, during the first 96 hours of 
growth the cells in this study were fed with media supplemented with serum to allow 
them to establish growth before comparing expression after different treatments. Tang 
et al. (1997) and Iihara et al. (1993) stated that they found it difficult to look at 
growth factor modulation following serum deprivation as after 48 hours the cells tend  
towards apoptosis. The cells in this investigation appeared to last around two days 
longer than this allowing testing to be extended to 72 hours without cell death. The 
flasks were washed with serum free media but the stimulus for the VEGF and EGFR 
expression may have come from the internal cellular reactions caused by the previous 
serum media, maybe promoting autocrine growth factor production and release. If the 
cells are deprived of serum for around an hour they should enter an altered state, 
known at G0 in the cell cycle, or resting phase. It is then predicted that it takes eight 
hours to emerge from this state and all protein synthesis is depressed (Pardee, 1989), 
although in this study the cells still seem to be expressing these proteins after one and 
three hours in control non- PGE2 treatments. As the cells are being serum starved over 
a period of days then the expression of such proteins may change as a response for 
survival, promoting growth in the case before cell death. There were no peer reviewed 
papers to support cellular serum deprived stress and PGE2 links. The issue is that 
there is not another significant reliable model to investigate growth factors without 
using an animal, which itself will present masses of external influence issues. The 
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body is a very complex organism therefore a good model will also need to have 
similar molecular influences. In the results of this study the different PGE2 
concentrations had increased growth responses compared to no treatment, therefore 
the effects of PGE2, on the cell line can be discussed with confidence that PGE2 has 
the largest effect on the results.  
In the cellular model, these cells taken from human tissues were immortalised by 
various methods, so they may have acquired a mutated growth stimulatory system, a 
factor which contributes to their survival in-vitro. Without studying the cells at a point 
of before they have VEGF and EGFR expression, it is difficult to determine whether 
it is the mutation of the cells that has caused this automated expression. The negative 
control here was to treat the cells with serum free media in a period that the cells do 
not show this expression, for example when serum starved and the cells enter 
senescence (explained above). This did not occur in the short term, as the cells in this 
investigation are starved for 3 days without any change in expression. As this chapter 
shows, the Het1a cell line can grow in serum free conditions in the short term; this 
could suggest that the cells have not entered a state of senescence maybe due to 
autocrine regulation of these required growth factors. Stern et al. (1987) have shown 
in an autocrine model that fibroblasts transfected with localised EGF release, 
exhibited uncontrolled proliferation. These same autonomous expression results are 
provided for the Oe21 cell line.  
The action of angiogenesis in the process of carcinogenesis should not be 
underestimated. Without this introduction of nutrients to the tumour, it cannot grow 
any larger than 1mm in diameter, hence, the huge amount of drug company attention 
on VEGF and cancer therapy. As discussed in section 1.6.5, it is commonly presented 
that VEGF has connections with the development of angiogenesis in tumours and 
some investigators have linked this to COX 2 interaction. A paper printed after the 
research for this thesis was undertaken, showed how polyunsaturated fatty acids like 
those found in fish oils, reduce the VEGF expression in human colon cancer cells. 
This was shown to interact with the growth factor activation pathway and to suppress 
the actions of PGE2, through COX 2 inhibition (Calviello et al., 2004). The process of 
the polyunsaturated acids suppressing VEGF could be due to this being a competitive 
substrate for the same enzymes as PGE2, hence, the decrease in the PGE2 action could 
 159
reduce the stimulation of VEGF activation. Investigations into this could provide 
information as to why people in the target population have a smaller chance of 
developing oesophageal cancer if they have a mix of fatty acids in their diet. Cianchi 
et al. (2004) suggest that the COX 2 activation of VEGF in colorectal cancer could be 
due to COX 2 activation mediated through the effect of nitric oxide.  
Overall it cannot be proven that there are any connections between the expression of 
VEGF and EGFR, and PGE2 treatment in the oesophageal cell lines from the results 
of this study without further models and methods in place. Should results suggest that 
VEGF is being up regulated then this could be via a positive feedback mechanism 
common in cell cycle pathways, as VEGF has been shown to increase the expression 
of COX 2 (Murphy and Fitzgerald, 2001). 
The research into the changes that PGE2 would have on the expression of the enzyme 
that produces it, COX 2, produced some very interesting results (section 7.3.5) that 
were not expected but seem to make sense, as described below. The COX 2 
expression, as suggested by the presence of the RT-PCR product bands from the 
treatment of different concentrations of PGE2 over various periods of time, is clearly 
different to that with no PGE2 treatment. A majority of the above results for both 
serum and serum free treatment of both cell lines has shown an increase in COX 2 
expression following PGE2 treatment compared to no treatment (Figures 7.19, 7.22, 
7.25 and 7.28). Figure 7.19 shows that after the 0.0005, 0.05 and 5 µg/ml PGE2 
treatment there were significant expression increases after one and three hours of the 
treatment in the “normal” Het1a cell line. After 48 hours and 72 hours the 0 and 
0.0005 µg/ml PGE2 treated COX 2 bands were only faintly seen, but the higher 
concentrations of 0.05 and 5 µg/ml had no bands, suggesting a loss of most of this 
expression. This suggests that the expression of the COX 2 has been brought on 
earlier by the PGE2 treatment in the Het1a cell line (Figure 7.17 and 7.18). To keep 
the cells healthy they have to be fed every 48/72 hours, therefore as the serum is used 
up by the cells over the first day or two then COX 2 in the cells may be expressed 
when the cells are starved, stressed or reach ‘crisis’ point, shown after 48 and 72 
hours. Increased PGE2 concentration may well cause this same stressed state more 
quickly therefore bringing the expression forward. A connection can be made as PGE2 
is released when tissues are damaged and stressed leading to inflammation in tissue, 
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stimulating the release of growth promoters to maintain local tissue damage (section 
1.6.7). It may also suggest that PGE2 is being broken down and COX 2 is being 
produced to replace this. Figure 7.17 shows that after the Het1a cells were treated 
with 0.0005 µg/ml of PGE2, the COX 2 was expressed after one and three hours as 
well as after 48 and 72 hours. This is for a much longer period of time than the control 
of no PGE2 treatment.  
As shown with the proliferation assays in chapter 6, the growth curves gave a bell 
sigmoidal growth curve (section 6.3), hence an optimal concentration of PGE2 has a 
maximum response, lesser or higher concentrations of PGE2 have a reduced response. 
If more COX 2 is produced over this period of time and the enzyme’s substrate is 
locally abundant then this may suggest that a higher concentration of PGE2 would be 
produced. It was shown in the previous chapter (section 6.3) that PGE2 has a 
stimulatory effect on the proliferation of cells. By combining the results in this 
chapter and the last it would suggest a positive feedback system where additional 
PGE2 can stimulate the expression of the COX 2 enzyme which itself could produce 
more PGE2. Providing the PGE2 does not reach too high a concentration to cause an 
inhibitory effect (seen in this study, figures 6.1 and 6.2) this repeated process could 
lead to increased cellular proliferation. In the normal oesophagus locally released 
PGE2 may promote cellular restitution following sloughing of cells by food. This 
localised damage and PGE2 may stimulate COX 2 to provide more PGE2 to 
orchestrate this restitution. As the substrate for the COX 2 is used up then this positive 
feedback mechanism breaks down. However, as a maize diet may damage the 
oesophagus, as stated previously by sharp ground maize (Rose, 1979) and provide 
unlimited arachidonic acid (derivative of linoleic acid in maize) for PGE2 production, 
then this positive feedback mechanism could last for much longer periods. Also, the 
regurgitation of stomach fluids provides increased cellular damage, PGE2 and 
arachidonic acid content, further pushing this local proliferative drive.   
Chapter 6 shows that the Oe21 cell line growth response is not as high following 
stimulation as that found with the Het1a Cell line. This could be for reasons 
previously discussed (section 6.4). This includes the concept that mutated proteins 
with in the cell cycle could amplify the receptor stimulus signal causing a slowing of 
cell growth through regulatory processes, producing normally distributed 
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concentration of growth curves. These results show the PGE2 concentrations for the 
Oe21 cell line seem to be too high for increased expression, as the increasing 
concentrations of PGE2 treatment seems to inhibit the expression of COX 2 (Figure 
7.22).  The cells that did not receive any PGE2 treatment seem to express COX 2 after 
one, three and 72 hours. The cells that were treated with PGE2 gradually have 
decreased expression as concentration increases. After one and three hours following 
0.0005 µg/ml PGE2 treatment the expression response was smaller, than one and three 
hours after 0.05 and 5 µg/ml PGE2 treatment. 
The RT-PCR band Figures 7.23, 7.24, 7.26 and 7.27 suggest that there does seem to 
be a small amount of COX 2 expressed following the addition of serum free media 
between the one and 72 hours. This suggests that the serum has an effect on the 
expression of COX 2 when these results are compared to the previous serum treated 
cells. The 0.0005 µg/ml PGE2 treatment showed a positive band after one hour of 
treatment, but not after any other time period. The 0.5 µg/ml PGE2 showed expression 
over one and three hours and the 5 µg/ml PGE2 showed strong expression after one 
and three hours, but also faint expression after 24, 48 and 72 hours. It appears that the 
cell proliferation assays (Chapter 6) and the serum treated cells showed a normal 
distribution in relation to PGE2 concentration and growth response, the expression 
studies have also shown this positive PGE2 concentration and response relationship. 
This provides strong evidence for the argument stated previously that these cells 
respond via a positive feedback mechanism, where increased PGE2 concentration 
increases COX 2 expression, which with the right local substrate concentrations 
would lead to further PGE2 concentration. Therefore, the increasing oesophageal 
cellular proliferation caused by the PGE2 treatment stated in Chapter 6, supports a 
case of pre-disposition to cancer. The Oe21 cell line shows similar results without 
such a positive relationship, which may be due to amplified stimulus response. This 
amplified response may cause the cell to shut down with large concentrations of 
stimulus. This may suggest that only very small amounts of stimulus provide a larger 
response, as previously discussed (section 6.4). The 0, 0.0005 and 0.05 µg/ml PGE2 
treated cells are expressing COX 2 after 48 and 72 hours and the 5 µg/ml treated cells 
are expressing the COX 2 gene after just 24 hours as well as the 48 and 72 hours - a 
longer period of time, but this does not indicate whether more of the COX 2 enzyme 
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is being produced. Using COX 2 protein measurements and further COX 2 
expressions methods would validate whether the PGE2 has a positive feedback 
mechanism increasing COX 2 expression. 
Overall, there is no strong evidence to suggest that PGE2 has an effect on the 
expression levels of EGFR and VEGF, but in light of recent research (Pai et al., 2002; 
Buchanan et al., 2003)  it would be more productive to look at the activation of these 
growth factors . In the Het1a cell line it has been shown that PGE2 increases the 
expression intensity and time of COX 2, which could suggest a positive feedback 
mechanism, which, with increased local substrate, could be a cause of hyper-
proliferation in the oesophagus. 
Summary of results supporting suggested theory: 
• Further investigation for HGF would be required, although the results would 
suggest that HGF is not present in the cell lines; therefore this does not provide a 
good model for this area of research. 
• The expression of VEGF and EGFR did not appear to change following PGE2 
treatment and remained constant. This does not support or disprove the theory. 
Further work needs to be carried out on the activation rather than the increased 
expression of, growth factor, as highlighted in recently released papers. 
• PGE2 treatment in the “normal cell line” increases COX 2 expression over a 
longer period of time compared to the control.  
• In a “normal” population the oesophagus may release PGE2 due to sloughing of 
cells by food, to promote localised growth. This damage and PGE2 may stimulate 
COX 2 faster to provide more PGE2 to orchestrate restitution. As the substrate for 
the COX 2 is used up, then this positive feedback system breaks down. In the 
target population the maize diet reflux may provide a much greater amount of 
PGE2 and arachidonic acid, further pushing local cellular proliferative drive. This 
could be exacerbated by the sharp ground maize ingested, as previously 
documented (Rose, 1969). 
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Figure 7.29:The Sammon Pink theory and how the research to this point supports it.
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 8. Validation of the COX 2 Positive Feed Back Loop 
 
8.1. Introduction 
 
It was established in the previous chapter that PGE2 could have a stimulatory effect on 
the expression of COX 2 in the oesophagus. Increases in COX 2 levels in the presence 
of the right substrate could further produce PGE2. This would form a positive 
feedback loop. It has been shown in Chapter 6 that PGE2 promotes oesophageal 
cellular proliferation at certain concentrations. Arachidonic acid, the precursor of 
PGE2, has been shown to be high in the maize diet ingested by the target population. 
It is suggested that PGE2 relaxes the oesophageal-gastric sphincter promoting 
regurgitation (known as ‘cleansing’ in Transkei), as witnessed in the target population 
(Chapter 2). This causes the stomach contents to flow back up into the oesophagus. 
This thesis therefore presents the novel theory that natural oesophageal restitution 
caused by food ingestion and gastric reflux would lead to localised PGE2 and 
arachidonic acid (derivative of linoleic acid of maize), respectively, in the 
oesophagus.  Should PGE2 stimulate COX 2 production, then this along with 
arachidonic acid, would produce more PGE2, hence, providing a positive feedback 
loop. PGE2 has a short half life in-situ which may work as a sensitive control 
mechanism, forming a positive feedback loop only when the required substrate is 
available. This could be due to PGE2 having huge energy and resource expenditures 
for the body, such as cellular proliferation in restitution.  The high concentrations of 
arachidonic acid in the reflux of the gastric content could provide this substrate 
driving this feedback loop. 
 
As much of this research has been investigated on a model in this thesis, it is 
important to be sure that PGE2 is stimulating COX 2 expression. In the previous 
chapter strong evidence for this was provided by using the reverse transcriptase 
polymerise chain reaction (RT-PCR). This is a fundamental method for analysing 
gene expression, although testing with another method would validate this work. 
Therefore a Northern blotting technique and quantitative nucleotide ELISA assay was 
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also used. As RNA is only stable for short periods of time, to achieve quantitative 
results new cells were PGE2 treated. The RT-PCR was repeated to check that it 
matched previous results and the new methods were carried out. To show that this 
expression related to COX 2 production, the COX 2 protein levels were recorded for 
the various PGE2 concentration treatments on the cells using an ELISA assay.  
 
8.2. Methods 
 
8.2.1. Cellular Model Used for COX 2 Expression Studies 
 
As described in section 7.2.3, Het1a and Oe21 cells were grown in T75 flasks with 
media containing different concentrations of PGE2 (A = 0, B = 0.0005µg/ml, C = 0.05 
µg/ml and D = 5 µg/ml) over different periods of time (1 = 1 hour, 2 = 3 hours, 3 = 24 
hours, 4 = 48 hours and 5 = 72 hours). The RNA and protein was extracted for COX 2 
investigation.  
 
8.2.2. COX 2 Expression Studies using RT-PCR  
 
The methods stated in section 7.2.3 were repeated by extracting RNA (RNeasy, 
Qiagen) from PGE2 treated cells. The cDNA was created by a reverse transcriptase 
reaction (Invitrogen Cloned AMV – first strand synthesis kit) from the RNA and the 
COX 2 expression levels were then investigated using the RT-PCR method. 
 
8.2.3. COX 2 Expression Studies Using an ELISA Assay 
 
The Quantikine colourimetric mRNA quantitation kit (R&D Systems, Abingdon, UK) 
was used for the detection of COX 2 expression in samples from Het1a and Oe21 
cells following different PGE2 concentration treatments over different periods of time 
(same method as section 8.2.1), to validate the results from the RT-PCR method. 
Unless stated the component composition was not disclosed by the manufacturer. 
Total RNA was extracted using the Qiagen RNeasy method, quantified and diluted so 
that all of the samples each have 50µg/ml total RNA. From these samples, 20µl was 
diluted with 280µl sample dilutent (composition unknown). A RNA calibrator 
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containing concentrations of cloned COX 2 cDNA was prepared using 800, 400, 200, 
100, 50, 25, 12.5, 6.2 and 0 aMol/mL, to produce a concentration curve to compare 
the samples against.  
 
The polystyrene 96 well microplate was washed with wash buffer (composition 
unknown). In to each well, 50µl of the COX 2 specific biotin-labelled capture 
oligonucleotide probe and 150µl of prepared sample/calibrator sample were 
hybridised at 65oC for one hour. A streptavidin coated plate was washed with wash 
buffer (composition unknown) and 150µl of hybridization mixture was added and 
incubated at room temperature for one hour on a shaker (500 rpm), binding to the 
plate. This was washed four times and 200µl of polyclonal antibody against 
digoxigenin conjugated to alkaline phosphatase was added to each well and placed on 
a shaker at room temperature for one hour. This plate was emptied and washed six 
times and 50µl of lyophilized nicotinamide adenine dinucleotide phosphate-oxidase 
(NADPH) substrate was added and incubated on a shaker for one hour at room 
temperature. To this 50µl of amplifier solution was added and incubated for 30 
minutes followed by 50µl of stop solution. This was read spectrophotometrically on a 
microplate reader (MRX, Dynex technologies, Worthing UK) at (490nm). Figure 8.1 
shows a schematic diagram of how the ELISA is built up on the plate. 
  
 
Figure 8.1: A schematic diagram of how the ELISA was constructed to produce a 
colourimetric change proportional to the RNA concentration. 
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The results obtained from this assay were compared against the results gained by the 
COX 2 RT-PCR electrophoresis results. 
 
8.2.4. COX 2 Expression Studies Using the Northern Dot Blot Technique 
 
To validate that COX 2 expression has changed by increases in PGE2 concentration in 
oesophageal cell lines a Northern dot blot technique (also known as RNA dot blot) 
was carried out on the same samples as stated above. Due to the lack of positive 
results when using the full Northern blot technique of formaldehyde electrophoresis a 
dot blot technique was adapted from Maniatis (1982). This method gave a positive 
result for beta-actin, but failed to give a result with COX 2. The optimisation methods 
used include different probes (PCR primers and RT-PCR products), different sample 
cell types previously shown to express COX 2 (SKMES, RT112 and OE33), different 
nucleotide cross linking techniques (heat and UV) and wash stringency tests. For 
optimum results with the dot blot assay the mRNA was substituted for cDNA due to 
the increased hybridisation strength of Sample DNA-DNA probe, previously stated as 
binding 25% more than RNA-DNA (Sagesser et al., 1997). 
 
Before any experimentation took place all the equipment was treated with RNase-
ZAP (Ambion) and all solutions were made up using DEPC treated H20. The cDNA 
samples were prepared as stated in section 8.2.2. Of each sample, 5.4µl was mixed 
with 5.4µl 6M glyoxal (all chemicals from Sigma), 16µl DMSO and 3µl 0.1M sodium 
phosphate (pH 7). These were incubated at 50oC for one hour and then chilled on ice. 
To a Hybond H+ membrane (Amersham), 2µl of prepared sample was applied 
without touching the surface, and allowed to dry. The sample nucleotides were cross 
linked to the membrane by baking the membrane at 80oC for two hours. To remove 
the glyoxal the membrane was soaked in 20mM Tris-HCl for five minutes. 
Hybridisation buffer was prepared using 6 x SSC, 2 x Denhardt’s reagent, 0.1% SDS 
w/v, 0.5M NaCl and 5% w/v blocking reagent (Amersham) and heated to 42oC. The 
membrane and 4ml of hybridisation buffer were incubated for one hour in a revolving 
hybridisation chamber at 42oC. The COX 2 probe was prepared by using the PCR 
product from a RT-PCR reaction using DIG labelled dUTP (Roche). Added to the 
hybridisation buffer was 20µl DIG labelled COX 2 probe at 10ng/ml and denatured 
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for 5 minutes at 95oC. This was hybridised for 16 hours at 42oC. The membrane was 
washed with primary wash buffer (appendix L) for 20 minutes at 42oC. The 
membrane was then washed with antibody wash (containing 0.1M maleic acid, 0.15M 
NaCl, NaOH to pH 7.5 and 0.3% v/v tween), for five minutes at room temperature. 
The membrane was blocked with the above wash solution containing 0.5% w/v 
hybridisation block for one hour at room temperature. The membrane was incubated 
with 1:200 horseradish peroxidase labelled anti-DIG antibody (Roche) in the above 
block solution for one hour at 37oC. The unbound components were washed away 
with antibody wash, twice, for 15 minutes each. The membrane was incubated with 
Enzymic ChemoLuminescence (ECL) detection solution for 1 minute, placed in cling-
film. This was placed in a film cassette with x-ray photography paper (Sigma) using a 
red safety light and left for one hour at room temperature. The film was placed in 
developer for 20 to 60 seconds until the small bands appeared on the film. This was 
washed in tap water and then placed in fixer for 5 minutes. If the specific protein was 
present then small bands will appear darker on the opaque film. A schematic diagram 
of this process is represented in Figure 8.2. 
 
Figure 8.2: A schematic diagram of how the Northern dot blot assay was constructed 
to produce a visual change proportional to the RNA concentration. 
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8.2.5. COX 2 Protein Quantification Studies Using an ELISA Assay. 
 
The additional expression assays described above were used to validate previously 
carried out work (section 7.3.5) that PGE2 increases COX 2 expression, this was 
extended by investigating COX 2 protein concentrations. Section 7.2.1.a explains how 
the protein samples were extracted from cells treated with PGE2 over different periods 
of time. As this is a commercial assay from IBL (Gunma, Japan) some of the 
concentrations or components are not stated. 
 
A polystyrene 96 well microplate, pre-treated with Anti-Human COX 2 Mouse 
monoclonal antibody, was filled with 100µl EIA buffer (1% BSA, 0.05% tween 20 in 
PBS).  The plate was incubated for one hour at 37oC following the addition of 100µl 
of sample or standard (68.75, 34.38, 17.19, 8.59, 4.3, 2.15 and 0 ng/ml). Each well 
was washed seven times with 0.05% tween 20 in phosphate buffer. To each well 
100µl of HRP conjugated anti-Human COX 2 rabbit polyclonal antibody was added 
and incubated for 30 minutes at 4oC. The wells were washed nine times with 0.05% 
tween 20 in phosphate buffer. To each well enzyme substrate tetra methyl benzidine 
was added and this was incubated at room temperature for 30 minutes. This gave a 
colour change which was proportional to COX 2 protein concentration. A stop 
solution (1M H2SO4) was added. This was read spectrophotometrically on a 
microplate reader  (450nm). A schematic diagram of this assay is represented in 
Figure 8.3.  
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8.3: A schematic diagram of how the COX 2 protein ELISA assay was constructed to 
produce a colourimetric change proportional to the COX 2 protein concentration. 
 
 
8.3. Results 
 
8.3.1. COX 2 Expression Results Using RT-PCR and RNA ELISA Assay  
 
The results for the quantitative RNA expression ELISA and RT-PCR results, both 
taken using the same samples, have been integrated below to make it easier to 
compare them both.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Substrate 
colour change TMB – enzyme substrate 
phosphate anti-dig 
Well base 
Anti-Human 
COX 2 Mouse 
IgG 
Anti-Human 
COX 2 Rabbit 
IgG 
Conjugated HRP 
COX 2 protein sample 
 171
 Figure 8.4: The graph shows a mean of two sets of ELISA CO
concentration readings from RNA samples extracted from Het1a ce
different concentrations of PGE2 over different time periods. These ar
a standard concentration curve. Above this graph the matching PGE
PCR result is shown using the same RNA samples. The sample label
PGE2 treatment concentration (A = 0, B = 0.0005µg/ml, C = 0.05 µ
µg/ml) and the number; different periods of treatment time (1 = 1 hou
= 24 hours, 4 = 48 hours and 5 = 72 hours). 
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Figure 8.5: The graph shows a mean of two sets of ELISA COX 2 expression 
concentration readings from RNA samples extracted from Oe21 cells treated with 
different concentrations of PGE2 over different time periods. These are given by using 
a standard concentration curve. Above this graph the matching PGE2 treatment RT-
PCR result is shown using the same RNA samples. The sample labels letter refers to 
PGE2 treatment concentration (A = 0, B = 0.0005µg/ml, C = 0.05 µg/ml and D = 5 
µg/ml) and the number; different periods of treatment time (1 = 1 hour, 2 = 3 hours, 3 
= 24 hours, 4 = 48 hours and 5 = 72 hours). 
 
It is clear from Figures 8.4 and 8.5 that the RT-PCR results show similar results to  
the RNA ELISA for both cell lines. These can be used to validate the results from the 
previous chapter showing a PGE2 increase compared to the time period of expression. 
Shown in Figure 8.4 the lower PGE2 concentrations for 0.005 and 0.05µg/ml gave a 
much higher expression result from the ELISA assay compared to no PGE2 treatment. 
Shown in Figure 8.5 for the Oe21 cell line, the expression has increased at 5µg/ml 
PGE2 treatment compared to no treatment. 
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8.3.2. COX 2 Expression Results Using the Northern Dot Blot Technique 
 
       Het1a                 Het1a                 Oe21                 Oe21 
A1  C1   A1 C1     
 
A2  C2   A2 C2 
 
A3  C3   A3 C3 
 
A4  C4   A4 C4 
 
A5  C5   A5 C5 
 
B1  D1   B1 D1 
 
B2  D2   B2 D2 
 
B3  D3   B3 D3 
 
B4  D4   B4 D4 
 
B5  D5   B5 D5 
 
 
Figure 8.6: Typical Northern dot blot results gained from cDNA of RNA samples 
extracted from Het1a and Oe21 cells treated with different concentrations of PGE2 
over different time periods. A = No PGE2 treatment, B = 0.0005µg/ml PGE2, C = 
0.05µg/ml PGE2 and D=5µg/ml PGE2. 1 = 1 hour treatment, 2 = 3 hours treatment, 3 
= 24 hours treatment, 4 = 48 hours treatment and 5 = 72 hours treatment. 
 
The Northern dot blot results showed similar results to that of the two other 
techniques, therefore validating the previous theory that increases in PGE2 causes 
COX 2 expression over longer periods of time. Figure 8.6 show similar intensities to 
that of the peaks on Figures 8.4 and 8.5. This also shows the same high values on the 
graph generally correspond to more intense spots on the dot blot, therefore, increases 
 174
of COX 2 expression over longer periods of time for increased PGE2. The results for 
Oe21 in Figure 8.6 also show this increase in COX 2 expression over longer periods 
of time compared to lower concentrations of PGE2, as seen in Figure 8.5. 
 
Therefore these results validate the theory that increased PGE2 concentration in 
oesophageal tissue causes increases of COX 2 expression for longer periods of time.  
 
8.3.3. COX 2 Protein Quantification Studies Using an ELISA Assay. 
 
 
Figure 8.7: The mean of two sets of ELISA COX 2 protein concentration readings 
from protein samples extracted from Het1a cells treated with different concentrations 
of PGE2 over different time periods.  
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Figure 8.8: The mean of two sets of ELISA COX 2 protein concentration readings 
from protein samples extracted from Oe21 cells treated with different concentrations 
of PGE2 over different time periods.  
 
Shown in Figures 8.7 and 8.8 the two higher PGE2 concentration treatments of 0.5 
and 5 µg/ml, in a majority of cases, show COX 2 protein to be higher compared to no 
PGE2 treatment. In Het1a, the COX 2 concentration reduced over time for all results, 
although the COX 2 remained at similar levels over the time period for the Oe21 cell 
line treated with the two highest PGE2 concentrations.  
 
µg/ml PGE2
8.4. Discussion 
 
The different methods in this chapter were all carried out with the same aim: To test 
the theory that increased PGE2 stimulates the expression of COX 2 in oesophageal 
cell lines. This is to provide evidence that PGE2 increases in oesophageal cancer 
resulting from a high maize diet caused by gastric reflux and cell restitution, this 
would promote COX 2 expression. This along with the high PGE2 substrate 
(arachidonic acid, high in maize) would provide a positive feedback loop causing 
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further PGE2 concentration increases. It has been shown in Chapter 6 that increases in 
PGE2 cause increases in cellular proliferation, thus predisposing the tissues to cancer. 
The results above would suggest that this is the case. The different methods used to 
measure COX 2 expression all support the suggestion that cellular COX 2 levels 
would also increase in the presence of increased PGE2 over various periods of time. 
This is also supported by the increased COX 2 concentration following PGE2 
treatment shown by using the COX 2 protein ELISA assay. 
 
The RNA quantitative ELISA results from Figures 8.4 and 8.5 appear to have broadly 
similar results to the RT-PCR electrophoresis results. When the ELISA results reach a 
required COX 2 concentration, around 55 amol/ml for Het1a and 90 amol/ml for 
Oe21 cell line, a band is seen from RT-PCR. This sensitivity difference could suggest 
two fundamental differences between the two methods. The RT-PCR method only 
provides a semi-quantitative method, were the ELISA is a direct quantitative method. 
This is because the RT-PCR requires a reverse transcriptase method to produce cDNA 
from RNA, adding error to the sample. The RT-PCR requires an optimisation process 
(determining the PCR cycle number that produces the greatest differential in the 
brightness of the RT-PCR electrophoresis result), therefore several steps where it can 
be limited and error occur. This would be overcome by use of a quantitative technique 
such as Taq Man which was unavailable for this study. The ELISA uses a direct 
binding mechanism (Figure 8.1). Therefore the validation shown in this chapter was 
required to be confident of the PGE2 affect conclusion summarised below.  
 
When treated with PGE2, the Het1a cells (Figure 8.4) show an increase in the amount 
of expression over the first three hours. After one hour of 0.0005 and 0.05 µg/ml 
PGE2 treatment there was a large increase in expression compared to one hour of 
untreated cells.  This increase in COX 2 expression is also shown with the Oe21 cell 
line. After the maximum PGE2 treatment in the Oe21 cells the COX 2 expression is 
around double that of the cells not treated with PGE2 over 24 hours. These ELISA 
results show that this quantitative increase is taking place over the first few hours of 
PGE2 stimulation compared to no PGE2 treatment. As this expression is increased 
with PGE2 concentration then any secondary promoters within the long chain of 
numerous cell communication proteins may also be stimulated and activated 
proportionally to PGE2 concentration. The orchestrated effect of cell surface receptors 
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may have a fundamental effect on many common pathways. As this increase in PGE2 
has both shown to increase cellular stimulation (section 6.4) and promote the 
expression of the COX 2 protein then many secondary proteins may have been 
stimulated to reach this expression promotion in the nucleolus (for an example see 
Figure 7.28). It can be suggested that the proliferative effect of PGE2 could be caused 
by an interaction with these secondary proteins, as suggested in the discussion of 
chapter 7 referring to growth factor path stimulation. Hence, mutations in these 
proteins could have an exacerbated effect on this intracellular stimulation. 
Environmental factors found in the sample population, such as smoking, fungus on 
maize and disease, that also have an effect on these same pathways may work in 
synergy with the PGE2 growth pathway promotion making the people of Transkei at 
much higher risk of uncontrolled cell growth, hence cancer. This exacerbated effect 
on the molecular growth pathways would explain why this target population has a 
much higher oesophageal rate than other countries that have similar environmental 
factors i.e. Central Africa. These results support the view that there would be a huge 
benefit of carrying out future work on the affect PGE2 has on the secondary proteins 
of the growth factor pathways. 
 
The Northern dot blot results show COX 2 expression to increase over longer periods  
following PGE2 treatment compared to no PGE2 treatment (Figure 8.6). The results 
appear to be different from the RT-PCR and ELISA methods, although this uses a 
very different method. This assay uses cDNA as the sample, similar to the RT-PCR 
but a direct probe for the detection of the COX 2 gene, similar to the ELISA. 
 
Further validation using a real time PCR was not available. However, these three 
methods have been judged to provide enough evidence to strongly suggest that PGE2 
has a stimulatory effect on the expression of COX 2 in the oesophageal cell lines. 
 
The ELISA assay for detection of COX 2 protein has supported the theory that PGE2 
stimulates the expression of COX 2. The analysis of protein shows the gene has been 
transcribed. The protein being analysed in this case is COX 2, therefore recording the 
COX 2 protein levels are essential to validate this work. As explained in the results 
the higher PGE2 concentration treatments promote greater COX 2 production over 
longer periods of time compared to no PGE2 treatment (Figure 8.7 and 8.8).  This is 
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the same for both cell lines. The Het1a results, shown in Figure 8.7, decrease with 
time, where the Oe21 results, shown in Figure 8.8, remain comparatively high with 
time. This provides an indication that the ‘normal’ Het1a cells may have an intact 
protective pathway inhibiting the production of COX 2, should the production not 
normally be necessary. For the ‘carcinoma’ Oe21 cells this feedback system may not 
be in place allowing the cells to manufacture COX 2 under a tightly controlled 
external receptor stimulatory system. There is a difference in the internal growth 
pathways caused by the carcinogenesis. It was questioned in a previous chapter that 
these cell lines could not be compared against each other as changes in their growth 
characteristics were unknown. These results may support the concept that these cell 
lines present two different characteristics fundamental to a normal versus carcinoma 
model; the normal cells control protein growth and the carcinoma cells do not in this 
case. Although this could not be stated without further validation using tissue and 
animal studies. 
 
Therefore the different assays used in this model have provided evidence that strongly 
supports the conclusion that PGE2 has a stimulatory effect on the expression of COX 
2 and its production in oesophageal tissue. Further work would be required to confirm 
this and analyse how PGE2 achieves this. It is predicted that PGE2 binds to an extra 
cellular receptor on the membrane, which in turn leads to a complex orchestrated 
cellular growth pathway producing by products such as COX 2. Careful intervention 
with this pathway could provide treatment for this population, although they could not 
afford treatment therefore a change of diet would provide a cheaper alternative. The 
study of this mechanism could provide information on the unknown drug action of 
treatments such as paracetamol and aspirin.  
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 9. Conclusion 
 
Cox 2 has become a huge area of research; since this work began, the papers 
documented on Pubmed linking Cyclooxygenase to cancer have more than doubled, 
increasing by around 25% every year. This is likely to be driven by the commercial 
interest in COX 2 inhibitors as cancer suppressors. This thesis supports this research 
at a time when the importance of COX 2 in cancer is being realised and can add 
valuable insights into cancer research overall. Further developments of this field are 
likely in the future. Following the presentation of this research at the American 
Association of Cancer Research (AACR), a paper is being submitted at the request of 
the editor of the ‘Nutrition and Cancer’ journal (Lawrence Erlbaum Associates 
Publishing). 
Much of the research in the literature review (Chapter 1) has stated the importance of 
COX 2 in the development of oesophageal cancer, mainly due to the increased use of 
knock out/down methods. From this exciting work it can be suggested that PGE2 has a 
particular effect due to the knowledge that COX 2 helps to produce PGE2. Therefore 
this current study postulates that PGE2 is the important factor increasing oesophageal 
cell proliferation, represented here by the use of an in-vitro cell line model. This 
investigation is novel in the context of showing PGE2 to have a mitogenic effect on 
oesophageal cell lines, not previously shown, and that PGE2 itself may have an effect 
on its own production via a positive feedback system (chapters 7 and 8). Growth 
patterns observed in these results have supported recent studies in that the PGE2, 
shown in this thesis to be high in gastric fluid of the sample population caused by a 
high maize diet (chapter 6), may be activating growth factor pathways downstream of 
the normally stimulated receptors, having a pre-disposing carcinogenic effect. The 
PGE2 may be lasting in the oesophageal lumen for much longer periods of time 
protected by transporter proteins. This, constitutes molecular evidence with which to 
expand the present Sammon theory (section 1.9). 
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9.1. The Mitogenic Effect of a High Maize Diet  
 
The measurement of the PGE2 concentrations in the gastric fluid samples of the 
people from the target population, was predicted to be higher than for people that 
ingest a “western diet”, using related pieces of research (Figure 5.3). Results in 
Chapters 5 and 6 support the theory that the high maize diet consumed by the target 
population increases PGE2 content in the stomach. This can suppress the smooth 
muscle of the gastric sphincter allowing gastric reflux into the oesophagus (section 
1.9.3). Gastric reflux has been documented in about 60% of the target population 
oesophagus (Sammon, 1994). 
The novel results of Chapter 6 show that in squamous cells, PGE2 has a proliferative 
effect, pre-disposing the tissue to oesophageal cancer. From this model it can be 
deduced that the regurgitation of gastric fluid, exacerbated by localised PGE2 released 
for natural restitution caused by sharp maize damage, would increase PGE2 to high 
concentrations in the oesophageal lumen. These studies show that, at a high enough 
concentration, this would drive a localised proliferative effect. This was supported by 
increased cellular proliferation of oesophageal cells following gastric fluid treatment, 
suggesting that the gastric fluid from the sample population promotes oesophageal 
cell hyperplasia due to its high concentration of PGE2.  
This concurs with present research and the Sammon theory. Sammon suggests that 
changes in oesophageal pH levels, due to this alkali regurgitation of gastric fluid 
suppresses the natural breakdown of growth factors by inhibiting the enzymes that 
cleave them, hence allowing growth factor stimulation to remain. Due to the short half 
life of growth factors this may not likely to be the case, but increases in local PGE2 
could have a direct proliferative effect on the squamous tissue. Therefore, the 
increased PGE2 levels have a direct influence on local squamous growth stimulation, 
perhaps through the intracellular manipulation of these growth factors. 
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9.2. The Mitogenic Effect of Maize at a Molecular Level 
Chapter 5 disscussed a study investigating the possible detrimental effects of the three 
day transportation of the samples. This showed the expected results of a drop in PGE2 
levels in the samples after transportation. Additionally a very interesting pattern was 
revealed. As explained in section 5.4 the PGE2 in the gastric fluid after the journey, 
and the PGE2 levels after the simulated journey showed a similar drop to a specific 
concentration in all the samples. It was suggested that these remaining PGE2 proteins, 
not degraded by the journey, appear more stable, perhaps bound to their transporter 
proteins (MRP4 and ABCC4), similar to that found with the related Prostaglandin I2 
stabilised by Apolipoprotein (Aoyama et al. 1990).  This may mean that not only 
could the increased localised PGE2 have a stimulatory effect on the cells, but due to 
increased stability the PGE2 would remain in the oesophagus for longer periods of 
time. Investigating this molecular interaction further would provide an insight into 
how a protected epithelium, like the mucus lined oesophagus, may be stimulated to an 
extent that could lead to cancer by short half-life unstable proteins.  
The mitogenic effect PGE2 on the oesophageal cell lines was optimal at a certain 
concentration, showing similar patterns to that found when treating cells with a 
growth factor, suggested as the PGE2 proliferative action. Therefore, it could be 
postulated that the PGE2 treatment may have a stimulatory effect on the growth 
factors directly, as suggested in recent papers (Pai et al, 2002; Buchanan et al., 2003). 
After discussing the results in Chapter 7, it became evident that it would be more 
significant to investigate the activation of growth factors and their receptors, for 
example, by looking at decreases in Rb phosphorylation (King, 2000), early response 
genes (Almendral et al., 1988) or changes in cyclins (Takeno et al., 2002). Since the 
start of this project it has been discovered that breast cancer progression can be 
inhibited through blocking COX 2, itself blocking vascularisation caused by VEGF 
(Saji, 2004). The VEGF and EGFR investigated in chapter 7 are two very important 
proteins that are implicated in oesophageal cancer. There has been growing interest in 
these proteins from the larger drug companies such as Astra Zeneca and Roche, In 
February 2004 the FDA approved the use of Avastin (Genentech Inc) for colon cancer 
patients which it thought to work by reducing tumour stimulated angiogenesis by 
inhibiting VEGF. This is marketed in the UK by Roche and is called Bevacizumab 
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and was given NICE appraisal in January 2007. Astra Zeneca have recently invested 
around 500 million dollars in buying Cambridge Antibody Technologies developing 
growth factor binding human specific antibodies for cancer therapy. This was 
achieved through phage library technology that would be ideal for mapping growth 
factor downstream protein interactions in this study, but is hugely expensive. 
PGE2 may naturally up-regulate EGFR and VEGF in normal tissues, as PGE2 is 
implicated in foetal development, and angiogenesis and epithelial proliferation are 
both required for tissue growth. Therefore, this shows the importance of pursuing 
research in this field. 
Throughout the development of the aims, the thesis concentrated on the PGE2 effect 
on growth factor expression rather than intracellular activation of these growth factor 
pathways. The concept of PGE2 having an effect on the activation of the growth factor 
downstream components was only realised following a talk on PTEN tumour 
suppressor gene and its unrelated interactions with other proteins, as well a recent 
discussion of this work following its presentation. This led to the late discovery of Pai 
et al’s. (2002) and Buchanan et al.’s (2003) work on PGE2 activation of growth 
factors in other tissues. The study of molecular and cellular biology has dramatically 
changed over the years the last few years. The groups at the forefront of cellular 
biology are studying how a protein affects many other cellular pathways at the same 
time; this is through software such as cPath, pathBLAST, Pathway Tools and 
microarray technology. Although the technology is expensive, this would greatly 
progress this research. 
 
9.3. Is this the Right Model? 
 
There are fundamental questions to be asked about the model used in this thesis. It is 
not that this was the wrong model, but issues have to be considered. This model is 
fundamental in cancer research. It is relatively cheap and represents the molecular 
pathology only second to carrying out animal studies.  
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This model only allows the study of a single cell population, although the suggested 
methods of carcinogenesis caused by increased maize ingestion would involve many 
cells interacting with each other. Therefore this model is limited in representing the 
proliferative interactions seen with in the human body. This model has its limitations 
but also allows single cell understanding without further variables affecting the 
stimulation of cells by paracrine factors. It is fundamental to take one step at a time 
with these complicated orchestrated cellular interactions. Once these are established 
then extra cell lines and animal models can be pursued as the next stage in model 
development. 
The study of growth factors outlined in Chapter 7 showed difficulties with using this 
model. Only after the observation of constant VEGF and EGFR expression following 
serum treatment in media, did it become apparent that the foetal calf serum may have 
a stimulatory effect on the growth factor expression rates. This presents a problem for 
designing a significant model that examines the measurement of expression just 
caused by PGE2 itself. As the cells require serum to stay viable, by removing the 
serum moments before RNA extraction for an expression measurement, there would 
still be no certainty that the serum was not having a stimulatory effect on the growth 
factor expression. Conversely, by serum starving the cells, it cannot be positively 
shown that the response is not due to serum withdrawal causing cellular stress, 
leading to various survival proteins to be expressed. Tang et al. (1997) and Iihara et 
al. (1993) stated that using a cellular model it is difficult to investigate growth factor 
modulation following serum deprivation, as after 48 hours the cells tend undergo 
apoptosis. This is not the case for the PGE2 treatment increasing COX 2 expression as 
discussed (section 7.4).  
Therefore, for the analysis of growth factors, it would be of more value to investigate 
the activation of growth factors quantitatively. For example, the activation of growth 
factors and receptors caused by PGE2, though the activation of ras or tyrosine kinase 
could be monitored using protein ELISA assays.  This may present a protein that 
could be studied that is not hugely affected by the serum, but more by the PGE2 itself. 
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9.4. The COX 2 Positive Feedback Theory 
 
Shown in Chapters 7 and 8, the PGE2 treatment on oesophageal cell lines gave 
significant differences of COX 2 expression over a period of one to 72 hours. The 
results demonstrated a very novel concept, that at an optimum concentration of PGE2 
treatment, the COX 2 is expressed for longer periods of time (Chapter 7), both at the 
RNA and protein levels (Chapter 8).  
If these findings revealed by this model have direct implications on the sample 
population, then increased PGE2 from the high maize diet is refluxed into the 
oesophagus for reasons previously explained. This PGE2 could have a proliferative 
effect on the oesophageal cells and should this localised PGE2 also stimulate COX 2 
expression, increases in its substrate (arachidonic acid in abundance in the gastric 
fluid following a high maize meal), then further PGE2 would be produced, having 
further stimulatory effects. This positive feedback mechanism may work as a natural 
process of oesophageal cellular restitution following damaged caused by swallowing 
food. Hence, the arachidonic acid content may be low inhibiting many cycles of this 
positive feedback loop. This increase in cellular proliferation could amplify the 
mutational effect of environmental carcinogens.  Due to the COX 2 enzyme having 
both oxygenase and peroxidase functions, one carcinogenic action could be to 
catalyse the conversion of pro-carcinogens to carcinogens. COX 2 activity is thought 
to be responsible for the conversion of the pro-carcinogen benzo(a)pyrene, present in 
tobacco smoke, into the carcinogen of mutagen benzo(a)pyrene diolepoxide (Kelley et 
al., 1997). 
 
9.5. Updating the Sammon Theory 
 
Much of this research supports the Sammon theory (section 1.9) by validating the 
theoretical postulates with evidence from these cellular models. As well as providing 
evidence on the mitogenic actions of the maize diet, it also provides understanding as 
to what may be happening on a molecular level and how this may affect the general 
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pathology seen in the target population. The general pathology is further supported by 
physiological factors witnessed in the target population, such as gastric regurgitation. 
Therefore, this suggests new areas for study in different genres of life sciences to 
further this work.  
There are many factors that could affect the homeostasis of the oesophageal cells, 
therefore it is hard to pin point which factors could be driving the cancer progression, 
especially with an unfamiliar target population studied for such a short time. As 
explained above, the results suggest that increased PGE2 in the diet, hence in gastric 
fluid, as seen in the Transkei population, may occupy the oesophagus following 
regurgitation. The Sammon theory states that this increase in pH would suppress the 
localised pepsin that would normally breakdown the growth factors present (Sammon 
& Alderson, 1998). This may allow the growth factors to stimulate cellular growth for 
increased periods of time. The results from this thesis suggest that the increase in 
PGE2 has a direct mitogenic effect on the oesophageal cells, bypassing growth factor 
release, although this cellular growth may still be through intracellular growth factor 
activation.  The proposed method suggested by Sammon may be questionable due to 
the growth factor’s short half-life. It can be predicted that in order to have constant 
cellular stimulation from the growth factors, they will have to be reproduced or 
activated at a constant rate. This could be due to changes in the habits of the cells, 
mutation, growth factor stimulating mechanisms such as tyrosine kinase or mutations 
in the production of ras. Direct stimulation by the PGE2 may produce an exaggerated 
proliferative effect explaining the large luminal oesophageal tissue growths seen in 
the target population. 
In order for oesophageal cell growth to take place many proteins will be expressed 
and activated. Through this constant increase in cellular proliferation there is 
increased production of cellular proteins, therefore, a greater chance for mutations in 
DNA to take place. A proto-oncogene could be mutated, hence, cancer initiated by 
tobacco smoke or fungal infection from the maize. It is not postulated here that the 
increased PGE2 from the high maize diet is the single carcinogenic factor, but it 
increases the pre-disposition of oesophageal cells to cancer by external carcinogens. 
This is not helped by the increased prevalence of local disease and high PGE2 
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amounts suppressing the immune system (Harris et al., 2002), therefore preventing 
carcinogenic reactions and carcinogens from being disposed of naturally. 
 
9.6. How Can this Help the Target Population? 
 
As the Sammon theory is updated with the work that has been presented in this thesis, 
it has become clearer how this research could translate into aiding the target 
population with its oesophageal cancer problem. This thesis has shown how 
fundamental PGE2 through diet is in the carcinogenesis of the oesophageal cancer in 
the Transkei population.  
To help the target population it is important to find a preventative rather than a 
treatment, as treatments are often expensive, which developing areas cannot afford. 
This is exacerbated by the fact that many of the Transkei people only visit their health 
centres when the symptoms have become greatly developed, past the stage of 
treatment. Should this developed “Sammon-Pink theory” be right, it would be 
important to investigate other dietary fats that would be cheap to produce, that 
naturally compete (Kinsella et al., 1990) with arachidonic acids for the COX 2 
enzyme, decreasing the gastric PGE2. Ideally a more varied diet would be undertaken 
that included other vitamins and vegetables, as all of these have been shown to have 
inhibitory effects on oesophageal cancer (Barone et al., 1992; De Stefani et al., 1999; 
Franceschi et al., 2000). Various South African plants have shown COX 2 inhibiting 
properties that could be investigated. The bark from the Erythrina species of plant, 
used by traditional healers, has been shown to have anti-bacterial and prostaglandin 
synthesis inhibiting properties (Pillay et al., 2001). This was also discovered in the 
extracts of other local plants: siphonochilus, aethiopicus and solanum (Lindsey et al., 
1999; Jäger et al., 1996). It is fundamental that the South African population are 
educated about how diet affects their health. Prevention through education is the 
cheapest and the most efficient way of eradicating this disease by allowing the 
population to take steps to helping themselves.    
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COX 2 inhibitors and NSAIDs, are of great interest to the large drug companies such 
as Pfizer and Merck. This is not only due to their suppression of PGE2 relieving 
arthritis sufferers, but also through their promise in the suppression of tumour growth. 
Aspirin is known to inhibit PGE2 production through COX1 and COX 2 suppression. 
Therefore it could be suggested that Aspirin could inhibit this excess PGE2 production 
in the target population caused by COX 2. A clinical trial could be set up where 
patients take aspirin or a placebo and the amount of regurgitation/cleansing is 
measured. Should the aspirin reduce this then histological studies investigating 
pathological changes could be carried out to see if these patients are at lower risk of 
oesophageal cancer than the patients not taking the aspirin. Even though aspirin has a 
detrimental effect on the stomach lining, the reduction in oesophageal cancer at the 
cheap price of aspirin may be considered worthwhile. As aspirin is no longer under 
patent there are little profits in its use, therefore clinical trials would have to be paid 
by the charitable grants. Even though the treatments are promising it is fundamental 
that this population are educated on how to help themselves through a more varied 
diet.  
 
9.7. Research Summary 
 
The key findings of this project are summarised as follows: 
• Gastric fluid from a population that regularly ingests high amounts of maize, 
contains high amounts of PGE2 
• PGE2 at certain concentrations increases oesophageal cellular proliferation, 
thought to be linked to growth factor increase due to common characteristics. 
• Proteins found in the gastric fluid from the sample population increases 
oesophageal cellular proliferation. It is postulated that the PGE2 in the sample 
may cause this hyper-proliferation. 
• HGF is not expressed at detectable levels in the cell lines used. 
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• It is suggested that the VEGF and EGFR mechanisms are activated by 
increased PGE2, rather than pH changes in the oesophagus not breaking down 
growth factors as originally suggested in the Sammon theory. 
• PGE2 increases the time period of COX 2 expression causing a positive 
feedback loop that, in the presence of COX 2 substrate and gastric reflux, 
leads to continuous local mitogenicity, predisposing the squamous epithelium 
to cancer. 
• Other local factors such as fungal infection of the maize, smoking and disease 
may then progress this proliferative state to in-situ carcinoma. 
 
Collectively, these findings contribute to the development of the Sammon theory, 
although much remains to be done to validate this, and translate the theory into 
actions which can help save lives of the people in the Transkei through inhibition of 
PGE2. An updated schematic representation of the Sammon theory is presented in 
Figure 9.1. 
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9.8. Suggested Pathways Contributing to Carcinogenesis of Oesophageal Cancer 
in Transkei, South Africa: 
 
Figure 9.1: Suggested epidemiological Carcinogenesis of oesophageal cancer in 
Transkei, South Africa  
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The References for Figure 9.1 on the epidemiological carcinogenesis of oesophageal 
cancer in Transkei, South Africa 
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25. Matsha et al., 2002 
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10. Further Work 
Although the research in this thesis has presented some very interesting findings, up 
dating the Sammon theory, this has just touched the surface of what can be 
investigated. From this work and peer reviewed studies, a diagram of the suggested 
molecular carcinogenesis of oesophageal cancer in the sample population of Transkei, 
South Africa was created (Figures 9.1). This shows huge areas of research required to 
further develop an understanding of the Sammon theory, both, the mitogenic action of 
PGE2 is required to understand why people in Transkei suffer from oesophageal 
cancer up to ten times more than other areas of the world, and what can be done to 
help them. In the following chapter the fundamental research areas are outlined.  
 
10.1. Further Investigation into the Discussion Points in this Thesis 
 
10.1.1. Activation of Growth Factors by PGE2 
 
As discussed in the conclusion, further investigations are required to study the 
relationship between the PGE2 proliferative effect on the oesophageal cells and the 
intracellular activation of growth factors. This information would be of greater value 
than the expression studies carried out in this thesis (Chapter 7). By studying specific 
kinases (e.g. Tyrosine kinase), secondary proteins (ras, p53), cyclins or the early 
response genes activation (fos, jun or myc), it may appear that PGE2 activates these 
growth factors faster or for longer periods of time, stimulating greater epithelial 
growth. Both tyrosine kinase and cyclin D have been shown to be over-expressed in 
oesophageal cancer (Nemoto et al., 1997; King, 2000). This increased stimulation 
could have been the cause of natural proteins such as PGE2. Mutational studies of 
these intracellular growth factor pathway proteins in the target population could raise 
progression and promotion factors in carcinogenesis, exacerbated by the proliferative 
effect of PGE2. New innovative techniques are on the market to investigate whole 
molecular pathways in short periods of time. Microarrays such as the Genechip, sold 
by Allymetrix, claims to be able to study tens of thousands of intracellular genes at 
one time, modelling pathways such as growth factors. This would be ideal for this 
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study, but the equipment is very expensive at £250,000 for the chip reader and 
between £50- £500 for the chips. The price is expected to fall as the chips are 
produced in a plastic format rather than metal and demand increases as more 
laboratories realise that, in the words of Vogelstein “the future of cancer research is 
based on the interaction of whole pathways” (AACR 2006). The study of how protein 
A affects protein B, tells us only about the effect, which may bypass many of the true 
cancerous proteins. 
 
10.1.2. PGE2 and Transporter Protein Protection 
 
In Chapter 5 the concept of PGE2 transporter protein protection was discussed 
following a pattern of intriguing results (section 5.4). The PGE2 levels seem to remain 
at higher concentrations for longer periods of time than previously documented 
(Klein, 1990). Aoyama et al. (1990) discovered that the half-life of prostaglandin I2 
(similar to PGE2) was stabilised by apolipoprotein A-I (Apo A-I), a major 
apolipoprotein of high density lipoprotein. Apolipoprotein synthesis in the intestine is 
regulated principally by the different fat contents of the diet, similar to this study 
(Eichner et al, 2002). Apo A-I bound proteins were stabilised for up to 90 minutes 
compared to one to six minutes without. The PGE2 and prostaglandin I2 have very 
similar structures, produced from the same protein, Prostaglandin H2, both produced 
by COX 2 (Figure 1.10); both could have stabilising proteins. By investigating the 
PGE2 transporter proteins like MRP4 and ABCC4 (Ruis et al., 2005), this could 
provide information on the protection of PGE2 from natural degradation, stimulating 
the oesophageal tissue for longer periods of time. 
 
10.1.3. Experimental Models 
 
Using oesophageal cell lines as a model has its limitations, due to many reasons, 
including this not representing localised different cell to cell interactions and the cell 
lines being developed to stay alive in synthetic conditions. Therefore, changes in the 
cell lines predominant growth characteristics compared to the body is inevitable. The 
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addition of foetal calf serum to cell media is required for cell growth; these contain 
large amounts of growth factors, therefore, when growth factor levels are being 
investigated the use of a more significant model should take place. Others have also 
discovered this; Tang et al. (1997) and Iihara et al. (1993) stated that they found it 
difficult to look at growth factor modulation following serum deprivation as after 48 
hours the cells tended to lead to apoptosis. They did not suggest a preferred method. 
The closest model to that of a human would be to use animals, such as mice. Mice 
could be fed with various concentrations of maize, linoleic acid and PGE2, and the 
protein and RNA levels in the oesophageal and gastric tissue could be investigated. 
Should PGE2 have a carcinogenic effect, this could be investigated and staged with an 
animal model.  
 
10.1.4. Laboratory Based in-vivo Studies 
 
Using a sensitive immuno-cyto-fluorescent method for tissue analysis, such as that 
shown in Figure 10.1 from a preliminary study, could take place investigating the 
areas in-vivo where the PGE2 and COX 2 may be produced. Slices of human or 
animal tissue from different stages of oesophageal squamous cell carcinoma could 
provide an insight into the PGE2 and COX 2 effect on the general stages of 
carcinogenesis, as this thesis can only suggest that PGE2 has a pre-carcinogenic effect 
increasing the chance of initiation, rather than promotion and progression.  
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 Figure 10.1:  A sensitive immuno-cyto-fluorescent method here used for staining the 
nucleus (green) and COX 2 protein (red). This was a preliminary study carried out on 
RT112 bladder cells visualised with the confocal microscope. 
 
10.2. Further Research into the Components of the Sammon Theory 
 
10.2.1. Gastric Reflux  
 
The reflux of gastric fluid into the oesophagus is fundamental to the Sammon theory. 
Due to the many components of gastric fluid, greater analysis of the effect the sample 
population’s gastric fluid, and the gastric fluid of a population eating a regular diet, 
has on squamous tissue should take place. This could include the analysis of other 
maize related constitutes. It was discovered by Sammon (2002) that the gastric fluid 
of the sample population, which refluxes into the oesophagus, is more alkali than the 
expected low pH of the stomach. This change in pH could have an effect on many of 
the chemical structures, hence, molecular reactions in the oesophagus. Therefore, 
investigating high pH changes on gastric or dietary components in the oesophagus 
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could present differences to suggest why Barretts oesophagus pre-disposes the 
oesophagus to adenocarcinoma. This may show an insight into any connections of the 
carcinogenesis between the squamous cancer and, any already discovered links from 
the heavily researched, adenocarcinoma.  
 
10.3. Epidemiological Investigations 
 
10.3.1. Environmental Factors and Mutagenicity 
 
The research in this thesis suggests that PGE2 has a proliferative effect on the 
oesophageal cells, therefore this may be a pre-disposing factor aiding initiation and 
promotion. Hence, studies need to be made to investigate any mutagenic reaction 
from the PGE2. These studies should also report on the synergistic action PGE2 may 
have with known environmental carcinogens. Testing the gastric samples and PGE2 
for mutagenicity with methods like the Ames test and its variations could support this. 
There are many potential carcinogenic environmental factors seen in the target 
population, which themselves present large areas of research. Examples of such 
environmental factors include aflatoxins found in the fungus of maize, and the 
consumption of tobacco products. Aflatoxins and tobacco consumption may be 
connected to specific transversions or transitions in the genome, therefore, the genetic 
analysis of the target population is oesophageal samples may present more 
information as to whether they have an effect. A full epidemiological study may help 
in the discovery of carcinogenic factors.  
 
10.3.2. Disease and Carcinogenesis  
 
A majority of the Transkei can be classed as economically and sociably poor 
compared to the western world. Diseases that are eradicated, or efficiently treated in 
the UK, are prevalent in many areas of South Africa, including the areas with high 
number of oesophageal cancer cases. There is a large chance that diseases such as H 
pylori gastric infections, tuberculosis, HPV and AIDS have an effect on the 
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development of oesophageal carcinomas. If this is not through direct molecular 
interactions then it could be through suppression of the immune system. There is little 
peer reviewed evidence to support this connection, although the chances are high and 
the research has not yet been carried out. For example, Helicobacter pylori is 
associated with gastric cancer (Jiang & Wong, 2003) and it was shown that H. Pylori 
infection may induce atrophic gastritis, which results in a less acidic gastric reflux, by 
neutralising gastric acid through the production of ammonia (Richter, Falk & Vaezi, 
1998). This may explain the increases in the pH of gastric fluid in the target 
population. It can be argued that many epithelial tissues react similarly to extra 
cellular stimulus, therefore if H. pylori has a carcinogenic effect on gastric tissue the 
conditions may apply for oesophageal tissue. Hence, studies in this area would be of 
value. 
Bachelor et al. (2004) has linked skin cancer to COX 2 increases, through mediated 
skin tumour promotion. Populations that ingest a high maize diet may be more at risk 
to skin cancer than people ingesting a varied diet. This theory could be tested in the 
target population who ingest a high maize diet, should the theory be correct that PGE2 
stimulates the expression of COX 2.  
 
 
10.4. Expanding the Sammon Theory 
 
10.4.1. Apoptosis (BCL and BAX) 
 
As shown in Figure 9.1 it is suggested that the same enzymes that produce 
prostaglandins, from the linoleic acid found in a high maize diet, could inhibit 
apoptosis upsetting the fine balance in normal cellular homeostasis. Research could be 
carried out on this half of the cellular growth control balance, affecting the rate of 
proliferation, hence, pre-disposition to cancer. Changes in linoleic acid treatment and 
apoptotic proteins such as BCL2 and BAX could be researched. Activational studies 
of mitochondrial enzymes could show the state of apoptosis as this is thought to be 
the area that initiates apoptotic cell death. By investigating the inhibition of any 
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adverse reactions caused by this high maize diet, for example LOX inhibitors, 
apoptosis may be stimulated slowing the development of cancer in the target 
population.  
 
10.4.2. Prostaglandin E Synthase 
 
This thesis shows that PGE2 has a proliferative effect on the oesophageal cell lines 
(section 6.4). In the production of PGE2, an enzyme called prostaglandin E synthase, 
which functions further downstream to COX 2, converts prostaglandin H2 to 
prostaglandin E2 (Figure 1.10). This enzyme has been implicated with tumourigenesis 
in colon cancer cell lines (Kamei et al., 2003) and non-small cell lung cancer, thought 
to be connected to ras (a growth factor secondary protein) activation increase 
(Yoshimatsu et al., 2001). Little has been investigated into the carcinogenic actions of 
this enzyme, although like COX 2, it is expected to be due to the production of PGE2. 
This enzyme could be researched by its suppression caused by anti-inflammatory 
glucocorticoids (Murakami et al., 2002). Inhibition of these enzymes could be as 
potent as COX 2 inhibition in the suppression of cancer. 
 
10.4.3. PGE2 Markers 
 
Should increased PGE2 prove to be the potent protein in the development of 
carcinogenesis, the measurement of PGE2 effects in the body could be used as a 
marker for the potential of oesophageal cancer. PGE2 attenuates vasopressin-induced 
NaCl reabsorbtion in the kidneys (Negishi et al., 1995), increases internal calcium 
levels (Toborek et al., 1997), is linked to periodontal disease (Harris et al., 2002) and 
induces bone formation (Kobayashi et al., 2002) PGE2 has been postulated as a 
histopathologic predictor for proliferation and invasion in urothrelial carcinomas of 
the bladder due to its relationship with cancer aggressiveness and concentration 
(Eschwège et al., 2003). These physiological states offer markers to predict high 
PGE2 levels in the body. Using these are markers to screen oesophageal cancer in the 
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target population could be too expensive, but by adapting this knowledge for cancer 
screening or treatment in the western world may provide a economic benefit for 
research in Transkei. 
 
10.4.4. Food Related Studies  
 
There are a number of foods that can be implicated by this study that are postulated to 
suppress the harmful effects of a high maize diet, providing ideal research 
opportunities. High levels of oleic acids, found in olive oil, have been shown to 
reduce the synthesis of arachidonic acid, by competing for the desaturase enzymes 
(Holman, 1964). De Schrijver and Privett (1982) showed how dietary fish oils high in 
polyunsaturated fatty acids depress the desaturase enzymes decreasing the arachidonic 
acid levels. Calviello et al (2004) has recently shown that these fish oil 
polyunsaturated fatty acids reduce VEGF expression in human colon cancer cells, 
modulating the COX 2 / PGE2 pathway. This reduction in VEGF blocking 
angiogenesis has also been shown with flavonoids and curcumin (also known as 
turmeric) (Fotsis et al., 1997). Aggarwal et al. (2003) later found curcumin to 
suppress the proliferation of tumour cells through the down-regulation of the 
expression of COX 2, LOX and EGFR. Another natural flavonoid, quercetin, has also 
been shown to inhibit COX 2 in the adenocarcinoma Oe33 cell line (Cheong et al., 
2004). Genistein, rich in soybean and some forage plants, has been shown to decrease 
the incidence of breast and prostate cancer (Nakagawa et al., 2000). Ye et al. (2004) 
showed that genistein inhibited COX 2 action in head and neck cancer cells similar to 
that of commercial COX 2 inhibitors. All of these could be tested in trial conditions 
offering a cheap preventative treatment, should variations of these foods be able to 
grow in Transkei. 
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10.4.5. Immunology 
 
It is established that PGE2 suppresses the immune system. Research into this area is 
growing due to the implications of COX 2 inhibitors being used in the treatment of 
arthritis sufferers. The detailed pharmacological effect on the epithelial tissue is 
unknown. The immune system has fundamental actions in suppressing the 
development of cancer, therefore its suppression is detrimental. T-helper lymphocytes 
have been shown to be suppressed by PGE2 (Choudhry et al., 1999;Cosme et al., 
2000). Studies into the relationship of immuno-suppression caused by a high maize 
diet are essential, not only in the study of cancer.  
 
 
10.4.6. Non-Steroidal Anti-Inflammatory Drugs  
 
Throughout the journals showing investigations of PGE2 and COX 2, it has been be 
shown that non-steroidal anti-inflammatory drugs (NSAID) suppress the action of 
COX 1 and fundamentally COX 2, which decreases the production of PGE2 (section 
1.7.1). This therapeutic action is widely used in the treatment of arthritis. It is 
suggested that aspirin and paracetamol relieve pain by suppressing the inflammatory 
action of PGE2. Therefore, clinical studies could be set up in the target population at 
high risk of oesophageal cancer. It can be tested if a cheap NSAID, such as aspirin, 
has a suppressive effect on the regurgitation of gastric fluid, high in PGE2.  
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Appendix A: Copyright Permission 
 
Copyright permission for the use of diagrams in the thesis 
The following article was an e-mail ( in blue) received on the 14th December 2006 
with reference to copy write issues with using diagrams taken from text books and 
papers for this thesis: 
This is from the copyright guidelines 
 (http://www.cranfieldlibrary.cranfield.ac.uk/help_information_guides/copyright_guidelines) 
provided by the University's copyright Officer, Heather Woodfield, who is one of the Cranfield 
library staff: 
"Copying for the purpose of providing the answers to an examination (and writing 
theses is included in this) goes beyond the basic fair dealing rights granted by fair 
dealing. You may, for example, want to include the article from the same issue of a 
journal in your appendices, and of course, the usual copyright restrictions regarding 
photographs, diagrams and charges do not apply." 
You do of course need to include the details of where the pictures came from. 
Chris Napper, Library Head 
 
Appendix B – Ethic Information 
The following sheets. 
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Appendix C: PGE2 concentration of the samples 
1) Raw results for PGE2 ELISA of the Gastric fluid Samples 
 xvi
 xvii
Label Reading 1 Reading 2 Average % B/Bo Minus NSB 
TA 0.229 0.24 0.2345   
sb 0.13 0.131 0.1305   
Bo 0.343 0.342 0.3425 100 0.2125 
NSB 0.13 0.13 0.13   
st 5000 0.135 0.141 0.138 3.764706 0.008 
st 2500 0.141 0.154 0.1475 8.235294 0.0175 
st 1250 0.155 0.162 0.1585 13.4117650.0285 
st 625 0.175 0.179 0.177 22.1176470.047 
st 312 0.204 0.224 0.214 39.5294120.084 
st 156 0.243 0.254 0.2485 55.7647060.1185 
st 78 0.284 0.288 0.286 73.4117650.156 
st 39 0.329 0.318 0.3235 91.0588240.1935 
1 0.258 0.25 0.254 74.16058 0.124 
2 0.252 0.236 0.244 71.24088 0.114 
3 0.237 0.236 0.2365 69.05109 0.1065 
4 0.275 0.293 0.284 82.91971 0.154 
5 0.287 0.27 0.2785 81.31387 0.1485 
6 0.276 0.274 0.275 80.29197 0.145 
7 0.306 0.294 0.3 87.59124 0.17 
8 0.309 0.311 0.31 90.51095 0.18 
9 0.305 0.287 0.296 86.42336 0.166 
10 0.282 0.281 0.2815 82.18978 0.1515 
11 0.198 0.188 0.193 56.35036 0.063 
12 0.296 0.304 0.3 87.59124 0.17 
13 0.288 0.289 0.2885 84.23358 0.1585 
14 0.28 0.269 0.2745 80.14599 0.1445 
15 0.216 0.205 0.2105 61.45985 0.0805 
16 0.279 0.287 0.283 82.62774 0.153 
17 0.323 0.3 0.3115 90.94891 0.1815 
18 0.276 0.259 0.2675 78.10219 0.1375 
19 0.261 0.274 0.2675 78.10219 0.1375 
20 0.324 0.299 0.3115 90.94891 0.1815 
 2) The PGE2 Concentrations of the Gastric Fluid Samples 
The PGE2 concentrations from the above PGE2 ELISA on the samples now and the 
concentrations of the PGE2 from the same samples taken when fresh before a long 
journey from South Africa to England, not at optimum temperatures. 
Sample no. Old PGE2 (pg/ml) New PGE2 (pg/ml) 
1 3920.00 600 
2 3950.00 850 
3 2590.00 910 
4 8150.000 540 
5 2600.00 590 
6 1530.00 600 
7 1720.00 430 
8 2350.00 400 
9 4870.00 480 
10 3500.00 550 
11 628000.00 1070 
12 2910.00 450 
13 29300.00 510 
14 3830.00 610 
15 79700.00 1030 
16 442000.00 540 
17 3060.00 400 
17 7000 400 
18  650 
19 2860.00 650 
20 96800.00 400 
21 3880.00 400 
22 64600.00 820 
23 55600.0 550 
24 119000 740 
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Appendix D: Sample transportation information from airplane specialists 
1) Professor John Fielding, Head of Aerospace Engineering group in the School of 
Engineering, Cranfield University. 
 
Q: What would the temperature of the baggage cabin be throughout the flight? 
 
A: About 20oC (same pressure and temp as cabin – poss slightly cooler) 
 
Q: How different would the pressure be in the baggage cabin compared to the 
passenger cabin? 
 
A: About 20oC (same pressure and temp as cabin – possibly slightly cooler) 
 
Q: Would take off or landing have any effects on the temperature of the baggage 
cabin? 
 
A: No - not significantly. depends on how long it was on the plane before take off  - it 
could be up to 2 hours turn around. 
 
Q: Can I quote you on this for the thesis? 
 
A: Yes 
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2) Dr Craig Lawson, Airframe Systems Design, Aerospace Engineering Group, 
Power, Propulsion and Aerospace Engineering Dept., School of Engineering, 
Cranfield University. 
 
Q: What would the temperature of the baggage cabin be throughout the flight? 
 
A: During cruise: usually slightly cooler than the passenger cabin - typically 
maintained around 15 Celsius, say +/- 5 Celsius. 
 
Before take-off and after landing (i.e. before/after the engines are shut down): 
depends on ambient temperature - the cabin temperature is still conditioned during 
boarding/disembarkation, but may not be regulated as tightly. For the baggage hold, 
the most extreme case is likely to be reaching ambient temperature, if the aircraft was 
to sit at the gate for a long time. It's worse for the passenger cabin; it may reach 5-10 
Celsius above ambient temperature, because of the windows and passengers. 
 
Q: How different would the pressure be in the baggage cabin compared to the 
passenger cabin? 
 
A: It is the same. So, typically varying from 1 bar to 0.7 bar. 
 
Q: Would take off or landing have any effects on the temperature of the baggage 
cabin? 
 
A: No. At all times while the engines are running, the cabin is subject to 
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the same temperature regulation. 
 
Q: Is there anything else I should be thinking about that is effected by the flight and 
loading/unloading? 
 
A: The ambient temperature is the significant factor during loading and unloading. 
Typically, baggage handlers are not gentle. 
 
Q: Can I quote you on this for the thesis? 
 
A: Yes, I hope this helps. Let me know if you need any clarification or want 
more details. 
 
 
Appendix E: Cell culture methods 
 
1) Conditions 
 
Cell lines were maintained at 37oC and 5% CO2 in an incubator. All manipulations 
were carried out in a class II laminar flow cabinet using aseptic technique. 
 
2) Reagents 
 
 xxi
All reagents were obtained from Sigma-Aldrich (Poole, UK) unless otherwise stated. 
 
3) Tissue Cultureware 
 
All tissue culture plasticware was obtained from NUNC (Ruskilde, Denmark) unless 
otherwise stated. 
 
4) Media Preparation 
 
In the class II laminar flow cabinet 50ml fetal calf serum (FCS), 5ml 
Penicillin/Streptomycin, 1ml Amphotericin was added to a 500ml bottle of RPMI 
1640 with bicarbonate media. Ten ml of this was aliquoted into a small vial and 
placed in the incubator to check for infection. A separate bottle was provided for each 
cell line, to minimize risk of cross-infection. 
 
5) Thawing the mammalian cell lines 
 
The cell line vials were removed from the liquid nitrogen bank and the details on the 
vial was recorded. Silver foil was placed over the lid of the vial and it was held in a 
beaker of 37oC until the contents had thawed. The vial contents were placed into a 
15ml centrifuge tube. Media was pipetted into the tube one drop at a time and gently 
swirled until after 5 minutes the tube contents reached 5ml. Over the next minute a 
further 5 ml was added with gentle swirling. This was centrifuged at 4oC at 100 x g 
(ALC MRC, model PK131R) for 5 minutes. The suspension was pipetted off and the 
pellet was resuspended in 1ml of media. This was mixed by pipetting and placed into 
a T25 cell culture flask with a breathable lid. A further 6 ml of media was added to 
the T25 and a gentle swirl of the flask ensured an even distribution of the cells. This 
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was then left to grow in a infection free 37oC incubator supplemented with 5% CO2 
and >95% humidity to prevent evaporation. 
 
6) Feeding the cell lines 
 
The old media was pipetted from the flask into equivalent amounts of Virkon 
disinfectant and new media at 37oC  was pipetted into the flasks. Six ml of media was 
placed in a T25 and 9ml of media was placed in a T75. 
 
7) Splitting the cell cultures 
 
Following 70-80 % confluence of cells in the flasks they were split into 1:3. The 
media was removed from the flask and rinsed with sterile PBS. Five ml of Trypsin x 1 
was pipetted into the flask and incubated at 37oC for 5 minutes. The flask was tapped 
and placed under the microscope to check the cells had come away flask base, if not 
this was repeated until all the cells were in the suspension. In a 15ml centrifuge tube 
5ml of media was added along with the suspension from the flask. This was 
centrifuged at 4oC at 66 x g for 5 minutes. The pellet was resuspended in 3ml of 
media and pipetted equally into three T75 flasks. To these flasks 9ml of media was 
added and gently swirled to ensure dispersion of the cells. The flasks were then placed 
into the incubator. 
 
8) Creating Frozen Cell Stocks 
 
The cells were stored in liquid nitrogen (-146oC) banks. Seventy to eighty percent 
confluent T75 flasks were washed with sterile PBS, 5ml trypsin was added and 
incubated at 37oC for 5 minutes. The contents was added to a 15ml centrifuge tube 
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along with 5ml of media. For 5 minutes the tube was centrifuged at 66 x g at 4oC. The 
suspension was added to Virkon and discarded. Three ml of FCS was used to 
resuspend the cells. Three ml Freezing media, made from 10% DMSO in FCS, with 
gentle swirling was slowly added to the cells. One ml aliquots were labeled with the 
cell line, passage number, dated and named. In each of the 6 aliquots 1ml of the cells, 
FCS and mixed freezing media was added. These were wrapped in three layers of 
cloth, placed in a freezing plastic box and were put in the –80oC for 24 hours. These 
were then transformed to the liquid nitrogen banks. 
 
9) Slide flasks for cell cultures 
 
For immunocytochemistry both cell lines were grown on slide flasks. At 70 - 80 % 
confluence the T75 flask was split into 10 slide flasks, by trypsinising the flask as 
above and the contents was centrifuged to obtain a cell pellet. The pellet was then 
suspended in 5 ml of media and 0.5ml of this suspension was placed into each of the 
slide flasks along with 2.5ml of media. Feeding with 2.5ml of media after two days. 
These were placed in the incubator. Once the slides were 100% confluent then they 
were fixed and stored.  
10) Fixing the slide flasks 
 
The 70% confluent slide flasks were washed with sterile PBS, repeated three times 
gently rolling the slide flasks over as not to wash off the cells. The slide and cells 
were submersed in 4% paraformadyhyde (Sigma) for 10 minutes, then cold methanol 
for 10 minutes at 4oC, and left to dry at 4oC. These were then labeled and wrapped in 
foil and stored at –20 oC until used. 
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Appendix F: Statistical Analysis of the Power of the Gastric Fluid Samples 
 
The basic statistical analysis of the PGE2 concentrations of the gastric fluid samples: 
 
 
T-test analysis results of the power calculation from the 24 samples: 
 
 
The estimated sample size required to have at least a 90% power goal: 
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 Appendix G: Cell Counts, MTT and BrdU Assay Raw Data 
 
1) PGE2 treated cell counts raw data 
Cell counts taken from two sets of T25 of Het1a cells treated with different 
concentrations of PGE2 over different periods of time: 
PGE2 (µl/ml) 1 Day Average 2 Days Average 3 Days Average 4 Days Average 
0 12 / 20 16 20 / 28 24 92 / 112 102 184 / 206 195 
0.0005 16 / 20 18 36 / 36 36 81 / 111 96 186 / 174 180 
0.005 13 / 17 16 42 / 33 37.5 96 / 138 117 396 / 342 369 
0.05 12 / 8 10 23 / 24 23.5 73 / 64 68.5 208 / 250 229 
0.5 15 / 19 17 27 23 25 74 / 65 69.5 218 / 220 219 
5 8 / 12 10 5 / 9 7 6 / 6 6 10 / 4 7 
 
Cell counts taken from two sets of T25 of Oe21 cells treated with different 
concentrations of PGE2 over different periods of time: 
PGE2 (µl/ml) 1 Day  Average 2 Days  Average 3 Days  Average 4 Days  Average
0 6 / 7 6.5 14 / 34 24 90 / 77 83.5 240 / 258 249 
0.0005 11 / 11 11 36 /20 28 141 / 154 147.5 262 / 342 302 
0.005 4 / 3 3.5 54 / 48 51 112 / 147 129.5 392 / 302 347 
0.05 10 / 6 8 52 / 48 50 83 / 79 81 312 / 246 279 
0.5 18 / 12 15 28 / 26 27 97 / 63 77 154 / 214 184 
5 0 0 0 0 165 / 175 170 192 / 192 192 
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2) PGE2 treated MTT Assay Raw Data 
 
Optical density of four sets of results from the MTT assay on the two cell lines treated 
with different concentrations of PGE2: 
 Optical Density For Het1a Cell Line (550nm)  
PGE2 (µl/ml) 1 2 3 4 Average 
0 0.106 0.126 0.113  0.115 
0.0005 0.191 0.168 0.15 0.162 0.16775 
0.005 0.18 0.192 0.179 0.194 0.18625 
0.05 0.135 0.195 0.212 0.139 0.17025 
0.5 0.153 0.204 0.213 0.179 0.18725 
5 0.171 0.19 0.194 0.175 0.1825 
 
 Optical Density For Oe21 Cell Line (550nm)  
PGE2 (µl/ml) 1 2 3 4 Average 
0 0.485 0.542 0.472  0.499667 
0.0005 0.618 0.554 0.51 0.658 0.585 
0.005 0.605 0.515 0.558 0.468 0.5365 
0.05 0.569 0.609 0.534 0.652 0.591 
0.5 0.492 0.665 0.545 0.671 0.59325 
5 0.661 0.659 0.545 0.671 0.634 
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3) PGE2 Treated BrdU Assay Results 
 
Optical density of two sets by four repeats of results from the BrdU assay from the 
Het1a cell line treated with different concentrations of PGE2 (µg/ml): 
 
Het1a set 1        
 1 2 3 4 average minus unspec % of A 
blank 0.086 0.083 0.087 0.085 0.08525   
unspecific 
binding 0.106 0.085 0.087 0.092 0.0925   
a 0.344 0.342 0.352 0.318 0.339 0.2465 100 
b 0.296 0.326 0.34 0.333 0.32375 0.23125 93.81338742
c 0.307 0.34 0.355 0.339 0.33525 0.24275 98.47870183
d 0.342 0.351 0.367 0.337 0.34925 0.25675 104.158215 
e 0.365 0.39 0.397 0.334 0.3715 0.279 113.1845842
f 0.361 0.335 0.314 0.348 0.3395 0.247 100.2028398
        
het1a set 2        
 1 2 3 4 average minus unspec % of A 
blank 0.088 0.085 0.094 0.079 0.0865   
unspecific 
binding 0.081 0.082 0.099 0.113 0.09375   
Control 0.283 0.317 0.31 0.35 0.315 0.22125 100 
0.0005 0.313 0.326 0.311 0.285 0.30875 0.215 97.17514124
0.005 0.323 0.314 0.246 0.199 0.2705 0.17675 79.88700565
0.05 0.315 0.368 0.36 0.319 0.3405 0.24675 111.5254237
0.5 0.349 0.315 0.317 0.329 0.3275 0.23375 105.6497175
5 0.307 0.306 0.297 0.292 0.3005 0.20675 93.44632768
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Optical density of two sets by four repeats of results from the BrdU assay from the 
Oe21 cell line treated with different concentrations of PGE2 (µg/ml): 
oe21 set 1        
 1 2 3 4 average minus unspec % of A 
blank 0.088 0.081 0.086 0.082 0.08425   
unspecific 
binding 0.093 0.1 0.099 0.097 0.09725   
a 0.404 0.108 0.092 0.104 0.177 0.07975 100 
b 0.106 0.404 0.446 0.348 0.326 0.22875 286.8338558
c 0.407 0.353 0.374 0.415 0.38725 0.29 363.6363636
d 0.408 0.383 0.377 0.396 0.391 0.29375 368.338558 
e 0.417 0.394 0.475 0.326 0.403 0.30575 383.3855799
f 0.367 0.353 0.313 0.374 0.35175 0.2545 319.1222571
        
oe21 set 2 1 2 3 4 average Minus Unspec % of A 
        
blank 0.084 0.086 0.101 0.086 0.08925   
unspecific 
binding 0.087 0.104 0.105 0.103 0.09975   
Control 0.121 0.1 0.109 0.112 0.1105 0.01075 100 
0.0005 0.341 0.423 0.426 0.42 0.4025 0.30275 2816.27907 
0.005 0.378 0.417 0.351 0.376 0.3805 0.28075 2611.627907
0.05 0.367 0.38 0.422 0.382 0.38775 0.288 2679.069767
0.5 0.412 0.411 0.376 0.382 0.39525 0.2955 2748.837209
5 0.329 0.352 0.33 0.36 0.34275 0.243 2260.465116
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4) MTT Assay Treated with the Gastric Sample Raw Data 
Optical density of two sets of results from the MTT assay from the Het1a cell line 
treated with gastric fluid samples: 
Sample No. 
1 (OD-
550nm) 
2 (OD-
550nm) Average 
N 0.163 0.085 0.100777778 
1 0.454 0.44 0.447 
2 0.611 0.65 0.6305 
3 0.527 0.497 0.512 
4 0.48 0.624 0.552 
5 0.419 0.38 0.3995 
6 0.607 0.549 0.578 
7 0.424 0.533 0.4785 
8 0.38 0.461 0.4205 
9 0.506 0.444 0.475 
10 0.518 0.581 0.5495 
11 0.425 0.394 0.4095 
12 0.492 0.533 0.5125 
13 0.462 0.492 0.477 
14 0.54 0.524 0.532 
15 0.394 0.394 0.394 
16 0.419 0.434 0.4265 
17 0.42 0.41 0.415 
18 0.527 0.357 0.442 
19 0.296 0.225 0.2605 
20 0.569 0.457 0.513 
21 0.38 0.301 0.3405 
22 0.422 0.351 0.3865 
23 0.517 0.384 0.4505 
24 0.433 0.427 0.43 
 xxx
Optical density of two sets of results from the MTT assay on the Oe21 cell line treated 
with gastric fluid samples: 
Sample No. 1 (OD-550nm) 2 (OD-550nm) Average 
N 0.117 0.085 0.106666667 
1 0.231 0.218 0.2245 
2 0.141 0.15 0.1455 
3 0.2 0.142 0.171 
4 0.34 0.247 0.2935 
5 0.224 0.248 0.236 
6 0.257 0.294 0.2755 
7 0.271 0.308 0.2895 
8 0.244 0.283 0.2635 
9 0.243 0.242 0.2425 
10 0.262 0.282 0.272 
11 0.262 0.25 0.256 
12 0.277 0.263 0.27 
13 0.326 0.328 0.327 
14 0.305 0.323 0.314 
15 0.239 0.307 0.273 
16 0.224 0.253 0.2385 
17 0.28 0.233 0.2565 
18 0.298 0.22 0.259 
19 0.332 0.241 0.2865 
20 0.214 0.19 0.202 
21 0.296 0.255 0.2755 
22 0.247 0.28 0.2635 
23 0.262 0.362 0.312 
24 0.211 0.331 0.271 
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5) MTT Optical Density Raw Data from Heat Treated Gastric Fluid Samples 
Optical density of two sets of results from the MTT assay from the Het1a cell line 
treated with gastric fluid samples that have been heat treated: 
 
Sample No. 1 2 Average 
N 0.071 0.088 0.0795 
4 0.17 0.187 0.1785 
7 0.192 0.119 0.1555 
8 0.283 0.199 0.241 
13 0.224 0.111 0.1675 
18 0.192 0.154 0.173 
 
Optical density of two sets of results from the MTT assay from the Oe21 cell line 
treated with gastric fluid samples that have been heat treated: 
 
Sample  
No. 1 2 Average 
N 0.123 0.161 0.142 
4 0.197 0.242 0.2195 
7 0.261 0.259 0.26 
8 0.201 0.262 0.2315 
13 0.231 0.252 0.2415 
18 0.191 0.282 0.2365 
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6) Raw Results for the Gastric Sample Treated Cells from the BrdU Assay 
Optical density of two sets of results from the BrdU assay from the Het1a and Oe21 
cell lines treated with gastric fluid samples: 
het1a        
 1 2 3 4 average minus unspec % of A 
blank 0.123 0.129 0.088 0.088 0.107   
unspecific 
binding 0.121 0.119 0.141 0.101 0.1205   
control 0.503 0.459 0.4 0.372 0.4335 0.313 100 
1 0.459 0.458   0.4585 0.338 107.9872204 
2 0.201 0.229   0.215 0.0945 30.19169329 
3 0.707 0.487   0.597 0.4765 152.2364217 
4 0.528 0.379   0.4535 0.333 106.3897764 
5 0.516 0.464   0.49 0.3695 118.0511182 
6 0.572 0.437   0.5045 0.384 122.6837061 
7 0.566 0.457   0.5115 0.391 124.9201278 
8 0.583 0.528   0.5555 0.435 138.9776358 
9 0.409 0.458   0.4335 0.313 100 
10 0.401 0.366   0.3835 0.263 84.02555911 
11 0.45 0.449   0.4495 0.329 105.1118211 
12 0.395 0.535   0.465 0.3445 110.0638978 
13 0.604 0.493   0.5485 0.428 136.7412141 
14 0.43 0.608   0.519 0.3985 127.3162939 
15 0.114 0.577   0.3455 0.225 71.88498403 
16 0.507 0.456   0.4815 0.361 115.3354633 
17 0.417 0.436   0.4265 0.306 97.76357827 
18 0.345 0.406   0.3755 0.255 81.46964856 
19 0.479 0.603   0.541 0.4205 134.3450479 
20 0.409 0.484   0.4465 0.326 104.1533546 
21 0.495 0.493   0.494 0.3735 119.3290735 
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22 0.535 0.502   0.5185 0.398 127.1565495 
23 0.502 0.527   0.5145 0.394 125.8785942 
24 0.531 0.577   0.554 0.4335 138.4984026 
 
oe21        
 1 2 3 4 average minus unspec % of A 
blank 0.092 0.113 0.098 0.099 0.1005   
unspecific 
binding 0.127 0.145 0.143 0.136 0.13775   
control 0.61 0.637 0.578 0.517 0.5855 0.44775 100 
1 0.558 0.644   0.601 0.46325 103.4617532 
2 0.692 0.601   0.6465 0.50875 113.6236739 
3 0.595 0.622   0.6085 0.47075 105.1367951 
4 0.601 0.521   0.561 0.42325 94.52819654 
5 0.613 0.705   0.659 0.52125 116.4154104 
6 0.684 0.545   0.6145 0.47675 106.4768286 
7 0.647 0.678   0.6625 0.52475 117.1970966 
8 0.679 0.601   0.64 0.50225 112.171971 
9 0.652 0.658   0.655 0.51725 115.5220547 
10 0.477 0.527   0.502 0.36425 81.35120045 
11 0.599 0.612   0.6055 0.46775 104.4667783 
12 0.661 0.59   0.6255 0.48775 108.9335567 
13 0.644 0.596   0.62 0.48225 107.7051926 
14 0.67 0.642   0.656 0.51825 115.7453936 
15 0.716 0.666   0.691 0.55325 123.5622557 
16 0.524 0.68   0.602 0.46425 103.6850921 
17 0.627 0.662   0.6445 0.50675 113.1769961 
18 0.553 0.59   0.5715 0.43375 96.87325516 
19 0.571 0.54   0.5555 0.41775 93.2998325 
20 0.675 0.579   0.627 0.48925 109.268565 
21 0.69 0.618   0.654 0.51625 115.2987158 
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22 0.749 0.599   0.674 0.53625 119.7654941 
23 0.656 0.698   0.677 0.53925 120.4355109 
24 0.638 0.595   0.6165 0.47875 106.9235064 
 
Appendix H: Optimisation Methods for the Detection of HGF 
1) Optimisation of HGF Western Blotting: 
Following failure to obtain results the following optimisation methods were 
undertaken: 
Coomassie blue staining to check that there was protein present, that the protein was 
running on the gel and the membrane transfer was working 
Use of protein from different cell lines that were known to give results with different 
antibodies (RT112 (bladder) cells and PC-3 (prostate) cells). 
Increased protein concentration using size specific Millipore microconcentrators 
(Millipore, Gloucestershire, UK). 
Changed the primary antibody concentration (1/25, 1/40, 1/100, 1/500, 1/1000, 
1/2000). 
Changed the secondary antibody concentration (1/100, 1/500, 1/1000 and 1/2000). 
Tested the secondary antibody on the ladder 
Increased secondary binding temperature 
Changed primary antibody binding time and temperature (one hour at room 
temperature and 48 hours at 4oC. 
Compared wet and semi-dry blotting methods 
2) Optimisation methods of HGF RT-PCR 
Following failure to obtain results using the previously published method the 
following optimisation methods were undertaken: 
 xxxv
Used RT112 (Bladder) and OE33 (Oesophageal adenocarcinoma) cell lines as an 
alternate source of RNA 
Changed annealing temperature (50, 52, 54, 58, 61, 62) 
Changed PCR cycles number (30, 35, 40) 
Changed primer concentration (20 and 50 picomolar) 
Changed MgCl2 concentration (0, 2, 4, and 6 µl of 25mM) 
Changed dNTP concentration (0.5 and 1 µl of 10mM each dNTPs) 
Changed Taq concentration (0.25, 0.5 and 1 µl of 5 Units/µl) 
Changed cDNA concentration (2, 5, and 10 µl from RT reaction, exact concentration 
unknown) 
Made DNA primers to check that the RT primers separately work (see appendix 7C) 
Used a commercial HGF primer kit (R&D Systems) 
Checked the original and HGF primer kit with HGF control 
 xxxvi
 3: HGF Gene and Primers 
Homo sapiens HGF gene for Hepatocyte growth factor: 
CGCTTTCTTCTTATGCTGCTTCCCCTTCCTCTTTTCCCAAATAGATATATAAACACATGTATTTTCCTGTTTAAATTG
AGCGAATTGGTCCCCTGCCTGTGCCTTGATTTAGCCATTGGGCTCAGCCTTGCTCCTCCCTTCCTTACTCGGATAGG
AGCCACTGGGATCTGGAGCTCCAGCTTCCAAATTGAAGCTGGCCTCAGGCCAGGTGACTTTTCTTTGTAAGTTTCTT
TCCTAAGCGTGGGGTTGGGGGGAGGCGGGGAATGGGGGGGGTTGCAGGGATCTGTTTGGTGCTGTTGAAGGGGGG
GCGAGTGAGGAAAGGAGGGGGCTGGAAGAGAGTAAAGGGCTGTTGTTAAACAGTTTCTTACCGTAAGAGGGAGT
TCAGACCTAGATCTTTCCAGTTAATCACACAACAAACTTAGCTCATCGCAATAAAAAGCAGCTCAGAGCCGACTG
GCTCTTTTAGGCACTGACTCCGAACAGGATTCTTTCACCCAGGCATCTCCTCCAGAGGGATCCGCCAGCCCGTCCA
GCAGCACCATGTGGGTGACCAAACTCCTGCCAGCCCTGCTGCTGCAGCATGTCCTCCTGCATCTCCTCCTGCTCCCC
ATCGCCATCCCCTATGCAG(exon1)GTTAGTTCCCTTCTTCTTCTTCATTATTAGTATTAGTATTTAACTCTCCTGCTA
ACCTTCCCTATTCCTTTTAACACCCTCTTTTTACCCTATTCCCAGCAATCACTTTCTTGTAGATGATCCTTAGGATTT
TTTTTATATATGAGCCTTAAAAACATTTCTCCAATGTTTATTTTTTTAAAACATTTTGTATTTAATAGAGGGACAAA
GGAAAAGAAGAAATACAATTCATGAATTCAAAAAATCAGCAAAGACTACCCTAATCAAAATAGATCCAGCACTG
AAGATAAAAACCAAAAAAGTGAATACTGCAGACCAATGTGCTAATAGATGTACTAGGAATAAAGGACTTCCATTC
ACTTGCAA(exon2)GTAAGTTACTTCATTTTCTTCTTAGAATAATTTTCCAAATATAGCATGCATGTATTATAATCATG
TGTCTTTTGTGTTGTAGTCAATGTGATTTGATCATATATTGTCCATATGCCCATGGACAAGATGAACCATATGCGCA
TTCTTTAAATACTGTATAATAGTAGTATTTCTTCTTTTCATTCTGATATTTTTTTCAGGGCTTTTGTTTTTGATAAAGC
AAGAAAACAATGCCTCTGGTTCCCCTTCAATAGCATGTCAAGTGGAGTAAAAAAAGAATTTGGCCATGAATTTGA
CCTCTATGAAAACAAAG(exon3)GTAACTGACTTCTCCCTAAATATTGCATAATGAAATAAAGTATAATGAAATGTA
TGTTTGTAATTTCCTGCCAGAGTGGTCTTTCTCACTGATTTTTCTATTACAAGAGTTAATTACTTACAGGTTTGAAC
GGAATTTTTTTCTTAAATACTGCATATGTTTTGCATAGTTGCAATAATTTTATCTACTTTCTTCAATAGACTACATTA
GAAACTGCATCATTGGTAAAGGACGCAGCTACAAGGGAACAGTATCTATCACTAAGAGTGGCATCAAATGTCAGC
CCTGGAGTTCCATGATACCACACGAACACAG(exon4)GTAAGAACAGTATGAAGAAAAGAGATGAAGCCTCTGTCT
TTTTTACATGTTAACAGTCTCATATTAGTCCTTCAGAATAATTCTACAATCCTAAAATAACTTTCTACCTTCAGCAA
AAACATACCCACTAATTAGTAAAATTAATAGGCAAAAAAAAGTTGCATGCTCTTATACTGTAATGATTATCATTTT
AAAACTAGCTTTTTGCCTTCGAGCTATCGGGGTAAAGACCTACAGGAAAACTACTGTCGAAATCCTCGAGGGGAA
GAAGGGGGACCCTGGTGTTTCACAAGCAATCCAGAGGTACGCTACGAAGTCTGTGACATTCCTCAGTGTTCAGAA
G(exon5)GTAAATAAACCTGAATGCCATGTGGGCCATTCTATTCCCCCTATGTGTAGAACTGTAACTCACATTAAAG
GTTAACAGCAACGAATCAATCATAACAAATAAATCTGTTTACTAAACAGGTGCTGTTCTTTAAATGGAACAGTGGT
GTTTTTGATTTTGCTGTCAGAAACAATTAACATGCCATACTTTAATTTTATTAGTTGAATGCATGACCTGCAATGGG
GAGAGTTATCGAGGTCTCATGGATCATACAGAATCAGGCAAGATTTGTCAGCGCTGGGATCATCAGACACCACAC
CGGCACAAATTCTTGCCTGAAAG(exon6)GTAAAATATTAATGAATCATGCTTTCAGTGATTCTTTACAAACTATTAT
TCACTCTATGACACACTGCTGTGGAAATTCTCTTTATATTATGTTTTCCCGTAGGTGTAGACAACCTAAGTGGAAAG
TTATTTTGTGAGCTGAGGGGTGGGTGGTGTTTCCAGGCAGATTTACGTGACACTTTTCTTGGTGTGGTTTGCAGATA
TCCCGACAAGGGCTTTGATGATAATTATTGCCGCAATCCCGATGGCCAGCCGAGGCCATGGTGCTATACTCTTGAC
CCTCACACCCGCTGGGAGTACTGTGCAATTAAAACATGCG(exon7)GTAAGTGAAGGTCAAATTTATTGCTTCCTTTT
CCTCTCACAGACTGGATCTAAGCAGGCGATTATTAGTGAGACAGGTTAACAACTATTTAACTTGATGCAAAAAAAT
CTGCTAATACAAATGCCAATGAACTCTAAGAGGCAAATGACATCTTCAAAGATTTTATATAAGTTTTTTTTGTTGTT
GTTTTTTGCCAATAGCTGACAATACTATGAATGACACTGATGTTCCTTTGGAAACAACTGAATGCATCCAAGGTCA
AGGAGAAGGCTACAGGGGCACTGTCAATACCATTTGGAATGGAATTCCATGTCAGCGTTGGGATTCTCAGTATCCT
CACGAGCATGACATGACTCCTGAAAATTTCAAGTGCAA(exon8)GTGAGTAAAGTAGGCAAATGTTATACATTTCAG
TAGGCCCTGGGGAAAATGAGGTAGAGTGGTTACTTTTTACTAATTTTGTGTTAGTGATCAAACTTCAATAAACATG
CATACATTCTAGAATTCTAGAAATGTAATAGCGCTGACTTCACCAACGTAAGAACTCCGGCAATTTACATTAACAT
GCTTATTCTCAATAGGGACCTACGAGAAAATTACTGCCGAAATCCAGATGGGTCTGAATCACCCT(primerHGF3)GG
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TGTTTTACCACTGATCCAAACATCCGAGTTGGCTACTGCTCCCAAATTCCA(primerHGF4)AACTGTGATATGTCACA
TGGACAAG(exon9)GTAATAGCTGACATTCTGCAGGGTGGGCATGATTAAATTCAGGGGAAATGCCTAAAGGGAGG
ACACATTTTACAGCATAAGATCTACTTCTTGCTGCACTTTTTTATGTTGATTTCATGATTCCATATACTTGTAAAAA
ATCTTTTTGTTTTATCCGCCTTGATATTCATTGGACTTATTTCTGTATATTTTATGTCTAGATTGTTATCGTGGGAATG
GCA(primerHGFa)AAAATTATATGGGCAACTTATCCCAAACAAGATCTGGACTAACATGTTCAATGTGGGACAAGA
ACATGGAAGACTTACATCG(exon10)GTGTGTAAATTTCTTCCTTTCAATATATAGAATGTAGTGATACCAACAGACT
GTGTATTTAGATATGTACATTGCTATTTCTTTCTATTCTTTTATATATCAGTGAAAGTAATGTGCTGAGATTATATCT
TTTTGTAATATTTTGTGTCTCTTGGATGGAATGAGCATCTTGTGATGTGCAAGGCCTGTTGTTTCCGCAGTCATATC
TTCTGGGAACCAGATGCAAGTA(primerHGF2)AGCTGAATGAGAATTACTGCCGAAATCCAGATGATGATGCTCATG
GACCCTGGTGCTACACGGGAAATCCACTCATTCCTTGGGATTATTGCCCTATTTCTCGTT(exon11)GTAAGTACAGT
TAGGGATTGGTGTCTTGTGAAATATTTTAAATGTACTACATTTCATCTAAAAGTTGTAAATAATATAGGTGGTCTG
GCATTTATTCCCACTGAATTCATTGATACTTGGATTTTAATATATATTTGGTTTTATATAACAGATATATGCATATA
TGAATTGTGTATTTATCTATACATTTATTTTTACAGGTGAAGGTGATACCACACCTACA(primerHGF5)ATAGTCAAT
TTAGACC(exon12)GTAAGTAATATTTCACAATATAAAGTATATCTGAGTCTCTCTCTGTGTGTCAGAAGTGTCATTA
TTTCTTTCAAAGAAAATTATCTATATTAGCTTCCATAGTTACATTTGTGTAATTATCATTGCATTTAAGAAAACTAA
GAGGCACTGATTATTTCAAATTCTTATTTTAAAAAATGTTATGTTTGGTCCTGTTTCAGATCCCGTAATATCTTGTG
CCAAAACGAAACAATTGCGAGTTGTAAATGGGATTCCAACACGAACAAACATAGGATGGATGGTTAGTTTGAGAT
ACAG(exon13)GTAATTATTAATAGATGCAAGTCATGCATATCCAGAATATGTACAAGAGAGTCCTATTCCCAGAAA
TATGGACACATGTGGTCCTGAAGGTTGTACCCTCGTGTATTTATTTTTAACAAATGGAGCCACAGGCTTTGCATTA
ATTGGCAGTCACTCTTTCTGCACAGATGTTACTTGTTTCTCTTTCCTCTTTTTCACAGAAATAAACATATCTGCGGAG
GATCAT(PrimerHGFb)TGATAAAGGAGAGTTGGGTTCTTACTGCACGACAGTGTTTCCCTTCTCG(exon14)GTAAAGT
GTTTTTAAAACTAGTATTATTTTGAGCCTTTAAAATGTGTATGTCTTCCACTTTGCTCTTAAGGTTATAATATGTATT
CATTTTACAGAGATTGTTATGTGCCTTAATAGTCTAAAATAACAATAGATAGGAATAATACTACAGAATTTGGAAT
TATTATGTTTTACATTTAAATTTTTTTCCTTCAAAACAGAGACTTGAAAGATTATGAAGCTTGGCTTGGAATTCATG
ATGTCCACGGAAGAGGAGATGAGAAATGCAAACAGGTTCTCAATGTTTCCCAGCTGGTATATGGCCCTGAAGGAT
CAGATCTGGTTTTAATGAAGCTTGCCAG(exon15)GTTAGTTACTTTAGAAGATTTTGTATTTTTCACCTGGACAAGA
ATTGTTGGAGCATTTTCTTCAGCTGTGTGGCAGTTCGTTCTCTCTCATACAGATGCATTCTCTGTAAATGCCATATT
AAACATGAACACTACATTTAATATGTTAATTTTGTGTTGTTACCAGTTGAGAGTACTTACCATGTATTTTGTGTTTT
CAGGCCTGCTGTCCTGGATGATTTTGTTAGTACGATTGATTTACCTAATTATGGATGCACAATTCCTGAAAAGACC
AGTTGCAGTGTTTATGGCTGGGGCTACACTGGAT(exon16)GTAAGCTAGTTTTCAAAAGATGAGGCCATATTTATTT
TATTTTAAAAAGAACACATTTGTCTTTGTTTCTTACTTTTCTCACCTTATTGTATGTTTTTTGCATCAATCTAGTGAT
CAACTATGATGGCCTATTACGAGTGGCACATCTCTATATAATGGGAAATGAGAAATGCAGCCAGCATCATCGAGG
GAAGGTGACTCTGAATGAGTCTGAAATATGTGCTGGGGCTGAAAAGATTGGATCAGGACCATGTGAG(exon17)GTA
AAAAGGAAGTTCTTTAATAAGGAGTATGTGATTCATAGCTTAGTGTTTCATGTTTATTTTTTTCTGTTTATTTTTCTC
AAATCAAAAATATTGTATATTCTGTATATATCTCTGAGATGCAAATCTATATATGATTATGTTAATGAGCTTTTTTT
TAATTCCTAATAATACTTTGTTTTTGTATGTCTTACTCCTAGGGGGATTATGGTGGCCCACTTGTTTGTGAGCAACA
TAAAATGAGAATGGTTCTTGGTGTCATTGTTCCTGGTCGTGGATGTGCCATTCCAAATCGTCCTGGTATTTTTGTCC
GAGTAGCATATTATGCAAAATGGATACACAAAATTATTTTAACATATAAGGTACCACAGTCATAG(exon18)CTGAA
GTAAGTGTGTCTGAAGCACCCACCAATACAACTGTCTTTTACATGAAGATTTCAGAGAATGTGGAATTTAAAATGT
CACTTACAACAATCCTAAGACAACTACTGGAGAGTCATGTTTGTTGAAATTCTCATTAATGTTTATGGGTGTTTTCT
GTTGTTTTGTTTGTCAGTGTTATTTTGTCAATGTTGAAGTGAATTAAGGTACATGCAAGTGTAATAACATATCTCCT
GAAGATACTTGAATGGATTAAAAAAACACACAGGTATATTTGCTGGATGATAAAGATTTCATGGGAAAAAAAATC
AATTAATCTGTCTAAGCTGCTTTCTGATGTTGGTTTCTTAATAATGAGTAAACCACAAATTAAATGTTATTTTAACC
TCACCAAAACAATTTATACCTTGTGTCCCTAAATTGTAGCCCTATATTAAATTATATTACATTTCATATGCTATATG
TTATAGTTCATTCATTTCTCTTCACCATGTATCCTGCAATACTGGTACACGAACACACTTTTTACAAAACCACATAC
CCATGTACACATGCCTAGGTACACATGTGCATGCACTACAGTTTAAATTATGGTGTACCTAATGTAACCCCTAAAT
ATTTTAGAAGTATGTACCTATAGTTTTACCTCAAAAAAACCAGAAATCTCTAAAGACCAGTAGAAATATTAAAAA
ATGATGCAAGATCAAAATGATTAGCTAATTCTCCATACATAATCTGCAGATGATCTTCTTTGGTTGGCATTTCAGGT
GTGGCCATCACCCAGAGTTAAATAACACCTAATCTAGGTGTTTACATGTATTCATTATCCTAGTTATTTCATGTAGT
TTCTAATTCTTAAAGGAAAGAGGGTAATAGTTCTATTTGTGTAATTTGTTTCCTCCAAACTTAAGGCCACTTATTTA
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CACAAGATATTTGTAGATCTATTTTCCTAAAGCATTTCTTAAGTGCTCAGATCAGTATCTAATTGAAGAAGTTTAAA
AGTGTTTTGGTCATTAAAAATGTACTTAAATAGGTTAAATCTAAGCCTTGCTGCTGTGATTGGCTTCTAGCTCACTG
CCTTTAAATTTTAAAAAATTTAAGAGGAAAATTTCCAAGTCTCCAAAGTTTTATAAATACCCTTCATCAAGTCATG
CATTAAAGTATATATTGGAGAAAAAAATAAAAATACTTTTCTCAACCTGGAAGATTTTAGCCTAATAAAGCTTTTT
TGAAGTAAAAGACAACTTGTAAAAGGAAAGAAACTAGTTTGTCTCAACTCTGTATTCATTTATTTTTTTTTTGAAGT
AGAGTGGAATCTGTTGAATCAGATATTTTATCAAGATATGTTTATTTTTTCTTATTTCATTTTACAAAGTTCACTCCT
AATGCCATATGTAACAGACATTTAAATTTTGTGTTCTGTATAACAGCCAAATTATCATATTTATCATTGTATTTGTC
ATGCTTAGCTAAAGATCATGTATTTGTTGAGAAATAGAATAACAAAAAGTAATAGCATAGGCTTTGAATTTTTGCA
GAAATCTTCCTGTACAAAACACCTTTAAAAATAATTTTTTGAATGGTGTGAATCCAGTAGTCCCATTTCTCTGACTT
AGTTTTCTTGAGTGATTTTTATCAAGGCCAAGTCCCCAAACAATTCCCTACCAGCTCTTTAGAGTACTGTTCAATCT
GGACTAAAATGGTTTTAAGTTTATGGAGAGCTTAGTCCACAGAATATAGGGCGGCGAGTCCAGAAATGCTTATAC
AATTTTTTTTTCATAATAAGATATGTGCTGGCATCAAGAAACTTAAAGTGGAAGCAAAAAGACATCCAACTAGTTG
CTGGTCTCTATCATCTTATCTGATGGTATTTCTATTTTCCTTATATAATACACCATTTTAGTAAGAACTCCTAGAAAT
TTCAAGAGCATATTGCCAAAATATAAAGTATATTTCATAGTTTCTTCTGGCTGAACCAGTGAAATTTTATTATTGCA
TATTAATGATATTTGTAAAACTTTTATAAAAATTGTCATAATTTTAAATACTCACATTTTAAAAATACTTCTTTAAT
GACTCTTCCTCTAAATTTCCTGGAAATACAGATAAAGATTAGCTAGATACAAGATACAGCTAAGTATTTAGACATT
TTGAGGCTAGTATTTTTCATTTTATTAAAGGCTAAAAACAATACCACCAATAAATCATCAAACAAACCGTACAAAG
TAATTCTCTCTTTGGGAGGCTCCTTTCGTGATAGAGGGACATGGGTGGAATTGACAATGAAACTTAGATGAACAAG
GTCCATGTTATTTTAGGTGGTAGAACAGGGTAGAGTCATGTCATTATTTGCTGGTGGAAGACACTATTTACCAGGT
GTTCTTTGCTGAATAAATCATTAAACATTTTTAAAAATCCAACAATCCACTTTATTTTGTGTCATTGACAAAAGGAT
CTTTTAAATCAGAAGGTTTCAATGCAATTTTTGGTTTGGCTGTTTGAATAATGGTTATGTACTGTTATAATTGTAGA
CATTTTCTCACGTCTACCAGGAATTGAAGTGTAAAACTAAAATATTTTTCATAATGCCTCTGCCGTGCAGAAGGAA
TGATAATCCTTTTGTATACTTCTTTAATTTTATTGTAAAATGTGTAATGACTTTTACCTATATGCTGTGGGCAGGTCC
TCAGTAAAATCTATTGAGTCAATTTCTAGTATTAACAGGCTTTTGCTTGCTATCTAAGTGTTTCAAATTATGGGAAG
TGTGAGACACTGGAAGGCAAGAAAATTAACAATAATGGCATGTGATAGCAAAATTGTATTTCACTTATTCCTGTGA
ATATTTCTTGTTGGTACCAATGGTACTGTACAAAGTGAATGTTATAGCCACAACATTCTCTTGAAAAGAACACTGT
CAAGAAGTGGGAAATTGCTGTCAGGCATTTCATTGTTGTTTTTAAACTTTTTTAAAAGAAATACTGGTTTTGCAATA
TAGAGATCATGTGGTAAAGAATTTTAATAAGATCTTATACTAAAAAGCCTTAAATCAATTTATTGAGATTCAAAAA
ATACTATTATAATTAATTACATCCCATACATATAGGCAAACTCATTTAAAAAATAAAACTAATTTTGGTAAAAGTA
CATGGCCTTTGTTTTTAAAATACATAATTTTAAAATAAATCACTTGTCATGATAAAGTCCAAAAAGAAGTTATCAT
TCAACATTCAACTAAGGTTGGAGCTAAGAATTTACTAATACAAAAAAAAGTTAAAATTTTTTGGACCATATATATC
TTGACAGTGTAACTTTTAAGTAGGTTCATTTCCATTTGCACAGAAAGTTTCTGTCTTTAGGAAACTGAAAATGAAA
TACTGTGGATGCATGACTGTTTGTCTTGTATGTAAATAGGAAAATAATAAGCTGCCTATTGAGTGGTATAGCTGTA
TGCTTACCCAAAAAAGGGAACACTGTGGTTATGACTTGTATTATAAACTTTCTGTAGTTAATAAAGTTGTTATTTTT
ATAACCATGATTATATTATTATTATTAATAAAATATTTTATCAAAATGCTTATTTTCTCTGTTATGTTATTTACATGT
ACATATTTATATCTGTCTTAGGGCCTAAATGCAGAAAATAGCAATGTTGACTTCACTGACAAAAATAAAATACACG
TTTTTGCAAAAACTATAATACAACTTGTTATAGAACTAAGACAAAAATCATTATTTTATTCCAACTAATATCCACA
GCAATATAGTTGGTCTTCAGTAAACCATTAATCTCTATGCACTTTAGTTTCTCCCACC 
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Appendix I: RNA methods 
1) RNA quantification 
 
Absorbances readings are taken of the RNA samples at 260nm and 280nm. The ratio 
was used to give the purity of the sample: Pure RNA: A260/A280 > 2.0 (Pure). The 
yield was gained by the following: 
 
Yield = 260nm x dilution x 40 (50 for DNA) = xµg/ml 
 
2) Reverse Transcriptase method for cDNA manufacture: 
  
Mix 1µl Random Primer (all Invitrogen), 5µl RNA, 2µl 10mM dNTP mix and add 
DEPC-treated water Up to 12µl. Denature the RNA and primer by incubating at 65C 
for 5 min and then place on ice. Vortex the 5x cDNA synthesis buffer for 5 sec 
immediately before the next step. Prepare following master reaction mix on ice and 
vortex (per reaction): 
 
4µl 5 x cDNA synthesis buffer 
1µl 0.1m DTT 
1µl Rnase out (40U/µl) 
1µl DEPC-treated water 
1µl Cloned AMV RT (15U/µl)* 
* - if RNA less than 1ng reduce to 0.5µl increase DEPC-H2O to 1.5µl 
 
 xl
Pipette 8µl of master mix into each reaction tube on ice and place in the thermocycler 
for the following: 
 
cDNA synthesis:  
25oC for 10minutes 
50oC for 30 minutes 
Terminate the reaction by incubating at 85oC for 5 minutes 
Store at –20C. 
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 Appendix J: Controls for RT-PCR 
RT-PCR controls for Het1a and Oe21 cell lines for EGFR. This includes a β-actin 
positive control (+), β-actin negative control (-) and a RT reaction without reverse 
transcriptase 
Het+ Oe+ Het- Oe- RT- 
 
 
RT-PCR controls for Het1a and Oe21 cell lines for VEGF. This includes a β-actin 
positive control (+), β-actin negative control (-) and a RT reaction without reverse 
transcriptase: 
Het+ Oe+ Het- Oe- RT- 
 
 
RT-PCR controls for Het1a and Oe21 cell lines for EGFR without the cells being 
treated with fetal calf serum in the media. This includes a β-actin positive control (+), 
β-actin negative control (-) and a RT reaction without reverse transcriptase: 
Het+ Het- Oe+ Oe- RT- 
 
 
RT-PCR controls for Het1a and Oe21 cell lines for VEGF without the cells being 
treated with fetal calf serum in the media. This includes a β-actin positive control (+), 
β-actin negative control (-) and a RT reaction without reverse transcriptase: 
 
 xlii
Het+ Het- Oe+ Oe- RT- 
 
 
RT-PCR controls for Het1a and Oe21 cell lines for COX 2. This includes a β-actin 
positive control (+), β-actin negative control (-) and a RT reaction without reverse 
transcriptase: 
Het+ Oe+ Het- Oe- RT- 
 
 
 
 
 
 
 
 
 
 
 
 
 xliii
Appendix K: Gene Sequences and Primers Designed 
1) The Complete Human Sequence for the COX 2 Gene, Showing the Primers and the 
Amplification Area 
 
GAGCTCACATTAACTATTTACAGGGTAACTGCTTAGGACCAGTATTATGAGGAGAATTTACCTTTCCCGCCTCTCTT
TCCAAGAAACAAGGAGGGGGTGAAGGTACGGAGAACAGTATTTCTTCTGTTGAAAGCAACTTAGCTACAAAGATA
AATTACAGCTATGTACACTGAAGGTAGCTATTTCATTCCACAAAATAAGAGTTTTTTAAAAAGCTATGTATGTATG
TGCTGCATATAGAGCAGATATACAGCCTATTAAGCGTCGTCACTAAAACATAAAACATGTCAGCCTTTCTTAACCT
TACTCGCCCCAGTCTGTCCCGACGTGACTTCCTCGACCCTCTAAAGACGTACAGACCAGACACGGCGGCGGCGGC
GGGAGAGGGGATTCCCTGCGCCCCCGGACCTCAGGGCCGCTCAGATTCCTGGAGAGGAAGCCAAGTGTCCTTCTG
CCCTCCCCCGGTATCCCATCCAAGGCGATCAGTCCAGAACTGGCTCTCGGAAGCGCTCGGGCAAAGACTGCGAAG
AAGAAAAGACATCTGGCGGAAACCTGTGCGCCTGGGGCGGTGGAACTCGGGGAGGAGAGGGAGGGATCAGACAG
GAGAGTGGGGACTACCCCCTCTGCTCCCAAATTGGGGCAGCTTCCTGGGTTTCCGATTTTCTCATTTCCGTGGGTAA
AAAACCCTGCCCCCACCGGGCTTACGCAATTTTTTTAAGGGGAGAGGAGGGAAAAAATTTGTGGGGGGGTACGAA
AAGGCGGAAAGAAACAGTCATTCACATGGGCTTGGTTTTCAGTCTTATAAAAAGGAAGGTTCTCTCGGTTAGCGA
CCAATTGTCATACGACTTGCAGTGAGCGTCAGGAGCACGTCCAGGAACTCCTCAGCAGCGCCTCCTTCAGCTCCAC
AGCCAGACGCCCTCAGACAGCAAAGCCTACCCCCGCGCCGCGCCCTGCCCGCCGCTCGGATGCTCGCCCGCGCCC
TGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGGTGAGTACCTGGCGCCGCGCACCGGGGACTCCGGTTCCAC
GCACCCGGGCAGAGTTTCCGCTCTGACCTCCTGGGTCTATCCCAGTACTCCGACTTCTCTCCGAATAGAGAAGCTA
CGTGACTTGGGAAAGAGCTTGGACCGCTAGAGTCCGAAAGAACTCCGTGGATATTCCAGCTTTCCCACAAGCACT
GATCATTATGAGCCAGTTACTTAACCGATCTGAGACACTCTCACCTCCTAAATAGGGATAGATGATACTAATTTGC
AGGTTGTCATTATGATAAGACAGGATCTGATCAATATATGTGAATTGTTTATATTTGGAACCTTTTTATTGAGTGGA
AGAAGTTGTTTTAAATATTCTAGTCAGTTCTTTCCTGCTCCCAGGAAAGCCCGGATTATGTTTTAAGATAAGCAAA
ATGTCTTAAAAGTAAGCTGTTTTACTTTGAATTTTTCCCTAAATGTTGATTAGTGTACTAGATCCATTTTAATTTGG
AAAGTGAAGTGCTACTTATTTGAACTTCTTAAAAATGCTAATTTTAACATCTAAAGAGTTAACTAAGAAAAGCTTA
GTAACATGATGTACCAAGTTGAATATGCTGTTATCCTTATTTAGAATAGAAAATTGGTATTTCTACGTTTTATCCAT
TCTAAGGCAGGTTAAAAAATTGTATTTCCATGACTACCTATATATTTCTTGAATTTATTATTGTAAAGTTGATTCAT
AGTCAAACAATTAAATGTTTAAATTAAGATTAAGACACTAGAGAATGATTTATTTGCTGTCCTTTAATTGCAGCAA
ATCCTTGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTATAAGTGCGATTG
TACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACGTAAGTTTGTCCTTTGGTTGCCTCATTAGGAGTGGGGC
TGGATACAGTTATCATTGTATAGATTTGTGTCTTATAATGAGTCCCATTAATTTCTCCCTCCCTTTCTTCGTCTTCTT
GCAGCGGAATTTTTGACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCACT
TCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGTTATGTCTTGACATGTAA
GTACAAGTGTCTTTCTAAGGTTTTTAGCCTTCTCAAAGAAAAATATGCTTTATAATACTGTAAGCCTAATCTAAAA
ACATATTTCCAAGCTTATCAAAAAGACTTTAAGATAGCTTTTAAGTTTGCCTTCCATCTTAATCGCCAAAAATATTG
ACATTTAGTCCCATCCAGTTTATACAGTCTGCTCACAACTCTGTATACCTCTTCTAACCTTTACTGTTTGGTCAGTTT
GTGGAGGTAGCATGGTCCAGCTGTTTATTGAATGCCCATGGGCCACAGAATTGTTCTGAACATGTAGCACCCATTA
AAATAAATTTGGATTTGGATCAGCAAGAAAATAACTTTCCATGATTCTAAAGTGGGTGCCATACTCAGCCATTCCT
TTCATAGGCCTCTTGGATAGTGAGCAGATGGCTACCTGAAAAATCAATATTGCCAGATTATAATGTGCAGAGTATA
TGTATTTTATTAAAGATGTATTTCAAGTGGCCATTAGACTATAAAGTGTAGTTGTTTAAAAATAGATTTTTTTTATT
TTGGAGTTACATTCAACCTCAGGTGCCACTTTCCACATTTTACAATAAAAATAATGGTTGATTTACTTAACAAATG
AGAATAAATAAAACATTTTTTTCTTTGAAAATTTCAGCCAGATCACATTTGATTGACAGTCCACCAACTTACAATG
CTGACTATGGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCTGTGCCTGAT
GATTGCCCGACTCCCTTGGGTGTCAAAGGTGAGTAAGAAGAATCCATTAGAGATGTATTAACTATAAGACGGGCT
GCATTGCTGCCAAAAAAAAAAATTGACCTTAGACTACATTTATTTATTAACAAAAGCAGTTTTTACTTTTAGCATG
GTTATCTATGGGTATTTTTTAAAGTATGAGTCTATATAAACTATTATGTAAAAGCAAATGAGCGTCTTGGTATAAT
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GTCTTAATATTTTCAAATTATTTCTTTAGAAATGAAATAATTCTAATTAAAATAGATAAAATCATTCAGTAAGAAG
TTGTTCCACCATATCTTAGAACTGTTGTTTATATTATGATCCTATTCACAATTGTAATTCTCATATAAATGAAGAAT
TCTTGGTAGATTGACAGTCACCATCTCCTTTCTTGAATACATAGATGGATTCTTACCTTAGCTTTCTCATTTTTCAGG
TAAAAAGCAGCTTCCTGATTCAAATGAGATTGTGGAAAAAT(primer) 
TGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCAAACATGATGTTTGCATTCTTTGCCCAGCACTTCAC
GCATCAGTTTTTCAAGACAGATCATAAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTAAGATAGAG
TTAATATCTTAGAGTTAGTAAAATTATACCAAATCATAGTCAAGGGCTAACATTAAAGGAGATATACAGATAGAT
AGATCCAAATAACTTATCCACTTTTTTTAAAAAGAAGTCTTATCTATAAAAACCTTAAAGGAATTTTCCATTTACTT
CACTGGTCTAGTAAAATTATACACACACACAGACATGCACACACATATATAAACATTCACACACATACATATGTAC
AGGTATTGTTATTTGTAATTTGACCCTTGTATTTTTTAGTTTAAAATGTTAGTACTGCAAAATGTTATGTCCTCAAA
AACACATTGTACCATGATTATGCCGCTTTCAATATTGTAAAGTGAGGTTTTTGCCGCATTATTATTTTTTGGATTTC
AATAGCATAGCTTCAAGTTATTCGTAAGAATTTTTTATAAATAATACATTTTTATACTTTTTTATAATTACCATATC
ATCATAGTGAAGTATATAATATATATGATATAAGCTCAATATAGTATATTAATTCCGTTAAACACAAAGACATATC
AGTTTGTAGCTTTGGTGGATAAACAAATTAATTTAGCAATTCATGGCTATGAAAAATGTATATTTTATTTAAAAATT
TTAAAGAAAGCTAAATGATCAAATTATTTAATGATGAATTATATGATAGACACTTTATATAAGAAAAACTTCAACA
GCAACAAATTAAAATTTTTTCATCATTTTCTAGGTGGACTTAAATCATATTTACGGTGAAACTCTGGCTAGACAGC
GTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATATCAGGTATGCTTCCTTTGACTATTAAGACTTAGTTATTA
CCGCTTATACCCATATTTTAAAATCCCTAAAAATGTGTTCCTTAACTTTTTAACTGATGTTTATTTATTTATTTATTT
TTTTAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATCT (primer2)(1164 
bases) 
ACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTGGTGCCTGGTCTGATGAT
GTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGATGTGCTTAAACAGGAGCATCCTGAATGGGGTGA
TGAGCAGTTGTTCCAGACAAGCAGGCTAATACTGATAGGTAAACAAGAAAATGATTTATATAAAACCCTCTTCCCC
AGGGAAAATTAGTGTGCTATCTTTGTTATGTTTTGAGTAAATGACAAGATGTGGTAAATGAAAACTCACACATTCT
ATATACATTAAATATGTAAGCATGACTGATAAAATAGCTATCTTTTGATACTGACAAGGAAGAAAACAGAAATGA
AGGAATAGCAAATTTTAAAAATTGCATTCCAGTTGCTTGAAAGCTTGTGATCAGATGCAATAAATGTTTTTATTAT
TTATTTTGTGCAAATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGCTATCACTTC
AAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAAAATCGTATTGCTGCTGAATTTAACA
CCCTCTATCACTGGCATCCCCTTCTGCCTGACACCTTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATC
TACAACAACTCTATATTGCTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGG
TAAGCATTATTATTGAAAACCAAAACAAAAGACTAGTCAGTAACTTTAGAATTTCTGCCACGGAAATTATTTTTCT
TAAACTTACTAAAAGAGTAGTTAGTTATATTGCTAGTAAAATTATTTTATTGATATAAGAAGCCTAACTTTGTTTGA
AAAGTCTAAACTTTTAGTCTAGTCTACAGTTGTCAGACAAATAGCAAATTGTACCCCTACCTTAAAAATATTTTCA
AAAAGTATCTATAATCTTATAGGAATAAATATTTTAGGCTTGAATACTAGTGTTATTTTTGAAATGTAAAAAGGCA
AATTAGTTCTAGGCTGGTGTCCCATTGAATTTTAAGCAGAGCTCCTGTTGAAATGTAGGTAAGCATCTTTCCAGCA
AATAAAAATTGTCTCCGCTGGGAGTTTCAGTTTTACCTGATTTGTACCTAAGGCAAGCTGAATACAAACAGTAAAT
ATGCCTAAAATTCTTGTTTTACAACTAATTTTACTTTCCACAGGTTGCTGGTGGTAGGAATGTTCCACCCGCAGTAC
AGAAAGTATCACAGGCTTCCATTGACCAGAGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCT
TTATGCTGAAGCCCTATGAATCATTTGAAGAACTTACAGGTAAGAAACAGTTTCTAAACTTCTTCGTTTTTTGTTTG
TTTGTTTGTTTTTGTTGTTTTTGGTTTTCTTTTCGAGATGGAGCCGCCCTCTGTCACCCAGGCTGGAGTGCAGTGGCG
CCATCTCGGCTCACTGCAACCTCCGCCTCCTGGGTTCAAGCAATTCTCCTGCCTCAACTTCCTGAGTAGCTGGGACT
ACAGGCTCACGTCGCACGCATGGATAATTTTTTGTATTTTCAGTATAGACGGGGTTTCACCGTGTTAGCCAGGCTG
GTCTCAAACTCCTGACCTAGTGATCCGCCGGCTTCGGCCTCCCGAAGTGCTGGGATTACAGGCGTGAGCCACCGCG
CCTGGCCCCTAAACTTCTTAAAAGAATCAGGGGTCAAATGGAAACAGAGAAGTTGGCAGCAAATTGAGCAAAAG
AATCAAACTGTTTTTTATTTTGTGAAGTTTGACATTGGTTGTATCTCTGTCTTCATCGCCTTCACAGGAGAAAAGGA
AATGTCTGCAGAGTTGGAAGCACTCTATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAG
CCTCGGCCAGATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTTATGGGTA
ATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTGGGTTTTCAAATCATCAACACTGC
CTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGCTGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCA
TTAAAACAGTCACCATCAATGCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGA
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ACGTTCGACTGAACTGTAGAAGTCTAATGATCATATTTATTTATTTATATGAACCATGTCTATTAATTTAATTATTT
AATAATATTTATATTAAACTCCTTATGTTACTTAACATCTTCTGTAACAGAAGTCAGTACTCCTGTTGCGGAGAAAG
GAGTCATACTTGTGAAGACTTTTATGTCACTACTCTAAAGATTTTGCTGTTGCTGTTAAGTTTGGAAAACAGTTTTT
ATTCTGTTTTATAAACCAGAGAGAAATGAGTTTTGACGTCTTTTTACTTGAATTTCAACTTATATTATAAGAACGAA
AGTAAAGATGTTTGAATACTTAAACACTATCACAAGATGGCAAAATGCTGAAAGTTTTTACACTGTCGATGTTTCC
AATGCATCTTCCATGATGCATTAGAAGTAACTAATGTTTGAAATTTTAAAGTACTTTTGGTTATTTTTCTGTCATCA
AACAAAAACAGGTATCAGTGCATTATTAAATGAATATTTAAATTAGACATTACCAGTAATTTCATGTCTACTTTTT
AAAATCAGCAATGAAACAATAATTTGAAATTTCTAAATTCATAGGGTAGAATCACCTGTAAAAGCTTGTTTGATTT
CTTAAAGTTATTAAACTTGTACATATACCAAAAAGAAGCTGTCTTGGATTTAAATCTGTAAAATCAGATGAAATTT
TACTACAATTGCTTGTTAAAATATTTTATAAGTGATGTTCCTTTTTCACCAAGAGTATAAACCTTTTTAGTGTGACT
GTTAAAACTTCCTTTTAAATCAAAATGCCAAATTTATTAAGGTGGTGGAGCCACTGCAGTGTTATCTCAAAATAAG
AATATTTTGTTGAGATATTCCAGAATTTGTTTATATGGCTGGTAACATGTAAAATCTATATCAGCAAAAGGGTCTA
CCTTTAAAATAAGCAATAACAAAGAAGAAAACCAAATTATTGTTCAAATTTAGGTTTAAACTTTTGAAGCAAACTT
TTTTTTATCCTTGTGCACTGCAGGCCTGGTACTCAGATTTTGCTATGAGGTTAATGAAGTACCAAGCTGTGCTTGAA
TAACGATATGTTTTCTCAGATTTTCTGTTGTACAGTTTAATTTAGCAGTCCATATCACATTGCAAAAGTAGCAATGA
CCTCATAAAATACCTCTTCAAAATGCTTAAATTCATTTCACACATTAATTTTATCTCAGTCTTGAAGCCAATTCAGT
AGGTGCATTGGAATCAAGCCTGGCTACCTGCATGCTGTTCCTTTTCTTTTCTTCTTTTAGCCATTTTGCTAAGAGAC
ACAGTCTTCTCATCACTTCGTTTCTCCTATTTTGTTTTACTAGTTTTAAGATCAGAGTTCACTTTCTTTGGACTCTGC
CTATATTTTCTTACCTGAACTTTTGCAAGTTTTCAGGTAAACCTCAGCTCAGGACTGCTATTTAGCTCCTCTTAAGA
AGATTAAAAGAGAAAAAAAAAGGCCCTTTTAAAAATAGTATACACTTATTTTAAGTGAAAAGCAGAGAATTTTAT
TTATAGCTAATTTTAGCTATCTGTAACCAAGATGGATGCAAAGAGGCTAGTGCCTCAGAGAGAACTGTACGGGGTT
TGTGACTGGAAAAAGTTACGTTCCCATTCTAATTAATGCCCTTTCTTATTTAAAAACAAAACCAAATGATATCTAA
GTAGTTCTCAGCAATAATAATAATGACGATAATACTTCTTTTCCACATCTCATTGTCACTGACATTTAATGGTACTG
TATATTACTTAATTTATTGAAGATTATTATTTATGTCTTATTAGGACACTATGGTTATAAACTGTGTTTAAGCCTAC
AATCATTGATTTTTTTTTGTTATGTCACAATCAGTATATTTTCTTTGGGGTTACCTCTCTGAATATTATGTAAACAAT
CCAAAGAAATGATTGTATTAAGATTTGTGAATAAATTTTTAGAAATCTGATTGGCATATTGAGATATTTAAGGTTG
AATGTTTGTCCTTAGGATAGGCCTATGTGCTAGCCCACAAAGAATATTGTCTCATTAGCCTGAATGTGCCATAAGA
CTGACCTTTTAAAATGTTTTGAGGGATCTGTGGATGCTTCGTTAATTTGTTCAGCCACAATTTATTGAGAAAATATT
CTGTGTCAAGCACTGTGGGTTTTAATATTTTTAAATCAAACGCTGATTACAGATAATAGTATTTATATAAATAATTG
AAAAAAATTTTCTTTTGGGAAGAGGGAGAAAATGAAATAAATATCATTAAAGATAACTCAGGAGAATCTTCTTTA
CAATTTTACGTTTAGAATGTTTAAGGTTAAGAAAGAAATAGTCAATATGCTTGTATAAAACACTGTTCACTGTTTTT
TTTAAAAAAAAAACTTGATTTGTTATTAACATTGATCTGCTGACAAAACCTGGGAATTTGGGTTGTGTATGCGAAT
GTTTCAGTGCCTCAGACAAATGTGTATTTAACTTATGTAAAAGATAAGTCTGGAAATAAATGTCTGTTTATTTTTGT
ACTATTTAAAAAAAAAAAAAAAAATCGATGTCGACTCGAGTC 
 
2) The Human cDNA Sequence for the COX 2 Gene, Showing the Primers and 
Amplification Area 
 
CTTGCAGTGAGCGTCAGGAGCACGTCCAGGAACTCCTCAGCAGCGCCTCCTTCAGCTCCACAGCCAGACGCCCTCA
GACAGCAAAGCCTACCCCCGCGCCGCGCCCTGCCCGCCGCTGCGATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGT
CCTGGCGCTCAGCCATACAGCAAATCCTTGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGA
TTTGACCAGTATAAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTGACAA
GAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCACTTCAAGGGATTTTGGAACGT
TGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGTTATGTGTTGACATCCAGATCACATTTGATTGACAGTC
CACCAACTTACAATGCTGACTATGGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCT
 xlvi
TCCTCCTGTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCAAATGAGATT
GTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCAAACATGATGTTTGCATTCTTTGCCC
AGCACTTCACGCATCAGTTTTTCAAGACAGATCATAAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGG
TGGACTTAAATCATATTTACGGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGA
AATATCAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATCT (305 bases) 
ACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTGGTGCCTGGTCTGATGAT
GTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGATGTGCTTAAACAGGAGCATCCTGAATGGGGTGA
TGAGCAGTTGTTCCAGACAAGCAGGCTAATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCA
ACACTTGAGTGGCTATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAAAAT
CGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACCTTTCAAATTCATGACCAGAA
ATACAACTATCAACAGTTTATCTACAACAACTCTATATTGCTGGAACATGGAATTACCCAGTTTGTTGAATCATTC
ACCAGGCAAATTGCTGGCAGGGTTGCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCC
ATTGACCAGAGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCCTATGAAT
CATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTCTATGGTGACATCGATGCTGTGG
AGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCAGATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGC
ACCATTCTCCTTGAAAGGACTTATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGA
GAAGTGGGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGCTGTCCCTTTA
CTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAATGCAAGTTCTTCCCGCTCCGGACTAGA
TGATATCAATCCCACAGTACTACTAAAAGAACGTTCGACTGAACTGTAGAAGTCTAATGATCATATTTATTTATTT
ATATGAACCATGTCTATTAATTTAATTATTTAATAATATTTATATTAAACTCCTTATGTTACTTAACATCTTCTGTAA
CAGAAGTCAGTACTCCTGTTGCGGAGAAAGGAGTCATACTTGTGAAGACTTTTATGTCACTACTCTAAAGATTTTG
CTGTTGCTGTTAAGTTTGGAAAACAGTTTTTATTCTGTTTTATAAACCAGAGAGAAATGAGTTTTGACGTCTTTTTA
CTTGAATTTCAACTTATATTATAAGAACGAAAGTAAAGATGTTTGAATACTTAAACACTGTCACAAGATGGCAAAA
TGCTGAAAGTTTTTACACTGTCGATGTTTCCAATGCATCTTCCATGATGCATTAGAAGTAACTAATGTTTGAAATTT
TAAAGTACTTTTGGTCATTTTTCTGTCATCAAACAAAAACAGGTATCAGTGCATTATTAAATGAATATTTAAATTAG
ACATTACCAGTAATTTCATGTCTACTTTTTAAAATCAGCAATGAAACAATAATTTGAAATTTCTAAATTCATAGGGT
AGAATCACCTGTAAAAGCTTGTTTGATTTCTTAAAGTTATTAAACTTGTACATATACCAAAAAGAAGCTGTCTTGG
ATTTAAATCTGTAAAATCAGTAGAAATTTTACTACAATTGCTTGTTAAAATATTTTATAAGTGATGTTCCTTTTTCA
CCAAGAGTATAAACCTTTTTAGTGTGACTGTTAAAACTTCCTTTTAAATCAAAATGCCAAATTTATTAAGGTGGTG
GAGCCACTGCAGTGTTATCTTAAAATAAGAATATTTTGTTGAGATATTCCAGAATTTGTTTATATGGCTGGTAACAT
GTAAAATCTATATCAGCAAAAGGGTCTACCTTTAAAATAAGCAATAACAAAGAAGAAAACCAAATTATTGTTCAA
ATTTAGGTTTAAACTTTTGAAGCAAACTTTTTTTTATCCTTGTGCACTGCAGGCCTGGTACTCAGATTTTGCTATGA
GGTTAATGAAGTACCAAGCTGTGCTTGAATAACGATATGTTTTCTCAGATTTTCTGTTGTACAGTTTAATTTAGCAG
TCCATATCACATTGCAAAAGTAGCAATGACCTCATAAAATACCTCTTCAAAATGCTTAAATTCATTTCACACATTA
ATTTTATCTCAGTCTTGAAGCCAATTCAGTAGGTGCATTGGAATCAAGCCTGGCTACCTGCATGCTGTTCCTTTTCT
TTTCTTCTTTTAGCCATTTTGCTAAGAGACACAGTCTTCTCATCACTTCGTTTCTCCTATTTTGTTTTACTAGTCTTAA
GATCAGAGTTCACTTTCTTTGGACTCTGCCTATATTTTCTTACCTGAACTTTTGCAAGTTTTCAGGTAAACCTCAGCT
CAGGACTGCTATTTAGCTCCTCTTAAGAAGATTAAAAAAAAAAAAAAAA 
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CGCCGCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCACAACC
ACCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGATGC
GACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGG
 xlvii
AAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAGTTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCA
GAGGATGTTCAATAACTGTGAGGTGGTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCC
TTCTTAAAGACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCCTTTGGAAA
ACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCAGTCTTATCTAACTATGATGCAAA
TAAAACCGGACTGAAGGAGCTGCCCATGAGAAATTTACAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAA
CCCTGCCCTGTGCATGTGGAGAGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGG
ACTTCCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGAGCTGCTGGGGTGCAGGAG
AGGAGAACTGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCCGGGCGCTGCCGTGGCAAGTCCCCCA
GTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGCACAGGCCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAAT
TCCGAGACGAAGCCACGTGCAAGGACACCTGCCCCCCACTCATGCTCTACAACCCCACCACGTACCAGATGGATG
TGAACCCCGAGGGCAAATACAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTGGTGACAGATC
ACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAAGACGGCGTCCGCAAGTGTAAGAAGT
GCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTA
CGAATATTAAACACTTCAAAAACTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGA
CTCCTTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCACAGGGTTT
TTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTTGAGAACCTAGAAATCATACGCGGCAGG
ACCAAGCAACATGGTCAGTTTTCTCTTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGG
AGATAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAAC
TGTTTGGGACCTCCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAG
GTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAAGGACTGCGTCTCTTGCCGGAATGTCA
GCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGT
GCATACAGTGCCACCCAGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTA
TCCAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGAGTCATGGGAGAAAACAACA
CCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGCCATCCAAACTGCACCTACGGATGCACTGG
GCCAGGTCTTGAAGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTC
TTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGGA
GGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAACCAAGCTCTCTTGAGGA
TCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCCGGTGCGTTCGGCACGGTGTATAAGGGACTCT
GGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCA
ACAAGGAAATCCTCGATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATCT
GCCTCACCTCCACCGTGCAGCTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGACTATGTCCGGGAACACAA
AGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAGATCGCAAAGGGCATGAACTACTTGGAGGACCG
TCGCTTGGTGCACCGCGACCTGGCAGCCAGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTT
TGGGCTGGCCAAACTGCTGGGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGGA
TGGCATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTACGGGGTGACCGTTTGGGA
GTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCCAGCGAGATCTCCTCCATCCTGGAGAAAGGAGA
ACGCCTCCCTCAGCCACCCATATGTACCATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGAT
AGTCGCCCAAAGTTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTCATTC
AGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCCCTGATGGATGAAGAAGACA
TGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAGCAGGGCTTCTTCAGCAGCCCCTCCACGTCACGGA
CTCCCCTCCTGAGCTCTCTGAGTGCAACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAG
CTGTCCCATCAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGACAGCAT
AGACGACACCTTCCTCCCAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGGCCCGCTGGCTCTGTGCAGAAT
CCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCCAGCAGAGACCCACACTACCAGGACCCCCACAGCACTGCA
GTGGGCAACCCCGAGTATCTCAACACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTGCCCACTGGG
CCCAGAAAGGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAAGCCAAGC
CAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTCGCGCCACAAAGCAGTGAATTTA
TTGGAGCATGACCACGGAGGATAGTATGAGCCCTAAAAATCCAGACTCTTTCGATACCCAGGACCAAGCCACAGC
AGGTCCTCCATCCCAACAGCCATGCCCGCATTAGCTCTTAGACCCACAGACTGGTTTTGCAACGTTTACACCGACT
 xlviii
AGCCAGGAAGTACTTCCACCTCGGGCACATTTTGGGAAGTTGCATTCCTTTGTCTTCAAACTGTGAAGCATTTACA
GAAACGCATCCAGCAAGAATATTGTCCCTTTGAGCAGAAATTTATCTTTCAAAGAG 
 
4) The Human cDNA Sequence for the VEGF Gene, Showing the Primers and 
Amplification Area 
 
AAGAGCTCCAGAGAGAAGTCGAGGAAGAGAGAGACGGGGTCAGAGAGAGCGCGCGGGCGTGCGAGCAGCGAAA
GCGACAGGGGCAAAGTGAGTGACCTGCTTTTGGGGGTGACCGCCGGAGCGCGGCGTGAGCCCTCCCCCTTGGGAT
CCCGCAGCTGACCAGTCGCGCTGACGGACAGACAGACAGACACCGCCCCCAGCCCCAGTTACCACCTCCTCCCCG
GCCGGCGGCGGACAGTGGACGCGGCGGCGAGCCGCGGGCAGGGGCCGGAGCCCGCCCCCGGAGGCGGGGTGGAG
GGGGTCGGAGCTCGCGGCGTCGCACTGAAACTTTTCGTCCAACTTCTGGGCTGTTCTCGCTTCGGAGGAGCCGTGG
TCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGCTCGGGCCGGGAGGAGCCGCAGCCGGAG
GAGGGGGAGGAGGAAGAAGAGAAGGAAGAGGAGAGGGGGCCGCAGTGGCGACTCGGCGCTCGGAAGCCGGGCT
CATGGACGGGTGAGGCGGCGGTGTGCGCAGACAGTGCTCCAGCGCGCGCGCTCCCCAGCCCTGGCCCGGCCTCGG
GCCGGGAGGAAGAGTAGCTCGCCGAGGCGCCGAGGAGAGCGGGCCGCCCCACAGCCCGAGCCGGAGAGGGACGC
GAGCCGCGCGCCCCGGTCGGGCCTCCGAAACCATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTTGCCTTGCT
GCTCTACCTCCACCATGCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAATCATCACGAAGT
GGTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCAATCGAGACCCTGGTGGACATCTTCCAGGAGTAC
CCTGATGAGATCGAGTACATCTTCAAGCCATCCTGTGTGCCCCTGATGCGATGCGGGGGCTGCTCCAATGACGAGG
GCCTGGAGTGTGTGCCCACTGAGGAGTCCAACATCACCATGCAGATTATGCGGATCAAACCTCACCAAGGCCAGC
ACATAGGAGAGATGAGCTTCCTACAGCACAACAAATGTGAATGCAGACCAAAGAAAGATAGAGCAAGACAAGAA
AATCCCTGTGGGCCTTGCTCAGAGCGGAGAAAGCATTTGTTTGTACAAGATCCGCAGACGTGTAAATGTTCCTGCA
AAAACACACACTCGCGTTGCAAGGCGAGGCAGCTTGAGTTAAACGAACGTACTTGCAGATGTGACAAGCCGAGGC
GGTGAGCCGGGCAGGAGGAAGGAGCCTCCCTCAGGGTTTCGGGAACCAGATCTCTCTCCAGGAAAGACTGATACA
GAACGATCGATACAGAAACCACGCTGCCGCCACCACACCATCACCATCGACAGAACAGTCCTTAATCCAGAAACC
TGAAATGAAGGAAGAGGAGACTCTGCGCAGAGCACTTTGGGTCCGGAGGGCGAGACTCCGGCGGAAGCATTCCC
GGGCGGGTGACCCAGCACGGTCCCTCTTGGAATTGGATTCGCCATTTTATTTTTCTTGCTGCTAAATCACCGAGCCC
GGAAGATTAGAGAGTTTTATTTCTGGGATTCCTGTAGACACACCCACCCACATACATACATTTATATATATATATA
TTATATATATATAAAAATAAATATCTCTATTTTATATATATAAAATATATATATTCTTTTTTTAAATTAACAGTGCT
AATGTTATTGGTGTCTTCACTGGATGTATTTGACTGCTGTGGACTTGAGTTGGGAGGGGAATGTTCCCACTCAGAT
CCTGACAGGGAAGAGGAGGAGATGAGAGACTCTGGCATGATCTTTTTTTTGTCCCACTTGGTGGGGCCAGGGTCCT
CTCCCCTGCCCAAGAATGTGCAAGGCCAGGGCATGGGGGCAAATATGACCCAGTTTTGGGAACACCGACAAACCC
AGCCCTGGCGCTGAGCCTCTCTACCCCAGGTCAGACGGACAGAAAGACAAATCACAGGTTCCGGGATGAGGACAC
CGGCTCTGACCAGGAGTTTGGGGAGCTTCAGGACATTGCTGTGCTTTGGGGATTCCCTCCACATGCTGCACGCGCA
TCTCGCCCCCAGGGGCACTGCCTGGAAGATTCAGGAGCCTGGGCGGCCTTCGCTTACTCTCACCTGCTTCTGAGTT
GCCCAGGAGGCCACTGGCAGATGTCCCGGCGAAGAGAAGAGACACATTGTTGGAAGAAGCAGCCCATGACAGCG
CCCCTTCCTGGGACTCGCCCTCATCCTCTTCCTGCTCCCCTTCCTGGGGTGCAGCCTAAAAGGACCTATGTCCTCAC
ACCATTGAAACCACTAGTTCTGTCCCCCCAGGAAACCTGGTTGTGTGTGTGTGAGTGGTTGACCTTCCTCCATCCCC
TGGTCCTTCCCTTCCCTTCCCGAGGCACAGAGAGACAGGGCAGGATCCACGTGCCCATTGTGGAGGCAGAGAAAA
GAGAAAGTGTTTTATATACGGTACTTATTTAATATCCCTTTTTAATTAGAAATTAGAACAGTTAATTTAATTAAAGA
GTAGGGTTTTTTTTCAGTATTCTTGGTTAATATTTAATTTCAACTATTTATGAGATGTATCTTTTGCTCTCTCTTGCTC
TCTTATTTGTACCGGTTTTTGTATATAAAATTCATGTTTCCAATCTCTCTCTCCCTGATCGGTGACAGTCACTAGCTT
ATCTTGAACAGATATTTAATTTTGCTAACACTCAGCTCTGCCCTCCCCGATCCCCTGGCTCCCCAGCACACATTCCT
TTGAAAGAGGGTTTCAATATACATCTACATACTATATATATATTGGGCAACTTGTATTTGTGTGTATATATATATAT
ATATGTTTATGTATATATGTGATCCTGAAAAAATAAACATCGCTATTCTGTTTTTTATATGTTCAAACCAAACAAGA
 xlix
AAAAATAGAGAATTCTACATACTAAATCTCTCTCCTTTTTTAATTTTAATATTTGTTATCATTTATTTATTGGTGCTA
CTGTTTATCCGTAATAATTGTGGGGAAAAGATATTAACATCACGTCTTTGTCTCTAGTGCAGTTTTTCGAGATATTC
CGTAGTACATATTTATTTTTAAACAACGACAAAGAAATACAGATATATCTTAAAAAAAAAAAA  
 l
Appendix L: Solutions 
 
Chaps Lysis Buffer 
 
1ml 1M Tris (pH 8) [final concentration 20mM] 
1.875 ml 4M NaCl [final concentration 0.15M] 
100µl 0.5M EDTA [final concentration 5mM] 
310mg Chaps 
1ml protease inhibitor 
make up final volume 50ml with RO H2O  
store at –4C 
 
10% SDS solution 
 
X % per 100g or 100ml 
100g SDS up to 1L RO H20 
Use the mask when dealing with SDS 
 li
 Prepare 6 % SDS main Gel 
 
2.5ml 1.5M Tris (pH 8.8) [18.165g Tris in 100ml H20] 
2ml 30 % Bis/acrylamide 29:1 [pre-made in –4C] 
100µl 10 % SDS 
50µl 10 % ammonium persulphate [0.1g AP in 1ml, make fresh weekly at –4C] 
10µl TEMED [in hood as neurotoxin] 
5.35ml RO H2O 
 
SDS Stacking Gel 
 
1.25ml 0.5M Tris (pH 7.5) 
0.65ml Bis/acrylamide 29:1 
50µl 10 % SDS 
25µl 10 % Ammonium persulphate 
10µl TEMED (to be added when required) 
3.05 ml RO H2O 
 lii
 Running Buffer x10 (use x1) 
 
30.3g Tris 
144g Glycine 
100g SDS 
RO H2O up to 1L 
 
Blotting buffer 
 
2.905g Tris 
1.465g Glycine 
0.5g SDS 
100ml Methanol 
RO H2O up to 1L 
Primary wash buffer for Northern blot 
6M Urea (360g) 
0.4% SDS (4g)  
0.5 x SCC (25ml 20xSCC) 
to be kept at 2-8C. 
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